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 40 
Abbreviations: 41 
ACS acute coronary syndrome 42 
aPTT activated partial thromboplastin time 43 
ARISTOTLE Apixaban for Reduction of Stroke and Other Thromboembolic Events in Atrial 44 
Fibrillation 45 
ATRIA AnTicoagulation and Risk factors In Atrial fibrillation 46 
AVERROES Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial 47 
Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K 48 
Antagonist Treatment 49 
b.i.d bis in die (twice daily) 50 
CABG coronary artery bypass graft 51 
CAP Continued Access to PROTECT AF 52 
CHA2DS2-VASc congestive heart failure, hypertension, age ≥75 (doubled), diabetes, stroke 53 
(doubled)-vascular disease, age 65–74 and sex category (female) 54 
CHADS2 congestive heart failure, hypertension, age, diabetes, stroke (doubled) 55 
CI confidence interval 56 
CrCl creatinine clearance 57 
DOAC direct oral anticoagulant drugs 58 
ECG electrocardiogram 59 
GRADE Grading of Recommendations, Assessment, Development, and Evaluation 60 
HAS-BLED hypertension, abnormal renal/liver function (1 point each), stroke, bleeding 61 
history or predisposition, labile INR, elderly (.65), drugs/alcohol concomitantly 62 
(1 point each) 63 
HF Heart Failure 64 
HFpEF Heart Failure with Preserved Ejection Fraction 65 
HFrEF Heart Failure with Reduced Ejection Fraction 66 
HR hazard ratio 67 
ICH intracranial haemorrhage 68 
INR international normalized ratio 69 
i.v. intravenous 70 
LAA left atrial appendage 71 
LAAO left atrial appendage occlusion 72 
o.d. omni die (every day) 73 
OAC oral anticoagulant 74 
NOAC non-vitamin K antagonist oral anticoagulant drugs 75 
NYHA  New York Heart Association 76 
PCI  percutaneous cardiovascular intervention 77 
PROTECT AF  System for Embolic PROTECTion in patients with Atrial Fibrillation 78 
RE-LY  Randomized Evaluation of Long-term anticoagulant therapY with dabigatran 79 
etexilate 80 
ROCKET-AF Rivaroxaban Once daily oral direct factor Xa inhibition Compared with vitamin 81 
K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation 82 
RRR  relative risk reduction 83 
TIA  transient ischaemic attack 84 
t.i.d.  ter in die (three times daily) 85 
TE thromboembolism 86 
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TEE  transesophageal echocardiogram 87 
TTR time in therapeutic range 88 
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Abstract 89 
Background: The risk of stroke is heterogeneous across different groups of patients with atrial 90 
fibrillation (AF), being dependent on the presence of various stroke risk factors.   We provide 91 
recommendations for antithrombotic treatment based on net clinical benefit for patients with AF at 92 
varying levels of stroke risk and in a number of common clinical scenarios.  93 
Methods:  Systematic literature reviews were conducted to identify relevant articles published from 94 
the last formal search perfomed for the Antithrombotic and Thrombolytic Therapy: American 95 
College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). The overall 96 
quality of the evidence was assessed using the GRADE (Grading of Recommendations, Assessment, 97 
Development, and Evaluation) approach.  Graded recommendations and ungraded consensus-based 98 
statements were drafted, voted on, and revised until consensus was reached. 99 
 100 
Results: For patients with AF without valvular heart disease, including those with paroxysmal AF, 101 
who are at low risk of stroke (e.g., CHA2DS2VASc score of 0 in males or 1 in females), we suggest no 102 
antithrombotic therapy. The next step is to consider stroke prevention (ie oral anticoagulation 103 
therapy) for patients with 1 or more non-sex CHA2DS2VASc stroke risk factors. For patients with a 104 
single non-sex CHA2DS2VASc stroke risk factor, we suggest oral anticoagulation rather than no 105 
therapy, aspirin or combination therapy with aspirin and clopidogrel; and for those at high risk of 106 
stroke (eg, CHA2DS2VASc ≥2 in males or ≥3 in females), we recommend oral anticoagulation rather 107 
than no therapy, aspirin, or combination therapy with aspirin and clopidogrel. Where we 108 
recommend or suggest in favor of oral anticoagulation, we suggest using a NOAC rather than 109 
adjusted-dose vitamin K antagonist therapy.  With the latter, it is important to aim for good quality 110 
anticoagulation control with a TTR >70%.   111 
Attention to modifiable bleeding risk factors (eg. uncontrolled blood pressure, labile INRs, 112 
concomitant use of aspirin or NSAIDs in an anticoagulated patient, alcohol excess) should be made 113 
at each patient contact, and HAS-BLED score used to assess the risk of bleeding where high risk 114 
patients (≥3) should be reviewed and followed up more frequently. 115 
Conclusions: Oral anticoagulation is the optimal choice of antithrombotic therapy for patients with 116 
AF with ≥1 non-gender CHA2DS2VASc stroke risk factor(s).  117 
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SUMMARY OF RECOMMENDATIONS 118 
Note: Shaded text refers to recommendations that remain unchanged from the previous version of 119 
the guideline 120 
 121 
1. For patients with AF, including those with paroxysmal AF, stroke risk should be assessed using 122 
a risk factor based approach, rather than an categorisation into low, moderate/high risk 123 
strata. We recommend use of the CHA2DS2VASc as a simple clinical based stroke risk score to 124 
initially identify ‘low stroke risk’ patients that should not be offered antithrombotic therapy to 125 
prevent stroke and reduce mortality (Strong recommendation, moderate quality evidence).  126 
 127 
Remark: Low risk patients are generally those age<65 and ‘lone AF’ irrespective of sex (this 128 
includes those with a CHA2DS2VASc score=0 in males, or 1 in females).  129 
 130 
2. Subsequent to this initial step, for patients with AF, including those with paroxysmal AF, we 131 
recommend stroke prevention should be offered to those AF patients with one or more non-132 
sex CHA2DS2VASc stroke risk factors (score of ≥1 in a male or ≥2 in a female)  (Strong 133 
recommendation, moderate quality evidence).  134 
 135 
Remark: Consideration of other less established clinical stroke risk factors, imaging (cardiac or 136 
cerebral) or biomarkers (urine, blood or genetics) may refine risk stratification based on simple 137 
clinical factors. A complex risk schema using a variety of such data that could accurately place 138 
more patients in the low risk stratum not requiring anticoagulants than current simple clinically-139 
based scores (personalised medicine) should be the goal of future research, but it will be very 140 
difficult to find non-anticoagulated patient cohorts for prospective validation. 141 
 142 
3. For patients with AF, we recommend bleeding risk assessment should be performed for all 143 
patients with AF at every patient contact and should initially focus on potentially modifiable 144 
bleeding risk factors (Strong recommendation, low quality evidence). 145 
 146 
Remark: Modifiable risk factors may include: Uncontrolled blood pressure; Labile INRs (in a 147 
patient taking VKA); Alcohol excess; Concomitant use of NSAIDs or aspirin in an anticoagulated 148 
patient; bleeding tendency or predisposition (e.g. treat gastric ulcer; optimise renal or liver 149 
function etc. 150 
 151 
4. For patients with AF, we recommend use of the HAS-BLED score to address modifiable 152 
bleeding risk factors in all AF patients.  Those potentially at high risk (HAS-BLED score ≥3) 153 
warrant more frequent and regular reviews or follow-up (Strong recommendation, moderate 154 
quality evidence). 155 
 156 
Remark: Given that bleeding risk is highly dynamic, attention to modifiable bleeding risk factors 157 
should be prioritized during every patient contact and review. 158 
 159 
5. In VKA treated patients, we suggest the use of the HAS-BLED score for bleeding risk 160 
assessment (Weak recommendation, low quality evidence) 161 
 162 
Remark: A high HAS-BLED score (≥3) is rarely a reason to avoid anticoagulation. The individual 163 
modifiable components of the score, when reviewed with the patient, can serve to ameliorate 164 
bleed risk 165 
 166 
 167 
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6. For patients with AF, we recommend against antiplatelet therapy alone (monotherapy or 168 
aspirin in combination with clopidogrel) for stroke prevention alone, regardless of stroke risk 169 
(Strong recommendation, moderate quality evidence). 170 
 171 
Remark: Patients with AF might have other indications for antiplatelet drugs (e.g. acute coronary 172 
syndrome, stents) 173 
 174 
7. In patients with AF who are eligible for OAC, we recommend NOACs over VKA (strong 175 
recommendation, moderate quality evidence). 176 
 177 
Remark: Patient and caregiver preferences, cost, formulary considerations, anticipated 178 
medication adherence or compliance with INR testing and dose adjustment should be 179 
incorporated into clinical-decision making. 180 
 181 
8. In patients on VKAs with consistently low time in INR therapeutic range (eg. TTR<65%), we 182 
recommend considering interventions to improve TTR or switching to NOACs (strong 183 
recommendation, moderate quality evidence) 184 
 185 
Remark:  Action required if TTR <65% - implement additional measures (more regular INR tests; 186 
review medication adherence; address other factors known to influence INR control; 187 
education/counselling) to improve INR control. 188 
 189 
9. In patients with prior unprovoked bleeding, warfarin-associated bleeding, or at high risk of 190 
bleeding, we suggest using apixaban, edoxaban, or dabigatran 110 mg (where available) as all 191 
demonstrate significantly less major bleeding compared with warfarin (Weak 192 
recommendation, very low quality evidence).  193 
 194 
Remark: In patients with prior gastrointestinal bleeding apixaban or dabigatran 110mg bid may 195 
be preferable as they are the only NOACs associated without an increased risk of gastrointestinal 196 
bleeding compared with warfarin. 197 
Remark: Dabigatran 150 mg twice daily recommended in patients at high risk of ischemic stroke 198 
as only agent/dose with superior efficacy compared with warfarin. However, bleeding risk would 199 
need to be assessed and patients monitored. 200 
 201 
10. For patients with non-valvular AF, when VKAs are used, we suggest the target should be INR 202 
2.0-3.0, with attention to individual TTR, ideally ≥70% (ungraded consensus-based statement). 203 
 204 
Remark:  Action required if TTR sub-optimal (i.e, <65-70%) - implement additional measures 205 
(more regular INR tests; review medication adherence; address other factors known to influence 206 
INR control; education/counselling) to improve INR control or consider a NOAC. 207 
Remark: When possible, experienced specialized anticoagulation clinics should be utilized for 208 
VKA and INR management. 209 
 210 
11. For patients with AF, we suggest the SAMe-TT2R2score to aid decision making to help identify 211 
patients likely to do well on VKA (ungraded consensus-based statement). 212 
 213 
Remark: Those with score 0-2 are likely to achieve a good TTR.  Those with score >2 are less 214 
likely to achieve a good TTR and would require more regular INR checks, education/counselling 215 
and frequent follow-up ‚or alternatively, NOAC should be considered as a better management 216 
option if high medication adherence can be expected. 217 
 218 
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12. For patients with AF of greater than 48 hours or unknown duration undergoing elective 219 
electrical or pharmacological cardioversion, we recommend therapeutic anticoagulation with 220 
well-managed VKA (INR 2-3) or a NOAC using dabigatran, rivaroxaban, edoxaban or apixaban 221 
for at least 3 weeks before cardioversion or a transesophageal echocardiography (TEE)-guided 222 
approach with abbreviated anticoagulation before cardioversion rather than no 223 
anticoagulation (Strong recommendation, moderate quality evidence). 224 
 225 
Remark: With NOACs adherence and persistence should be strongly emphasized 226 
 227 
13. For patients with AF of greater than 48 hours or unknown duration undergoing elective 228 
electrical or pharmacologic cardioversion, we recommend therapeutic anticoagulation (with 229 
VKA or NOAC) for at least 4 weeks after succesful cardioversion to sinus rhythm rather than no 230 
anticoagulation, regardless of the baseline risk of stroke (strong recommendation, moderate 231 
quality evidence) 232 
 233 
Remark: Decisions about anticoagulation beyond 4 weeks should be made in accordance with 234 
our risk-based recommendations for long-term antithrombotic therapy in recommednations 1 235 
and 2, and not on the basis of successful cardioversion  236 
 237 
14.  In patients in which LAA thrombus is detected on TEE, cardioversion postponed, and OAC 238 
continued for another 4-12 weeks, to allow thrombus resolution or endothelisation, we 239 
suggest that a decision on whether a repeat TEE is performed should be individualized 240 
(ungraded consensus-based statement). 241 
 242 
15. For patients with AF of documented duration of 48 hours or less undergoing elective 243 
cardioversion (electrical or pharmacologic), we suggest starting anticoagulation at 244 
presentation (low-molecular-weight heparin or unfractionated heparin at full venous 245 
thromboembolism treatment doses) and proceeding to cardioversion rather than delaying 246 
cardioversion for 3 weeks of therapeutic anticoagulation or a TEE-guided approach (weak 247 
recommendation, low quality evidence).  248 
 249 
16. For patients with AF and hemodynamic instability undergoing urgent cardioversion (electrical 250 
or pharmacologic), after successful cardioversion to sinus rhythm, we suggest therapeutic 251 
anticoagulation (with VKA or full adherence to NOAC therapy) for at least 4 weeks rather than 252 
no anticoagulation, regardless of baseline stroke risk (weak recommendation, low quality 253 
evidence). 254 
Remark: Decisions about long-term anticoagulation after cardioversion should be made in 255 
accordance with our risk-based recommendations for long-term antithrombotic therapy in 256 
recommendations 1 and 2 257 
 258 
17. For patients with AF and hemodynamic instability undergoing urgent cardioversion (electrical 259 
or pharmacologic), we suggest that therapeutic-dose parenteral anticoagulation be started 260 
before cardioversion, if possible, but that initiation of anticoagulation must not delay any 261 
emergency intervention (weak recommendation, low quality evidence). 262 
 263 
18.  For patients with AF and hemodynamic instability undergoing urgent cardioversion (electrical 264 
or pharmacologic), After successful cardioversion to sinus rhythm, we suggest therapeutic 265 
anticoagulation for at least 4 weeks after successful cardioversion to sinus rhythm rather than 266 
no anticoagulation, regardless of baseline stroke risk (weak recommendation, low quality 267 
evidence). 268 
 269 
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Remark: Decisions about anticoagulation beyond 4 weeks should be made in accordance with 270 
our risk-based recommendations for long-term antithrombotic therapy in recommendations 1 271 
and 2. 272 
 273 
19. For patients with atrial flutter undergoing elective or urgent pharmacologic or electrical 274 
cardioversion, we suggest that the same approach to thromboprophylaxis be used as for 275 
patients with atrial fibrillation undergoing cardioversion (ungraded consensus-based 276 
statement). 277 
 278 
20. In AF patients presenting with an ACS and/or undergoing PCI/stenting, we recommend 279 
assessment of stroke risk using the CHA2DS2-VASc score (Strong recommendation, moderate 280 
quality evidence) 281 
Remark: All such patients are not ‘low risk’ and should be considered for concomitant OAC. 282 
 283 
21. In AF patients presenting with an ACS and/or undergoing PCI/stenting, we suggest attention to 284 
modifiable bleeding risk factors at every patient contact, and assessment of bleeding risk using 285 
the HAS-BLED score (weak recommendation, low quality evidence). 286 
Remark: Where bleeding risk is high (HAS-BLED ≥3), there should be more regular review and 287 
follow-up. 288 
 289 
22. In AF patients requiring OAC undergoing elective PCI/stenting, where bleeding risk is low 290 
(HAS-BLED 0-2) relative to risk for recurrent ACS and/or stent thrombosis, we suggest triple 291 
therapy for 1-3 months, followed by dual therapy with OAC plus single antiplatelet (preferably 292 
clopidogrel) until 12 months, following which OAC monotherapy can be used (weak 293 
recommendation, low quality evidence). 294 
 295 
23. In AF patients requiring OAC undergoing elective PCI/stenting, where bleeding risk is high 296 
(HAS-BLED ≥3), we suggest triple therapy for one month, followed by dual therapy with OAC 297 
plus single antiplatelet (preferably clopidogrel) for 6 months, following which OAC 298 
monotherapy can be used (weak recommendation, low quality evidence) 299 
 300 
24. In AF patients requiring OAC undergoing elective PCI/stenting , where bleeding risk is 301 
unusually high and thrombotic risk relatively low, we suggest use of OAC plus single 302 
antiplatelet (preferably clopidogrel) for 6 months, following which OAC monotherapy can be 303 
used (weak recommendation, low quality evidence) 304 
 305 
Remark: Patients at unusually high bleeding risk may include patients with HAS-BLED ≥3 and 306 
recent acute bleeding event. High thrombotic risk may include those with left main stent, 307 
multivessel PCI/stenting, etc. 308 
 309 
25. In AF patients requiring OAC presenting with an ACS, undergoing PCI/stenting, where bleeding 310 
risk is low (HAS-BLED 0-2) relative to risk for ACS or stent thrombosis, we suggest triple 311 
therapy for 6 months, followed by dual therapy with OAC plus single antiplatelet (preferably 312 
clopidogrel) until 12 months, following which OAC monotherapy can be used (weak 313 
recommendation, low quality evidence) 314 
 315 
26. In AF patients requiring OAC presenting with an ACS, undergoing PCI/stenting, where bleeding 316 
risk is high (HAS-BLED ≥3), we suggest triple therapy for 1-3 months, followed by dual therapy 317 
with OAC plus single antiplatelet (preferably clopidogrel) up to 12 months, following which 318 
OAC monotherapy can be used (weak recommendation, low quality evidence). 319 
 320 
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27. In AF patients requiring OAC presenting with an ACS, undergoing PCI/stenting where bleeding 321 
risk is unusually high and thrombotic risk low, we suggest OAC plus single antiplatelet 322 
(preferably clopidogrel) for 6-9 months, following which OAC monotherapy can be used. (weak 323 
recommendation, low quality evidence). 324 
 325 
Remark: Patients at unusually high bleeding risk may include patients with HAS-BLED ≥3 and recent 326 
acute bleeding event. High thrombotic risk may include those with left main stent, multivessel 327 
PCI/stenting, etc. 328 
 329 
28. In AF patients with ACS or undergoing PCI in whom OAC is recommended, we suggest using 330 
VKA with TTR>65-70% (INR range 2.0-3.0), or to use a NOAC at a dose licensed for stroke 331 
prevention in AF (weak recommendation, low quality evidence).  332 
 333 
Remark: Only Dabigatran 150mg bid or (not licensed in USA) 110mg bid or Rivaroxaban 15mg qd 334 
are currently supported by clinical trial evidence. A NOAC based strategy has lower bleeding risk 335 
compared to a VKA-based strategy. 336 
 337 
29. In AF patients in which aspirin is concomitantly used with OAC, we suggest a dose of 75-100mg 338 
qd with concomitant use of PPI to minimize gastrointestinal bleeding (Weak recommendation, 339 
low quality evidence) 340 
 341 
30. In AF Patients in which a P2Y12 inhibitor is concomitantly used with OAC, we suggest the use 342 
of clopidogrel (Weak recommendation, low quality evidence) 343 
 344 
Remark: Newer agents (eg. Ticagrelor) can be considered where bleeding risk is low. Data on the 345 
combination of ticagrelor with either dabigatran 110mg bid or 150 bid (without concomitant aspirin 346 
use) are available from the RE-DUAL PCI trial. 347 
31. For patients with AF and stable coronary artery disease (eg, no acute coronary syndrome 348 
within the previous year) and who choose oral anticoagulation, we suggest OAC with either a 349 
NOAC or adjusted-dose VKA therapy alone (target international normalized ratio [INR] range, 350 
2.0-3.0) rather than the combination of OAC  and aspirin (Weak recommendation, low quality 351 
evidence) 352 
32. In patients with AF in whom catheter ablation of AF or implantation of cardiac electronic 353 
implantable devices is planned, we suggest performing the procedure on uninterrupted VKA in 354 
the INR therapeutic range, dabigatran or rivaroxaban (weak recommendation, low quality 355 
evidence). 356 
 357 
 358 
33. In patients in whom sinus rhythm has been restored, we suggest that long-term 359 
anticoagulation should be based on the patient’s CHA2DS2-VASc thromboembolic risk profile, 360 
regardless of whether sinus rhythm has been restored via ablation, cardioversion (even 361 
spontaneous), or other means (Weak recommendation, low quality evidence). 362 
 363 
 364 
34. In AF patients with acute ischaemic stroke, we suggest that very early anticoagulation (<48h) 365 
using heparinoids or VKA should not be used (ungraded consensus-based statement). 366 
 367 
Remark: Heparinoids should not be used as bridging therapy in the acute phase of ischaemic 368 
stroke because they appear to increase the risk of symptomatic intracranial haemorrhage 369 
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without net benefit. The optimal timing of anticoagulation after acute ischaemic stroke is 370 
unknown.   371 
 372 
35. In AF patients with acute stroke without contraindications, we recommend that long term oral 373 
anticoagulation is indicated as secondary prevention (Strong recommendation, high quality 374 
evidence).   375 
Remark: The optimal timing of anticoagulation early after acute ischaemic stroke is unknown. 376 
Early use of NOACs shows promise but requires testing in randomised controlled trials. 377 
 378 
36. In AF patients with acute ischaemic stroke, We suggest that oral anticoagulation should 379 
usually be started within 2 weeks of acute ischaemic stroke, but the optimal timing within this 380 
period is not known (ungraded consensus-based statement). 381 
 382 
Remark: Although infarct size is clinically used to guide timing of anticoagulation, it is predictive 383 
of a higher risk of early recurrent ischaemia, haemorrhagic transformation of the infarct, and 384 
poor outcome, so might not be helpful in determining the net benefit of early treatment. 385 
Remark: Anticoagulation with NOACs soon after stroke (earlier than 1 week) has not been tested 386 
in randomised trials, but shows promise in observational studies. 387 
 388 
37. In patients with AF and high ischaemic stroke risk, we suggest anticoagulation with a NOAC 389 
after acute spontaneous ICH (which includes subdural, subarachnoid and intracerebral 390 
haemorrhages) after careful consideration of the risks and benefits (ungraded consensus-based 391 
statement). 392 
 393 
Remark: The balance of net benefit from long term oral anticoagulation might be more 394 
favourable in those with deep ICH or without neuroimaging evidence of cerebral amyloid 395 
angiopathy. 396 
Remark: In ICH survivors with AF, clinicians should aim to estimate the risk of recurrent ICH 397 
(using ICH location and, where available, MRI biomarkers including cerebral microbleeds) and 398 
the risk of ischaemic stroke 399 
Remark: The optimal timing of anticoagulation after ICH is not known, but should be delayed 400 
beyond the acute phase (~48 hours) and probably for at least ~4 weeks. Randomised trials of 401 
NOACs and left atrial appendage occlusion are ongoing. 402 
 403 
38. In ICH survivors at high risk of recurrent ICH (e.g. those with probable cerebral amyloid 404 
angiopathy), we suggest left atrial appendage occlusion (ungraded consensus-based 405 
statement).  406 
Remark: Cerebral amyloid angiopathy should be diagnosed using validated clinico-radiological 407 
criteria. 408 
 409 
39. In patients with AF and symptomatic carotid stenosis (>50%), we suggest carotid 410 
revascularisation with endarterectomy or stenting in addition to OAC as indicated (Weak 411 
recommendation, moderate quality evidence). 412 
 413 
40. In patients with AF and carotid stenosis treated with revascularisation, we suggest OAC 414 
therapy, without long-term antiplatelet therapy (ungraded consensus-based statement). 415 
 416 
Remark: There is limited evidence to guide the optimal treatment of patients with AF and carotid 417 
stenosis not requiring revascularisation.  418 
Remark: Short-term concomitant antiplatelet therapy (dual or mono) is generally used in the 419 
immediate post-revascularisation period (e.g. 1-3 months) 420 
 421 
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41. For patients that present with a clinically documented episode of AF (12-lead ECG or other 422 
means, eg. external devices with validated rhythm detection), we suggest that the presence or 423 
absence of symptoms must not influence the process of decision making with regard to the 424 
need for anticoagulation based on risk stratification (ungraded consensus-based statement). 425 
 426 
42. In cases of AHRE (atrial high rate episodes) detected by a CIED of at least 5 min duration, we 427 
suggest that direct analysis of electrograms corresponding to AHRE is clinically indicated to 428 
exclude artifacts or other causes of inappropriate detection of atrial tachyarrhythmias or AF 429 
(ungraded consensus-based statement). 430 
 431 
Remark: In patients with CIED detected AHRE a complete cardiological evaluation is indicated, 432 
with 12-lead ECG, general assessment of clinical conditions and clinical risk stratification for 433 
stroke using CHA2DS2VASc score. 434 
Remark: There is no evidence in support or against prescription of oral anticoagulants in patients 435 
at risk of stroke (intermediate to high risk according to CHA2DS2VASc) who present with AHREs, 436 
corresponding to atrial tachyarrhythmias/AF at electrograms assessment of less than 24 hours 437 
duration. 438 
 439 
43. In patients with AF, we suggest prescription of oral anticoagulants as a result of an 440 
individualized clinical assessment taking into account overall AHRE burden (in the range of 441 
hours rather than minutes) and specifically, the presence of AHRE > 24 hours, individual stroke 442 
risk (using CHA2DS2VASc), predicted risk benefit of oral anticoagulation and informed patient 443 
preferences (ungraded consensus-based statement).   444 
 445 
Remark: In patients with CIED detected AHRE continued patient follow-up is recommended, 446 
preferentially combining clinical follow up with remote monitoring of the CIED or else more 447 
frequent device interrogation than standard for CIED follow-up, to detect the development of 448 
clinical AF (symptomatic or asymptomatic), to monitor the evolution of AHRE or AF burden and 449 
specifically the transition to AHRE lasting more than 24 hours,onset or worsening of heart 450 
failure, or any clinical change that might suggest a change in clinical profile or clinical conditions. 451 
 452 
44. For patients with atrial flutter, we suggest that antithrombotic therapy decisions follow the 453 
same risk-based recommendations as for AF. (ungraded consensus-based statement).  454 
 455 
45. For women receiving OAC for prevention of stroke/TE in AF who become pregnant, we suggest 456 
discontinuation of OAC with a VKA between weeks 6 and 12 and replacement by LMWH twice 457 
daily (with dose adjustment according to weight and target anti-Xa level 4-6 hours post-dose 458 
0.8-1.2 U/mL), especially in patients with a warfarin dose required of >5 mg/day (or 459 
phenprocoumon >3 mg/day or acenocoumarol >2mg/day). OAC should then be discontinued 460 
and replaced by adjusted-dose LMWH (target anti-Xa level 4-6 hours post-dose 0.8-1.2 U/mL) 461 
in the 36th week of gestation (ungraded consensus-based statement). 462 
 463 
46. For women on treatment with long-term vitamin K antagonists who are attempting pregnancy 464 
and are candidates for LMWH substitution, we suggest performing frequent pregnancy tests 465 
and use LMWH instead of VKA when pregnancy is achieved rather than switching to LMWH 466 
while attempting pregnancy (ungraded consensus-based statement). 467 
 468 
47. For pregnant women, we suggest avoiding the use of NOACs (ungraded consensus-based 469 
statement) . 470 
Remark: For women on treatment with a NOAC we suggest switching to vitamin K antagonists, 471 
rather than switching to LMWH while attempting pregnancy 472 
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 473 
48. For lactating women using warfarin, acenocoumarol, or UFH who wish to breastfeed, we 474 
suggest continuing the use of warfarin, acenocoumarol, LMWH or UFH (ungraded consensus-475 
based statement) 476 
 477 
49. For breast-feeding women, we suggest alternative anticoagulants rather than NOACs 478 
(ungraded consensus-based statement). 479 
 480 
 481 
50. For mild CKD (Stage II, CrCl 60-89 ml/min), we suggest that oral anticoagulation clinical 482 
decision making and treatment recommendations match that of patients without CKD (weak 483 
recommendation, very low quality evidence). 484 
 485 
51. For moderate CKD (Stage III, CrCl 30-59 ml/min), we suggest oral anticoagulation in patients 486 
with a CHA2DS2VASc ≥2 with label-adjusted NOACs or dose adjusted vitamin K antagonists 487 
(Weak recommendation, very low quality evidence). 488 
Remark: With VKA, good quality anticoagulation control (TTR>65-70%) is recommended. 489 
 490 
52. In severe non-dialysis CKD (Stage IV CrCl 15-30), we suggest using VKAs and selected NOACs 491 
(rivaroxaban 15mg QD, apixaban 2.5mg bid, edoxaban 30mg QD and (in USA only) dabigatran 492 
75mg bid) with caution, based on pharmacokinetic data (ungraded consensus-based 493 
statement). 494 
 495 
53. In end-stage renal disease (CrCl < 15 or dialysis-dependent), we suggest that individualized 496 
decision-making is appropriate (ungraded consensus-based statement). 497 
 498 
54. In end-stage renal disease (CrCl < 15 or dialysis-dependent , we suggest using well managed 499 
VKA with TTR>65-70% (ungraded consensus-based statement). 500 
 501 
Remark: NOACs should generally not be used, although in USA, apixaban 5mg bid is approved for 502 
use in AF patients receiving hemodialysis 503 
Remark: In patients with CKD who initiate OAC, concomitant antiplatelet therapy including low-504 
dose aspirin is likely to substantially elevate bleeding risk and should be used very judiciously. 505 
 506 
55. In patients with AF at high risk of ischaemic stroke who have absolute contraindications for 507 
OAC, we suggest using LAA occlusion (Weak recommendation, low quality evidence). 508 
 509 
Remark: When taking into account LAAO as a potential option, the risk of bleeding related to 510 
antiplatelets agents that need to be prescribed in the first months has to be considered and the 511 
possibility to use NOACs. 512 
 513 
56. In AF patients at risk of ischaemic stroke undergoing cardiac surgery, we suggest surgical 514 
exclusion of the LAA for stroke prevention, but the need for long term OAC is unchanged 515 
(Weak recommendation, low quality evidence). 516 
 517 
57. In AF patients taking warfarin without high risk of thromboembolism or who do not have a 518 
mechanical valve, we suggest pre-operative management without bridging (Weak 519 
recommendation, low quality evidence). 520 
 521 
58. In AF patients on antithrombotic prophylaxis with warfarin with a high risk of 522 
thromboembolism or with a mechanical valve, we suggest pre-operative management with 523 
bridging (Weak recommendation, low quality evidence). 524 
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 525 
59. In AF patients on antithrombotic prophylaxis with a NOAC, we suggest pre-operative 526 
management without bridging (Weak recommendation, low quality evidence). 527 
 528 
 529 
60. In AF patients who have previously refused OAC, we suggest reinforcing educational messages 530 
at each contact with the patient and revisit OAC treatment decisions (ungraded consensus-531 
based statement). 532 
 533 
Remark: Patient and physician treatment objectives often differ significantly and it is important 534 
to elicit from the patient what outcomes of OAC treatment are important to them. 535 
Remark: Explain the risk of stroke and benefit/risks of treatment in terms the patient can 536 
understand and signpost the patient to appropriate educational resources (see e-Table 25. 537 
INTRODUCTION 538 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, with an increasing 539 
prevalence and incidence with age.  In adults aged >40 years, there is a 1 in 4 lifetime risk of 540 
developing AF, with incident AF commonly related to various associated cardiovascular and non-541 
cardiovascular risk factors.  AF without associated valvular heart disease (so-called ‘non-valvular AF’) 542 
is associated with a five-fold increase in stroke risk (approximately 5%/year), but this risk is 543 
dependent on the presence of various stoke risk factors
1
.   Many of the risk factors leading to 544 
incident AF are also risk factors for ischemic stroke, and the promotion of an integrated or holistic 545 
approach to AF management is needed, incorporating stroke prevention, addressing symptoms and 546 
risk factor management
2
. 547 
Stroke prevention is the principal priority  in the holistic approach to AF management
1
.  Even since 548 
the last edition of the ACCP guidelines published in 2012
3
, there have been substantial 549 
developments in AF thromboproprophylaxis, whether with regard to risk assessment, 550 
antithrombotic drugs or non-drug approaches.  551 
It is clear that AF should not be considered in isolation, at the stage of detection, prevention or 552 
treatment. For example, the majority of deaths in individuals with AF are from cardiac causes, 553 
including HF, whereas stroke and bleeding represent a small subset of deaths, yet most 554 
interventions focus on stroke prevention
4
.  Thus, a more holistic approach is needed to take 555 
comorbidities and cross-disease sequelae of AF, bridging primary and secondary care
2
. 556 
Aside from stroke prevention (‘Avoid Stroke, use Anticoagulants), AF management requires patient 557 
centered and symptom directed decisions on rate or rhythm control (‘Better symptom 558 
management’) as well as ‘Cardiovascular and other risk factor, and lifestyle management’
2
.  The 559 
latter includes addressing risk factors (cardiac ischemia, heart failure, hypertension, sleep apnea, 560 
diabetes, etc.) and lifestyle (obesity, alcohol excess, stimulants etc.). This simple ABC approach 561 
(Atrial fibrillation Better Care approach) would simplify an integrated approach to AF management in 562 
a holistic manner. (Figure 1)
2
 563 
 564 
 565 
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This guideline focuses on stroke prevention and begins with a brief discussion of the methods used 566 
to develop these guidelines and the recommendations for antithrombotic therapy in patients with 567 
AF. Next, we provide our treatment recommendations, divided into the following sections:  568 
• Stroke and bleeding risk assessment 569 
• Antithrombotic therapy in patients with AF in general (includes patients with permanent, 570 
persistent, or paroxysmal AF [PAF])   571 
• Antithrombotic therapy in patients with AF in special situations:  572 
o Managing Bleeding 573 
o Antithrombotic therapy for patients with AF undergoing cardioversion  574 
o Acute coronary syndrome (ACS) and stenting 575 
o Stable coronary artery disease  576 
o Rhythm control and electrophysiological procedures 577 
o Acute ischemic stroke, ICH, ESUS, carotid disease 578 
o AHRE on devices 579 
o Chronic atrial flutter   580 
o Pregnancy 581 
o Chronic Kidney Disease 582 
o Valvular heart disease 583 
The article ends with a discussion of practical and patient-centered issues as well as suggestions for 584 
future research.  585 
 586 
METHODS 587 
Expert Panel Composition 588 
The chair of the panel (G.Y.H.L.) was appointed and subsequently reviewed and approved by CHEST’s 589 
Professional Standards Committee (PSC).  Panelists were nominated by the chair based on their 590 
expertise relative to potential guideline questions.  591 
Conflicts of Interest 592 
All panel nominees were reviewed for their potential conflicts of interest (COI) by CHEST’s PSC. After 593 
review, nominees who were found to have no substantial COIs were approved, whereas nominees 594 
with potential intellectual and financial COIs that were manageable were “approved with 595 
management”.  Panelists approved with management were prohibited from participating in 596 
discussions or voting on recommendations in which they had substantial COIs.  A grid was created 597 
listing panelists’ COIs for each recommendation for use during voting.  Of note, the chair (G.Y.H.L.) 598 
recused himself from any voting on recommendations.  The COI grid can be found in e-Table 1. 599 
Formulation of Key Questions 600 
Table 1 specifies the clinical questions being addressed in this article (in PICO [population, 601 
intervention, comparator, outcomes] format) and the types of studies included.  602 
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Consistent with the 9
th
 edition of the guideline, the outcomes most relevant to patients with AF 603 
include death, nonfatal stroke, systemic embolism, nonfatal major extracranial bleeding, and the 604 
burden and lifestyle limitations associated with outpatient antithrombotic therapy.
3
 To facilitate 605 
decision-making, the term ‘stroke’ in this guideline includes both ischemic stroke and hemorrhagic 606 
stroke, which together with systemic embolism was the principal outcome in most stroke prevention 607 
trials.  Additional considerations were all-cause and cardiovascular mortality.  For bleeding 608 
outcomes, we focused on major bleeding, which was the principal safety outcome in most stroke 609 
prevention trials.  Major bleeding included intracranial bleeding, the most severe and disabling form 610 
of anticoagulant-related bleeding. 611 
 612 
 613 
Literature Searches and Study Selection 614 
To inform our guideline development, we searched for relevant articles published since the last 615 
formal literature search performed for the Antithrombotic and Thrombolytic Therapy: American 616 
College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition) which were 617 
published in 2012
3
.  Searches were also conducted specifically for existing guidelines and systematic 618 
reviews.  In cases which existing, good quality systematic review(s) were retrieved, the results of the 619 
review informed our recommendations.  620 
Specifically, for literature regarding the assessment of stroke risk in patients with AF, we searched 621 
MEDLINE via PubMed and the Cochrane Library for articles published from October 2009, to October 622 
2017 using the search terms “atrial fibrillation,” “atrial flutter,” “risk assessment,” “risk factors,” “risk 623 
stratification,” “stroke,” and “thromboembolism.”  624 
For literature regarding prevention of stroke and thromboembolism in patients with AF, we searched 625 
MEDLINE via PubMed and the Cochrane Library for articles published from January 1, 2007, to 626 
October 2017 using the search terms “coumarins,” “warfarin,” “dicumarol,” “phenprocoumon,” 627 
“acenocoumarol,” “fondaparinux,” “idraparinux,” “aspirin,” “triflusal,” “indobufen,” “dabigatran,” 628 
“ximelagatran,” “rivaroxaban,” “apixaban,” “ticlopidine,” “clopidogrel,” “catheter ablation,” 629 
“watchman,” “PLAATO,” “cardioversion,” “atrial fibrillation,” and “atrial flutter.”  630 
Titles and abstracts of the search results were reviewed independently and in parallel to identify 631 
potentially relevant articles based on the inclusion and exclusion criteria from the PICO elements. 632 
Discrepancies were resolved by discussion.  Studies deemed eligible then underwent a second round 633 
of full-text screening following the same methodology used during title/abstract review.  Important 634 
data from each included study were then extracted into structured evidence tables. 635 
Risk of Bias Assessment 636 
The methodologist assessed the risk of bias in all included studies. The Cochrane Risk of Bias tool 637 
was used to assess the risk of bias for randomized controlled trials
5
 and the Risk of Bias in Non-638 
randomized Studies of Interventions (ROBINS-I) tool to evaluate risk of bias for observational 639 
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studies.
6
 In cases in which existing systematic reviews were available, we used the Documentation 640 
and Appraisal Review Tool to assess methodological quality.
7
  641 
Meta-Analysis 642 
When individual studies were available or an existing meta-analysis needed to be updated, we used 643 
the Cochrane Collaboration Review Manager, version 5.2
8
 to pool the results across individual 644 
studies. We used a random-effects model and the method of DerSimonian and Laird to pool the 645 
individual estimates.
9
 Relative risk (RR) was used to report the results for dichotomous outcomes 646 
and mean difference (MD) for continuous outcomes with accompanying 95% confidence intervals 647 
(CI). Statistical heterogeneity of the pooled results was assessed using the Higgins’ I
2 
and the Chi-648 
square tests. A Higgins’I
2
 value of ≥50% or Chi-square p<0.05 was considered to represent significant 649 
heterogeneity.   650 
Assessing the Overall Quality of the Evidence 651 
The overall certainty (quality) of the evidence was assessed for each critical or important outcome of 652 
interest using the GRADE approach.
10
 Evidence profiles were created using the Guideline 653 
Development Tool (GDT), which categorized the overall quality of the body of evidence into one of 654 
four levels: high, moderate, low, or very low.  655 
Drafting Recommendations 656 
The panel drafted and graded recommendations based on the results of the meta-analyses and 657 
evidence profiles. Recommendations were graded according to CHEST’s grading system which uses 658 
the GRADE approach (Table 2).
11,12
 The recommendations were either “strong” or “weak” according 659 
to this approach.  Strong recommendations use the wording “we recommend” and weak 660 
recommendations use the wording “we suggest”.  The implications of the strength of 661 
recommendation are summarized in e-Table 2. 662 
In instances in which there was insufficient evidence, but a clinically relevant area was felt to require 663 
a guiding comment, a weak suggestion was developed and “Ungraded Consensus-Based Statement” 664 
replaced the grade.
13
 665 
In developing our treatment recommendations, we attempted to account for patient values and 666 
preferences regarding these outcomes, and had two patient advocates (MTH and DAL) who 667 
participated in the panel discussion, and specifically addressed patient-centered issues.  668 
 669 
Consensus Development 670 
All drafted recommendations and suggestions were presented to the panel in an anonymous online 671 
voting survey to reach consensus and gather feedback. Panelists were requested to indicate their 672 
level of agreement on each statement based on a five-point Likert scale derived from the GRADE 673 
grid.
14
 Panelists with COIs related to the individual recommendations recused themselves from 674 
voting on those statements). Of note, the chair (G.Y.H.L.) recused himself from any voting on 675 
recommendations.  According to CHEST policy, each recommendation and statement required a 75% 676 
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voting participation rate and at least 80% consensus to “pass”. Any recommendation or suggestion 677 
that did not meet these criteria was revised by the panel based on the feedback, and a new survey 678 
that incorporated those revisions was completed.  679 
Peer Review Process 680 
Reviewers from the GOC, the CHEST Board of Regents, and the CHEST journal reviewed the methods 681 
used and the content of the manuscript for consistency, accuracy and completeness. The manuscript 682 
was revised according to feedback from the reviewers. 683 
 684 
STROKE RISK IN ATRIAL FIBRILLATION 685 
The extensive data on epidemiological burden of stroke associated with AF and well as the 686 
pathophysiology is detailed in the Online Supplement. It is beyond the scope of this document to 687 
consider the epidemiology of all comorbidities in AF.  688 
 689 
In summary, healthcare systems face increasing prevalence, incidence and lifetime risk of AF, which 690 
is as high as 1 in 4 in contemporary studies in high-income settings
15
. Epidemiologic studies largely 691 
represent Western countries and Caucasian populations
16
.  However, reported prevalence varies 692 
substantially by world region (see e-Figure 1) and with more rigorous screening methods to detect 693 
AF.  694 
 695 
Individuals with AF have increased risk of stroke (4-5 fold increase), heart failure (2-3 fold increase) 696 
and mortality (2-fold increase) (see web Supplement 1.1).   Patients with AF also experience higher 697 
rates of morbidity, hospital admissions, as well as early dementia. The high AF-attributable risk of 698 
stroke, especially in the elderly, is evident since at least one in 3 to 4 individuals with an ischemic 699 
stroke, and over 80% of those with ischemic stroke of cardioembolic subtype, also have AF
17
. Overall, 700 
non-white ethnicity shows evidence of association with lower risk of incident AF.  701 
 702 
Several of the risk factors for incident AF are also risk factors for stroke in AF. 
18
  Primary prevention 703 
strategies for AF have not been conclusively proven in randomized trials, opportunistic screening is 704 
the recommended strategy to detect AF at the population-level
19
. A systematic review of the 705 
associations of 23 cardiovascular risk factors and incident AF including 20,420,175 participants and 706 
576,602 AF events, respectively, found hypertension, obesity, taller height and coronary heart 707 
disease showed consistent, direct associations with incident AF
18
.  Ethnic differences in co-708 
morbidities in AF patients have been reported.
20-36
 Hypertension is the leading comorbid risk factor 709 
and is equally distributed in different races.  Coronary heart disease (CHD) seems more common in 710 
Caucasians and the Middle East, than in Asians. The annual risk of AF-associated stroke in Asians is 711 
higher than that in Caucasians
37
 
28
 
29
 
38
 and the risk of stroke may start to increase at a younger age 712 
in Asians.
37
  713 
 714 
Classification of AF  715 
AF is classified as paroxysmal (self-terminating within 7 days), persistent (continuous for >7 days), 716 
long-standing persistent (continuous for >1 year), or permanent (chronic). AF becomes increasingly 717 
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persistent and resistant to therapy over time, perhaps due to the development of atrial fibrosis, as 718 
well as other pathophysiological processes (e-Figure 2).  AF and atrial flutter frequently co-exist, and 719 
share similar risk factors for arrhythmia development and stroke risk
39
. Lone AF is a low risk patient 720 
group that is a diagnosis of exclusion, after ensuring no comorbidity risk factors are evident
40
.  721 
“Lone” atrial flutter (without any recognizable underlying disease), like lone AF, is also rare – only 2% 722 
of atrial flutter patients
41
. The role of anticoagulation in atrial flutter has not been assessed in clinical 723 
trials, but since individuals with atrial flutter often have concomitant AF or are at increased risk of 724 
developing AF, the risk of stroke and thromboembolism is assumed to be the same and the same risk 725 
stratification approaches are recommended. 726 
 727 
Risk factors for ischemic stroke.   728 
 729 
Clinical risk factors for ischemic stroke in AF  730 
Although AF is an independent risk factor for stroke, not all patients with AF have equal stroke risk. 731 
In order to correctly assess the risk of stroke in order to inform anticoagulation, risk prediction or 732 
stratification tools have been developed, based on the risk factors most strongly and consistently 733 
associated with stroke.   734 
 735 
A systematic review of stroke risk factors found that prior stroke or transient ischemic attack (15/16 736 
studies positive, risk ratio [RR] 2.86), hypertension (11/20 studies positive, RR 2.27), aging (9/13 737 
studies positive, RR 1.46 per decade increase), structural heart disease (9/13 studies positive, RR 2.0) 738 
and diabetes (9/14 studies positive, RR 1.62) were independent predictors of stroke. Supportive 739 
evidence was found for sex (8/22 studies positive, RR 1.67), vascular disease (6/17 studies positive, 740 
RR 2.61) and heart failure (7/18 studies positive, RR 1.85)
42
. Non-paroxysmal atrial fibrillation is 741 
associated with a highly significant increase in thromboembolism (multivariable adjusted hazard 742 
ratio 1.384, 95% CI 1.19-1.61, P < 0.001)
43
.  743 
 744 
In individuals with HF, AF is associated with worse prognosis than sinus rhythm
44,45
. HF is an 745 
independent predictor of stroke/TE, mortality and other clinical outcomes in individuals with AF, 746 
compared with no HF
46
. Moreover, HF is a predictor of development of AF and has been 747 
incorporated in tools for risk prediction of incident AF
47
.  All-cause mortality is higher in AF patients 748 
with HFrEF (HF with reduced ejection fraction) compared to HFpEF (HF with preserved ejection 749 
fraction) (RR 1.24, 95% CI 1.12-1.36, p<0.001), although stroke risk (RR 0.85, 0.70-1.03, p=0.094) and 750 
heart failure hospitalization (RR 1.21, 95% CI 0.96-1.53, p=0.115) are not significantly different
48
. 751 
 752 
Chronic kidney disease (CKD) is an independent predictor of risk of stroke/thromboembolism. AF 753 
patients with estimated glomerular filtration rate <60 mL/min compared with those with estimated 754 
glomerular filtration rate ≥60 mL/min have increased risk of stroke/thromboembolism (RR 1.62, 95% 755 
CI, 1.40-1.87; p<0.001), with a 0.41% (0.17%-0.65%) annual increase in rate for a 10 mL/min 756 
decrease in renal function
49
. The risk is higher in individuals requiring renal replacement therapy (HR 757 
1.83; 95% CI, 1.57 to 2.14; p<0.001). There is also increased risk of bleeding in individuals with AF 758 
and CKD, compared with those without CKD.
50
 Conversely, AF is associated with increased risk of 759 
chronic kidney disease (CKD) (RR 1.64, 1.41-1.91)
51
. The clinical relevance of renal function is not 760 
only for risk prediction, but also for choice of anticoagulation and other therapies
52-54
 (See Atrial 761 
Fibrillation and Chronic Kidney Disease section).  762 
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 763 
Over the last decade, rigorous detection strategies have shown that prevalence of AF in cryptogenic 764 
stroke is likely to be as high as 30%
55
. A systematic review and meta-analysis after transient ischemic 765 
attack (TIA) has shown a pooled AF detection rate for all methods of 4% (95% CI: 2-7%)
56
.    766 
 767 
Echocardiographic risk factors  768 
The role of echocardiography in evaluation before cardioversion or ablation, and in predicting the 769 
presence of left atrial (LA) appendage thrombus is dealt with in sections ‘Cardioversion’ and 770 
‘Catheter or Surgical Ablation, Electrophysiological Procedures’. There may also be a role in 771 
evaluating thromboembolic risk stratification to select appropriate antithrombotic therapy. e-Table 772 
4 summarizes major studies which have shown an association between transthoracic 773 
echocardiographic (TTE) parameters and ischemic stroke.  However, there are very limited data to 774 
suggest that there would be any incremental clinical benefit in risk prediction, and moreover there is 775 
no evidence that management (in terms of OAC) would be changed
57
.    776 
 777 
Nevertheless, the most consistent independent predictor of ischemic stroke on TTE is the presence 778 
of moderate-severe LV systolic dysfunction. In patients undergoing transesophageal 779 
echocardiography (TEE), LA appendage thrombi
58
 and LA spontaneous echo contrast
59
 are both 780 
associated with increased thromboembolism, as well as the presence of low LA appendage velocities 781 
and complex aortic plaque; however, the same limitations as for TTE parameters apply
57
.  782 
 783 
Biomarkers 784 
e-Table 5 summarizes important studies involving currently available biomarkers (‘biological 785 
markers’) that have shown associations with stroke and thrombosis in AF, but both study design and 786 
scale of the studies limit possible conclusions. Caveats with the use of these biomarkers include the 787 
inter- and intra- patient and assay variability, some have a diurnal variation and can be highly 788 
influenced by associated comorbidities and drug therapies.  Many biomarkers are non-specific for a 789 
particular endpoint, and can be equally predictive not only of stroke but bleeding, death, 790 
hospitalization, heart failure etc., as well as non-cardiac conditions e.g., glaucoma.  791 
 792 
The importance of biomarkers probably lies in the ‘very low risk’ strata of clinical scores (e.g., 793 
CHA2DS2VASc= 0-1 group) where they may influence the decision to anticoagulate, yet there are 794 
limited data available in these patients. There are several other hurdles including variations in 795 
availability in healthcare systems, biomarker assays, access to laboratories, biomarkers diurnally, by 796 
comorbidities and by anticoagulation and other therapies.  For these reasons, the clinical application 797 
of biomarkers in management of AF is unlikely to be significant. 798 
 799 
Other potential novel risk factors for ischemic stroke in AF 800 
As with established risk factors, novel risk factors may improve prediction of thromboembolic risk in 801 
AF patients, where current risk scores are suboptimal
60
. These novel factors include clinical risk 802 
factors (e.g., burden of AF), serum biomarkers (e.g., NT-proBNP), imaging (e.g., left atrial fibrosis on 803 
cardiac MRI) and echocardiography (e.g., left atrial volume index and longitudinal strain). However, 804 
these factors are currently neither proven to significantly add to risk prediction, nor likely to 805 
influence the decision to anticoagulate.  806 
 807 
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 808 
Risk stratification for stroke and thromboembolism in AF  809 
 810 
A comparison of features included in various published stroke risk stratification schemes in AF is 811 
shown in e-Table 6.  A summary of studies comparing the various stroke risk stratification schema is 812 
available in e-Table 7.  The risk stratification scheme commonly used in many guidelines is the 813 
CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, 814 
stroke/transient ischemic attack/thromboembolism [doubled], vascular disease [prior myocardial 815 
infarction (MI), peripheral arterial disease (PAD), or aortic plaque], age 65-74 years, sex category 816 
[female]) score
1
.    817 
 818 
All risk schemes based on clinical risk factors have broadly similar predictive value for ‘high risk’ 819 
patients who sustain stroke and TE events (all c-indexes approx. 0.60-0.65).   Adding more and more 820 
clinical variables and complexity (i.e., simple versus more complex clinical risk scores) would only 821 
modestly increase the c-index to approximately 0.65-0.70.  Many score comparisons focus on 822 
identification of ‘high risk’ and do not focus on ‘low risk end of the spectrum’ and so are not helpful 823 
for decision-making on whether to anticoagulate or not. 824 
 825 
Event rates per score point varies according to study setting, ethnicity, cohort, and community  vs. 826 
hospitalized population etc (as might be expected)
61
. Also, reported events depends on use of highly 827 
selected clinical trial cohort vs. ‘real world’ unselected, and anticoagulated vs. non-anticoagulated 828 
patients
62
.    Mortality rates from observational cohorts may also include fatal strokes as 829 
postmortems are not mandated, outcomes are non-adjudicated (as in clinical trials) and cerebral 830 
imaging is not performed.  Analytical methodology matters and outcomes depend on thresholds for 831 
treatment, varying risk profile during the study (which this does not remain static) and statistical 832 
analysis methods
63
. Some analyses which exclude patients on anticoagulants are flawed by 833 
‘conditioning on the future’ methodology, and follow-up can be dependent on continuation in a (US) 834 
healthcare plan. 835 
 836 
Ethnic differences are also evident in stroke risk related to AF. In a Taiwanese cohort, the risk of 837 
stroke was 1.78%/year in patients aged 50-64 years and a CHA2DS2-VASc 0.
64
 The risk exceeds the 838 
threshold for OAC use for stroke prevention. A modified CHA2DS2-VASc (mCHA2DS2-VASc) score has 839 
been proposed, assigning one point for patients aged 50 to 74 years.
65
 The mCHA2DS2-VASc score 840 
performed better than CHA2DS2-VASc score in predicting ischemic stroke assessed by C indexes and 841 
net reclassification index. For patients having an mCHA2DS2-VASc score of 1 (males) or 2 (females) 842 
because of the resetting of the age threshold, use of warfarin was associated with a 30% lower risk 843 
of ischemic stroke and a similar risk of ICH compared with no-treatment. Net clinical benefit analyses 844 
also favored the use of warfarin in different weighted models. These findings suggest that the age-845 
based treatment threshold for stroke prevention may need to be reset in East Asians.
65
 846 
 847 
Adding biomarkers would (statistically) improve prediction but c-indexes are still approximately 848 
0.65-0.70.  Recent studies in real world cohorts do not support the clinical usefulness of biomarker-849 
based scores over clinical risk scores such as the CHA2DS2VASc score.  The use of biomarkers have to 850 
balance the assay availability, lab variability, costs and added complexity and lower practicality for 851 
everyday use.   Also, many biomarker studies are based on anticoagulated highly selected clinical 852 
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trial cohorts, with all included subjects already in the high risk group (CHA2DS2VASc or CHADS2 score 853 
of 2 or greater).   There are few/no studies on non-anticoagulated AF patients, to ascertain the true 854 
impact of biomarkers on (non-anticoagulation treated) stroke rates. Current studies do not inform 855 
whether the biomarkers will discriminate/identify low risk in lower/intermediate risk patients who 856 
are not anticoagulated.   857 
 858 
Rather than focus on identifying ‘high risk’, the focus should be on initially identifying ‘low risk’ 859 
patients.  A ‘low risk’ categorization by the CHA2DS2-VASc (0 in males and 1 in females) consistently 860 
identifies low risk patients, with event rates around 1%/year or under, notwithstanding the possible 861 
need to re-categorize the age 65-74 criterion in Asians
65
. 862 
 863 
The majority of published studies and systematic reviews suggest that the CHA2DS2VASc score is 864 
generally better than CHADS2, ATRIA and CHADS65 in identifying ‘low risk’ patients, although the 865 
proportion of the population assigned as low risk is small. However, there are conflicting data in 866 
different cohorts for performance of the ATRIA score (UK CPRD and Swedish cohorts vs Danish and 867 
Taiwan cohorts). Differences between the ATRIA and CHA2DS2VASc disappear when cut-points are 868 
optimized for stroke risk of the cohort.  There are discrepancies between individual studies on the 869 
relative performance of ATRIA and CHA2DS2VASc scores in identifying low risk patients, but the 870 
CHA2DS2VASc score is easier to calculate. 871 
 872 
Rather than using risk scores in a categorical manner - recognizing the various limitations of scores 873 
to predict ‘high risk’ patients that sustain events - and given that for each risk strata or given risk 874 
score point, we recognized there is wide variation in reported event rates based on reported study 875 
clinical setting, patient population, ethnicity etc.  Notwithstanding that the default should be stroke 876 
prevention for all AF patients unless deemed to be ‘low risk’, the focus should be to use scores to 877 
initially identify ‘low risk’ patients who do not need antithrombotic therapy, rather than focus on 878 
identification of ‘high risk’ patients. Prior guidelines have also opted for the CHA2DS2VASc score to 879 
define a low risk group.  880 
 881 
The ‘C’ in CHA2DS2-VASc refers to recent decompensated heart failure, irrespective of the ejection 882 
fraction (thus including heart failure with reduced ejection fraction (HFrEF) or preserved ejection 883 
fraction (HFpEF)) or the presence of moderate-severe LV systolic impairment on cardiac imaging, 884 
whether symptomatic or asymptomatic.  The ‘H’ refers to history of hypertension or uncontrolled 885 
blood pressure, while ‘S’ refers to stroke, systemic embolism or a confirmed diagnosis of transient 886 
ischemic attack (TIA). ‘V’ refers to complicated vascular disease, including myocardial infarction or 887 
peripheral artery disease, or if performed, the presence of complex aortic plaque on TEE.  Female 888 
sex (Sc criterion) is only relevant as a risk modifier if age>65 or additional associated risk factors are 889 
present, given that at females age <65 with no other risk factors are not at excess stroke risk
66
. 890 
Stroke risk is also dynamic, and risk should be re-assessed at every patient contact.  This was seen in 891 
a study where the ‘delta CHA2DS2VASc score’, representing the change in stroke risk between 892 
between baseline and followup) was the best predictor for ischaemic stroke
67
.     893 
 894 
A stepwise approach to thromboprophylaxis would allow initial identification of low risk using 895 
CHA2DS2VASc (Step 1), following which stroke prevention can be offered to all others (Step 2) 896 
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irrespective of stroke point score or biomarkers used.  This would approach uses stroke risk scores in 897 
a reductionist manner to aid decision-making, and balances simplicity and practicality (and costs). 898 
 899 
 900 
Recommendations 901 
 902 
1. For patients with AF, including those with paroxysmal AF, stroke risk should be assessed using 903 
a risk factor based approach, rather than an categorisation into low, moderate/high risk 904 
strata. We recommend use of the CHA2DS2VASc as a simple clinical based stroke risk score to 905 
initially identify ‘low stroke risk’ patients that should not be offered antithrombotic therapy to 906 
prevent stroke and reduce mortality (Strong recommendation, moderate quality evidence).  907 
Remark: Low risk patients are generally those age<65 and ‘lone AF’ irrespective of sex (this 908 
includes those with a CHA2DS2VASc score=0 in males, or 1 in females).  909 
 910 
2. Subsequent to this initial step, for patients with AF, including those with paroxysmal AF, 911 
stroke prevention should be offered to those AF patients with one or more non-sex 912 
CHA2DS2VASc stroke risk factors (score of ≥1 in a male or ≥2 in a female)  (Strong 913 
recommendation, moderate quality evidence).  914 
Remark: Consideration of other less established clinical stroke risk factors, imaging (cardiac or 915 
cerebral) or biomarkers (urine, blood or genetics) may refine risk stratification based on simple 916 
clinical factors. A complex risk schema using a variety of such data that could accurately place 917 
more patients in the low risk stratum not requiring anticoagulants than current simple clinically-918 
based scores (personalised medicine) should be the goal of future research, but it will be very 919 
difficult to find non-anticoagulated patient cohorts for prospective validation. 920 
 921 
 922 
BLEEDING RISK IN ATRIAL FIBRILLATION 923 
Observational studies 924 
The rates of major bleeding on VKA among observational cohorts are shown in e-Table 8 and 925 
demonstrate highly variable rates, ranging from 1.4%/year
68,69
 to 10.4%/year.
70
  Nevertheless, there 926 
is significant heterogeneity between the study population characteristics, the inclusion of inception 927 
versus ‘experienced’ OAC cohorts, significant disparity in the exposure period (follow-up) and 928 
differences in the definitions of major bleeding employed.  In addition, information on the specific 929 
risks of bleeding of the individual cohorts, using a validated bleeding risk score are lacking, the 930 
definitions of major bleeding were often not provided and the quality of anticoagulation, such as 931 
TTR, is generally lacking. Therefore, direct comparison of the rates of major bleeding on VKA 932 
between observational cohorts and with RCTs is problematic.  933 
 934 
Clinical trials 935 
The definitions of major bleeding are available in most clinical trials, especially in the NOACs trials 936 
where ISTH definitions were used.
71
 Before the NOAC era, the rates of major bleeding due to VKA 937 
were generally in the range of 1% to 3% per year  (e-Table 9). In the 5 NOAC trials,
72-76
 the annual 938 
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rates of major bleeding of warfarin were between 3% to 4% (Table 2). Data from NOACs trials are 939 
more reliable, because patients were randomized to treatment, the majority were double-blinded 940 
and the quality of anticoagulation (such as TTR) was generally better than observational studies. The 941 
risk of major bleeding on NOACs, especially the low-dose regimen (dabigatran 110 mg and edoxaban 942 
30 mg), was generally lower than that on warfarin, except in the ROCKET AF trial.
73
  943 
 944 
Risk factors for bleeding with NOAC, VKA and antiplatelet therapy   945 
 946 
Numerous risk factors for bleeding among AF patients receiving antithrombotic therapy have been 947 
identified and incorporated into bleeding risk scores (see Section on Bleeding Risk Score).  Bleeding 948 
risk varies from person to person depending on their pre-existing comorbidities, current 949 
antithrombotic regimen and adherence, concomitant medication, and lifestyle choices.  Many of 950 
these factors cannot be altered but some are modifiable or potentially modifiable (see Figure 2).  In 951 
order to reduce antithrombotic-treatment associated bleeding it is important to recognize that 952 
bleeding risk is also dynamic and should be reassessed at every patient review.  While modifiable 953 
bleeding risk factors that can be changed or managed should clearly be addressed as part of a 954 
holistic approach to AF patient assessment and management, non-modifiable bleeding risks are 955 
important drivers of bleeding events when occurring synergistically with modifiable ones
77
.  An 956 
approach to bleeding risk assessment soley based only on modifiable bleeding risk factors is an 957 
inferior assessment strategy compared to use of a formal bleeding risk score
78-80
. 958 
 959 
Blood pressure control 960 
Good control of blood pressure is vital to reduce the risk of stroke and is essential to decrease the 961 
risk of bleeding on antithrombotic therapy; adherence to current guidelines on the management of 962 
hypertension should be followed. 963 
 964 
Anticoagulation control 965 
Among patients receiving VKA, maintenance of an INR in the therapeutic range (2.0-3.0) is essential.  966 
The proportion of time spent in this range (TTR) should be at least 65% but the ultimate aim/target 967 
should be 100% (see Optimal INR target range section). The risk of bleeding increases when the INR 968 
exceeds 3.0, particularly for ICH risk when INR >3.5.
81-86
.  969 
 970 
INR control can potentially be improved by more frequent monitoring and review of factors 971 
influencing INR control (diet-, alcohol-, and drug-interactions).  There is evidence that improving 972 
patient education about INR control,
87
 INR management by dedicated anticoagulation clinics with 973 
experienced personnel,
88-90
 and self-monitoring/self-management in selected patients
91
 can increase 974 
TTR.  Increasing patient’s awareness of the importance of OAC medication adherence and the 975 
potential bleeding risks associated with over-dose are also essential to minimize bleeding 976 
complications.  977 
 978 
Concomitant medication pre-disposing to bleeding 979 
Non-essential use of concomitant anti-platelet drugs and NSAIDs should be avoided since these 980 
medications increase the risk of bleeding in patients receiving OAC.  Where concomitant anti-981 
platelet therapy is necessary (i.e. post-coronary stent implantation), the duration of combination 982 
OAC and anti-platelet drugs should be kept to the minimum.
92
  Since anti-platelet drugs/NSAIDs are 983 
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widely available over-the-counter, patients need to be made aware of the bleeding risk associated 984 
with their use in combination with OAC. 985 
 986 
Alcohol intake 987 
Excessive alcohol intake (chronic or binge-drinking) increases the risk of bleeding predominantly due 988 
to the risk of trauma, but in chronic alcohol abuse through poor medication adherence, hepatic and 989 
variceal disease. OAC should not initiated among patients consuming alcohol in excess >14U/week. 990 
There is no clear definite threshold where bleeding risk is increased.  Patients also need to be made 991 
aware of the potential dangers associated with excessive alcohol consumption in combination with 992 
OAC/antithrombotic therapy. 993 
 994 
Lifestyle factors 995 
Avoidance of work and/or leisure activities that have the potential to cause serious trauma (e.g. 996 
contact sports, rock-climbing, occupations working at height or operating heavy machinery) should 997 
be advised. 998 
 999 
Bridging periods off anticoagulation 1000 
Interruption of OAC should be avoided to reduce stroke risk since the majority of cardiovascular 1001 
procedures (e.g., pacemaker implantation or percutaneous coronary intervention) can be safely 1002 
performed on OAC.  Bridging (that is, stopping OAC and providing anticoagulation cover with 1003 
heparin) should be used in patients with mechanical heart valves but does not appear to be 1004 
otherwise advantageous.
93,94
. 1005 
 1006 
Appropriate choice of OAC  1007 
Choice of OAC should be made on an individual basis after stroke and bleeding risk assessment and 1008 
discussion with the patient.  Before a NOAC is initiated, the patient’s age, body weight and renal 1009 
function should be considered to allow for appropriate dose adaptation where necessary.  1010 
 1011 
Falls risk and cognitive impairment 1012 
In frail patients and those at high risk of falls an individual risk assessment needs to be undertaken 1013 
prior to OAC initiation.  In cases where the risk is that of mechanical falls, strategies to improve 1014 
walking/reduce risk of tripping should be explored (i.e. walking aids, appropriate footwear, home 1015 
review to remove trip hazards), whereas neurological assessment is warranted if falls are 1016 
unexplained.  The benefits of ischaemic stroke reduction generally outweigh the risk of harm from 1017 
serious bleeding with OAC use; one estimate was that the patient would need to fall 295 times per 1018 
year for the risk from falls to outweigh the benefits of stroke reduction
95
. In patients with cognitive 1019 
impairment or dementia, OAC should only be withheld if there is no available caregiver who can 1020 
guarantee medication adherence.  1021 
 1022 
Reversal of biochemical anomalies 1023 
Patients with anemia or reduced platelet count or function should be treated where possible to 1024 
improve their Hb or platelet count.  Causes of renal impairment should be investigated and where 1025 
possible reversed.  1026 
 1027 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 25
Patients with liver function abnormalities were generally excluded from the randomised trials, and 1028 
especially where there is abnormal clotting tests, such patients may be at higher risk of bleeding on 1029 
VKA, possibly less so on NOACs; in cirrhotic patients, ischaemic stroke reduction may outweigh 1030 
bleeding risk 
96,97
.   1031 
 1032 
Bleeding risk assessment   1033 
 1034 
Since 2006, six risk scores have been developed and validated for the assessment of bleeding risk in 1035 
AF populations.
98-103
 The number of risk factors included in the bleeding risk schemas varies 1036 
considerably, from three
101
 to 12
103
 and the score or weighting associated with each risk factor also 1037 
differs (see Table 2).   1038 
 1039 
Age and prior bleeding are included as risk factors in all six bleeding risk scores but different age cut-1040 
offs are utilized, with three scores employing age 75 years or older
99,100,102
 to indicate greater 1041 
bleeding risk. Following age and prior bleeding, the most prevalent bleeding risk factors included in 1042 
the scores are anemia,
99-103
 renal disease,
98-100,102
 hypertension
99,103
 or uncontrolled systolic blood 1043 
pressure,
98
 concomitant anti-platelets,
98,102,103
 and alcohol excess,
98,100,103
 and prior stroke
98,100
 or 1044 
hepatic disease.
98,100
  A variety of other risk factors including cancer,
103
 labile INR,
98
 genetic factors,
100
 1045 
falls risks,
100
 female sex,
103
 diabetes mellitus,
103
 and biomarkers
101
 are included only in one bleeding 1046 
risk score. For a comprehensive review of bleeding risk factors in AF patients see Zulkifly et al.
104
 1047 
 1048 
The bleeding risk scores range in the simplicity of calculation and the cut-offs employed to indicate 1049 
low, intermediate and high-risk of bleeding, and the prevalence of bleeding events reported in the 1050 
validation cohorts (see Table 2).   1051 
 1052 
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Table 2: Risk factors, risk categories and bleeding events in the validation cohorts [partly reproduced with permission from Zukifly et al
104
] 1053 
 1054 
 
 
 
Risk score 
 
 
 
Risk factors (score for each factor) 
 
Risk categories 
Bleeding events in validation 
cohort (per 100 patient years) 
 
Low 
 
Intermediate 
 
High 
 
Low 
 
Intermediate 
 
High 
ABC
101
 Age(†); Biomarkers (†) (GDF-15 or cystatin C/CKD-EPI, cTnT-hs, & 
Hb); Previous bleed (†) 
<1% 1-2% >3% 0.62 1.67 4.87 
ORBIT
102
 Age ≥75 (1); ↓Hb/Hct/anemia (2); Bleeding history (2); ↓ renal 
function (1); APT (1) 
0-2 3 ≥4 2.4* 4.7 8.1 
ATRIA
99
 Anemia (3); Severe renal disease (3); Age ≥75 (2); Prior bleed (1); 
Hypertension (1) 
0-3 4 5-10 0.83 2.41 5.32 
HAS-BLED
98
 ↑SBP (1); Severe renal/hepa\c disease (1 each); Stroke 
(1);Bleeding (1); Labile INR (1); Age >65 (1); APT/NSAIDs (1); 
Alcohol excess (1) 
0-1 2 ≥3 1.02-
1.13 
1.88 ≥3.74 
HEMORR2HAGES
100
 Hepatic/renal disease (1); Ethanol abuse (1); Malignancy; Age 
>75 (1); ↓Plt (1); Re-bleeding risk (2); ↑BP (1); Anemia (1); 
Genetic factors (1); ↑ falls risk (1); Stroke (1) 
0-1 2-3 ≥4 1.9-2.5 5.3-8.4 10.4-
12.3 
Shireman et al
103
 Age ≥70 (0.49);  Female (0.31); Previous bleed (0.58); Recent 
bleed (0.62); Alcohol/drug abuse (0.71); DM (0.27); Anemia 
(0.86); APT (0.32) 
≤1.07 >1.07/ <2.19 ≥2.19 0.9%
 a
 2.0%
 a
 5.4%
 a
 
APT = antiplatelet therapy; BP = blood pressure; cTnT-hs = Troponin T; DM = diabetes mellitus; GDF-15 = growth differentiation factor-15; Hb = hemoglobin; 1055 
Hct = hematocrit; INR = international normalised ratio; Plt = platelet count or function; SBP = systolic blood pressure 1056 
* bleeding event in original derivation cohort; 
a
 at 3 months; ↓ reduced/decreased; ↑ elevated/increased; † score for each variable in ABC score is based 1057 
on a nonogram (see reference
101
) 1058 
  1059 
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Use of bleeding risk scores 1060 
As seen in Table 2 above, there are multiple bleeding risk scores that have been proposed for 1061 
bleeding risk stratification, with the HEMORR2HAGES, HAS-BLED, ATRIA, ORBIT and ABC-bleeding 1062 
derived and validated in AF populations
104
.  The risk factors included vary by scores [Table 2], and 1063 
their derivation from selected clinical trial cohorts or ‘real world’ populations
104
.  Various validation 1064 
studies have been summarized in e-Table 10. 1065 
Unsurprisingly, stroke risk scores are also associated with bleeding, as stroke and bleeding risks 1066 
correlate with each other.  For example, higher CHADS2 and CHA2DS2-VASc scores are also associated 1067 
with greater bleeding risk, but the HAS-BLED score outperforms the CHADS2 and CHA2DS2-VASc 1068 
scores for predicting serious bleeding
105,106
, which was also evident in the systematic review by Zhu 1069 
et al
107
.  Composite risk scores that include stroke and bleeding endpoints have also been proposed 1070 
but have not been shown to perform incrementally better over the individual scores
108,109
.  The 1071 
bleeding risk scores in AF are also predictive of bleeding in non-AF populations, for example, in 1072 
patients with ACS undergoing PCI-stenting
110
. 1073 
Adding more clinical variables marginally improves the predictive value (at least statistically) but the 1074 
c-indexes still remain approx. 0.6.  The addition of biomarkers would all improve the c-indexes (to 1075 
approx. 0.65) over scores based on clinical risk factors alone.  Many of these risk scores have been 1076 
derived from highly selected clinical trial cohorts, and biomarkers measured at baseline (or within a 1077 
few months of study entry) then endpoints determined many years later.  Biomarkers are also 1078 
expensive, and may be subject to laboratory variability, inter-assay differences, diurnal variation and 1079 
may change in individual patients depending on how risk factors and drug treatments change over 1080 
time. Many biomarkers (e.g. troponin, natriuretic peptides, inflammatory markers, coagulation 1081 
markers, etc.) are also predictive of stroke, bleeding, death, heart failure, hospitalization 
111
and even 1082 
non-cardiovascular conditions such as (for example, as in the case of GDF-15 used in the ABC-bleed 1083 
score) glaucoma progression
112
. The performance of biomarker-based scores in real world clinical 1084 
practice (outside highly selected trial cohorts) has also been disappointing
113,114
, given that baseline 1085 
(or near-baseline) determination of biomarkers to predict bleeding risks after many years is 1086 
bedeviled by the changing clinical risk profile of patient’s risks as well as modification of risk factors.   1087 
Given that modifiable bleeding risk factors should be addressed in all patients, the appropriate and 1088 
responsible way to use a clinical risk score is to identify those patients at particularly high risk, for 1089 
appropriate early review and follow-up (e.g. in 4 weeks, rather than 4-6 months) – and depending on 1090 
the outcome of interest, to address the associated modifiable risk factors accordingly [Figure 2].   A 1091 
high bleeding risk score is not a reason to withhold OAC, as the net clinical benefit is even greater in 1092 
those patients with high bleeding risk.   1093 
While bleeding risk is highly dynamic and depends on many potentially modifiable bleeding risk 1094 
factors
115
, simply focusing on bleeding risk assessment using modifiable bleeding risk factors alone is 1095 
an inferior strategy compared to using a validated bleeding risk score which has been designed to 1096 
formally assess bleeding score
78-80
. 1097 
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A comparison of the different bleeding risk scores has been addressed in 2 systematic reviews and 1098 
the studies are summarized in e-Table 10.  As with stroke risk scores, most bleeding risk scores based 1099 
on simple clinical risk factors only have modest predictive value for identifying the high risk patients 1100 
that sustain events (c-indexes approx. 0.6).   1101 
The systematic review by Caldera et al
116
 reported that the sensitivity, specificity and diagnostic odds 1102 
ratio (DOR) were respectively 0.53 (0.52–0.54), 0.65 (0.65–0.65) and 2.11 (1.91–2.35) for HAS-BLED, 1103 
and 0.27 (0.26–0.27), 0.89 (0.89–0.89) and 2.90 (2.77–3.04) for HEMORR2HAGES. When comparing 1104 
HAS-BLED with ATRIA, sensitivity, specificity, and DOR were respectively 0.41 (0.35–0.48), 0.78 1105 
(0.76–0.79) and 2.22 (1.08–4.55) for HAS-BLED, and 0.23 (0.17–0.29), 0.91 (0.90–0.91) and 1.98 1106 
(1.29–3.03) for ATRIA.  They concluded that HAS-BLED, due to its sensitivity (compared to other 1107 
scores) and ease to apply, is recommended for the assessment of AF patients’ major bleeding risk.  1108 
The systematic review by Zhu et al
107
 (11 studies) found that discrimination analysis demonstrates 1109 
that HAS-BLED has no significant C-statistic differences for predicting bleeding risk in the low (risk 1110 
ratio [RR]: 1.16, 95% confidence interval [CI]: 0.63-2.13, P = 0.64) risk stratification but under 1111 
predicts risk in the moderate (RR: 0.66, 95% CI: 0.51-0.86, P = 0.002) and high (RR: 0.88, 95% CI: 1112 
0.70-1.10, P = 0.27) risk strata (e-Table 11).  Zhu et al
107
 concluded that the HAS-BLED score 1113 
performed better than the HEMORR2HAGES and ATRIA bleeding scores, but was superior to the 1114 
CHADS2 and CHA2DS2-VASc stroke scores for bleeding prediction. In a real world AF cohort, there was 1115 
no long term advantage of the ABC-bleeding score over the HAS-BLED score, for predicting bleeding; 1116 
in contrast, HAS-BLED was better in identifying those patients at low risk of bleeding 
114
.  1117 
Given that the patient pathway may include AF patients initially on no antithrombotic therapy, 1118 
aspirin or anticoagulants, and the latter can include VKA or NOACs, a bleeding risk score needs to be 1119 
applicable throughout the patient pathway.  The HAS-BLED score has been validated in AF patients 1120 
from clinical trial and non-trial cohorts, whether on no antithrombotic therapy, aspirin or 1121 
anticoagulants, VKA or non-VKA anticoagulants, and is predictive of bleeding in AF and non-AF 1122 
cohorts, and in different ethnic groups 
115,117,118
.    It is also the only bleeding score predictive of 1123 
intracranial bleeding
119
.  1124 
The HAS-BLED score has also been shown to be similar or out-perform older bleeding scores, as well 1125 
as more simple bleeding scores that include less clinical parameters. Amongst VKA-treated patients, 1126 
the non-consideration of TTR would also mean that the HEMORR2HAGES, ORBIT and ATRIA scores 1127 
would all perform sub-optimally in VKA-treated patients
120,121
. Finally, bleeding risk assessment is 1128 
dynamic, and should be formally reassessed and recorded at every patient contact.  Indeed, follow-1129 
up HAS-BLED or 'delta HAS-BLED score' was more predictive of major bleeding compared with 1130 
baseline HAS-BLED or the simple determination of 'modifiable bleeding risk factors
77
.   1131 
Recommendations 1132 
 1133 
3. For patients with AF, bleeding risk assessment should be performed in all patients with AF at 1134 
every patient contact and should initially focus on potentially modifiable bleeding risk factors 1135 
(Strong recommendation, low quality evidence). 1136 
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Remark: Modifiable risk factors may include: Uncontrolled blood pressure, Labile INRs (in a 1137 
patient taking VKA), Alcohol excess; Concomitant use of NSAIDs or aspirin, in an anticoagulated 1138 
patient, bleeding tendency or predisposition (e.g. treat gastric ulcer, optimise renal or liver 1139 
function etc.). 1140 
 1141 
4. For patients with AF, we recommend use of the HAS-BLED score to address modifiable 1142 
bleeding risk factors in all AF patients. Those potentially at high risk (HAS-BLED score ≥3) 1143 
warrant more frequent and regular reviews or follow-up (Strong recommendation, moderate 1144 
quality evidence). 1145 
Remark: Given that bleeding risk is highly dynamic, attention to modifiable bleeding risk factors 1146 
should be prioritized during every patient contact or review. 1147 
 1148 
5. In VKA treated patients, we recommend use of the HAS-BLED score for bleeding risk 1149 
assessment (Weak recommendation, low quality evidence) 1150 
Remark: A high HAS-BLED score (≥3) is rarely a reason to avoid anticoagulation. The individual 1151 
modifiable components of the score, when reviewed with the patient, can serve to ameliorate 1152 
bleed risk 1153 
 1154 
ANTITHROMBOTIC THERAPY AND OTHER APPROACHES FOR STROKE 1155 
PREVENTION   1156 
 1157 
The principal goal of OAC in AF is to reduce the risk of stroke and systemic embolism, while 1158 
minimizing the incremental bleeding risk associated with OAC.  Although these outcomes may be in 1159 
part mechanistically related to lower risk of bleeding and ischemic stroke compared to therapies in 1160 
the control arms, cardiovascular composite or survival outcomes presently do not reflect the primary 1161 
rationale for therapy.  1162 
 1163 
Randomized trials 1164 
Vitamin K antagonists compared to placebo or control  1165 
In a meta-analysis of 2900 subjects from six randomized trials, adjusted-dose warfarin was 1166 
associated with a 64% relative risk reduction in stroke (95% CI, 49%-74%) (e-Table 12). The absolute 1167 
risk reduction was 2.7%/year (from 4.5%/year in controls) in primary prevention subjects and 1168 
8.4%/year (from 12%/year in controls) in secondary prevention subjects.
122
 1169 
Aspirin and antiplatelet therapy compared to placebo or control  1170 
In a meta-analysis of 8 trials of 4876 subjects, antiplatelet therapy compared to control or placebo 1171 
was associated with a 22%  (95% CI 6-35%) relative risk reduction in stroke (e-Table 13).
122
 The 1172 
Stroke Prevention in AF (SPAF-I) study demonstrated decrease in risk of stroke from 6.3%/year in 1173 
placebo subjects to 3.6%/year (95% CI 9-63%)
123
, but a meta-analysis of 7 trials of 3990 subjects 1174 
found no significant benefit.  SPAF-I was the only trial suggestive of a benefit for aspirin compared to 1175 
placebo, but there was internal heterogeneity between the anticoagulation-eligible and 1176 
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anticoagulation-ineligible subgroups, and given the trial was stopped early, the effect size could have 1177 
been exaggerated.  Aspirin also showed no benefit in the elderly, or in preventing severe strokes.  All 1178 
these trials had significant heterogeneity in study design, variability in aspirin dose tested, short 1179 
follow-up, and predated contemporary use of oral anticoagulation in AF.  1180 
 1181 
The ACTIVE-A trial, which also predated the investigation of NOACs, compared aspirin plus 1182 
clopidogrel versus aspirin monotherapy among patients in whom VKA was unsuitable.
124
 The study 1183 
found a decrease in risk of stroke with dual antiplatelet therapy, but the major bleeding rates with 1184 
aspirin-clopidogrel were comparable to rates seen with warfarin (approx. 2%/year). 1185 
Vitamin K antagonists compared to antiplatelet therapy  1186 
Of 12 studies comparing warfarin to antiplatelet therapy, warfarin was associated with a 39% 1187 
relative risk reduction (95% CI, 22%-52%) in strokes (e-Table 14).
122
 In ACTIVE-W, the largest of these 1188 
studies, warfarin was superior to dual antiplatelet therapy to warfarin for stroke and a 1189 
cardiovascular composite outcome, with similar rates of major bleeding.
125
 1190 
Non-VKA oral anticoagulants (NOACs) compared to vitamin K antagonists  1191 
Several NOACs that directly inhibit thrombin (factor IIa) or activated factor X (factor Xa) have been 1192 
approved as alternatives to VKAs for stroke prevention in AF. They differ from VKAs in that they have 1193 
a rapid onset/offset of action, absence of an effect of dietary vitamin K intake on their activity and 1194 
fewer drug interactions. The predictable anticoagulant effects of the NOACs enable their 1195 
administration in fixed doses without the need for routine coagulation monitoring, thereby 1196 
simplifying therapy.   1197 
 1198 
Individually in their respective phase 3 trials (Table 3), dabigatran, rivaroxaban, apixaban, and 1199 
edoxaban have been shown to be at least as safe and effective as warfarin for preventing stroke and 1200 
systemic embolism in patients with AF.
73,74,76,126
  1201 
 1202 
A meta-analysis of the four phase 3 trials compared patients taking NOACs (higher-dose) (n=42,411) 1203 
with warfarin (n=29,272) (e-Table 15).
127
 NOACs significantly reduced stroke or systemic embolic 1204 
events by 19% compared with warfarin (RR 0.81; 95% CI 0.73-0.91; p<0.0001). The benefit was 1205 
driven primarily by a 51% reduction in hemorrhagic stroke (RR 0.49; 95% CI 0.38-0.64; p<0.0001). 1206 
Ischemic stroke was similar between NOACs and warfarin. (RR 0.92; 95% CI 0.83-1.02; p=0.10). 1207 
NOACs were also associated with a significant 10% reduction in all-cause mortality (RR 0.90; 95% CI 1208 
0.85-0.95; p=0003).  With regards to safety, NOACs were associated with a non-significant 14% 1209 
reduction in major bleeding (RR 0.86; 95% CI 0.73-1.00; p=0.06) but a substantial 52% reduction in 1210 
intracranial hemorrhage (RR 0.48; 95% CI 0.39-0.59; p<0.0001), NOACs were, however, associated 1211 
with a significant increase in GI bleeding (RR 1.25; 95% CI 1.01-1.55; p=0.04). The relative efficacy 1212 
and safety of NOACs was consistent across all patient subgroups with the exception that the relative 1213 
reduction in major bleeding with NOACs was greater at centers with poor INR control as defined as a 1214 
center-based time in therapeutic range <66% (RR 0.69, 95% CI 0.59-0.81; p-interaction=0.02).  1215 
 1216 
Lower-dose NOAC regimens (dabigatran 110 mg and edoxaban 30/15 mg) showed similar overall 1217 
reductions in stroke or systemic embolism but a more favorable bleeding profile than warfarin but 1218 
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were associated with more ischemic strokes [the lower-dose regimen edoxaban 30/15 mg is not 1219 
approved for the stroke prevention indication]. 1220 
 1221 
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Table 3: Phase 3 AF trials of NOAC versus warfarin – Summary of key efficacy and safety results 1222 
 Trial 
 RE-LY 
 
 
ROCKET-AF  ARISTOTLE ENGAGE AF-TIMI 48 
Outcome 
Dabigatran 
150 mg 
(n=6076) 
Dabigatran 
110 mg 
(n=6015) 
Warfarin 
(n=6022) 
Rivaroxaban 
20/15 mg 
(n=7131) 
Warfarin 
(n=7133) 
Apixaban 
5/2.5 mg 
(n=9120) 
Warfarin 
(n=9081) 
Edoxaban 
60/30 mg 
(n=7035) 
Edoxaban 
30/15 mg 
(n=7034) 
Warfarin 
(n=7036) 
Efficacy           
Stroke/SEE           
Event Rate (%/year) 1.11 1.54 1.71 2.1 2.4 1.27 1.60 1.57 2.04 1.80 
HR (95% CI) 
0.72  
(0.58-0.90) 
0.90  
(0.74-1.10) 
NA 
0.88  
(0.75-1.03) 
NA 
0.79  
(0.65-0.95) 
NA 
0.87  
(0.73-1.04) 
1.13  
(0.96-1.34) 
NA 
p-value 0.004 0.29 NA 0.12 NA 0.01 NA 0.08 0.10 NA 
Ischemic Stroke           
Event Rate (%/year) 0.92 1.34 1.22 1.34 1.42 0.97 1.05 1.25 1.77 1.25 
HR (95% CI) 
0.76  
(0.59-0.97) 
1.11 
 (0.88-1.39) 
NA 
0.94  
(0.75-1.17) 
NA 
0.92  
(0.74-1.13) 
NA 
1.00  
(0.83-1.19) 
1.41  
(1.19-1.67) 
NA 
p-value 0.03 0.35 NA 0.58 NA 0.42 NA 0.97 <0.001 NA 
Hemorrhagic Stroke           
Event Rate (%/year) 0.10 0.12 0.38 0.26 0.44 0.24 0.47 0.26 0.16 0.47 
HR (95% CI) 
0.26  
(0.14-0.49) 
0.31  
(0.17-0.56) 
NA 
0.59  
(0.37-0.93) 
NA 
0.51  
(0.35-0.75) 
NA 
0.54  
(0.38-0.77) 
0.33  
(0.22-0.50) 
NA 
p-value <0.001 <0.001 NA 0.02 NA <0.001 NA <0.001 <0.001 NA 
MI           
Event Rate (%/year) 0.81 0.82 0.64 0.91 1.12 0.53 0.61 0.70 0.89 0.75 
HR (95% CI) 
1.27  
(0.94-1.71) 
1.29  
(0.96-1.75) 
NA 
0.81  
(0.63-1.06) 
NA 
0.88  
(0.66-1.17) 
NA 
0.94  
(0.74-1.19) 
1.19  
(0.95-1.49) 
NA 
p-value 0.12 0.09 NA 0.12 NA 0.37 NA 0.60 0.13 NA 
All-Cause Death           
Event Rate (%/year) 3.64 3.75 4.13 1.87 2.21 3.52 3.94 3.99 3.80 4.35 
HR (95% CI) 
0.88  
(0.77-1.00) 
0.91  
(0.80-1.03) 
NA 
0.85  
(0.70-1.02) 
NA 
0.89  
(0.80-1.0) 
NA 
0.92  
(0.83-1.01) 
0.87  
(0.79-0.96) 
NA 
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p-value 0.05 0.13 NA 0.07 NA 0.047 NA 0.08 0.006 NA 
Safety           
Major Bleeding           
Event Rate (%/year) 3.32 2.87 3.57 3.6 3.4 2.13 3.09 2.75 1.61 3.43 
HR (95% CI) 
0.93  
(0.81-1.07) 
0.80  
(0.70-0.93) 
NA 
1.04  
(0.90-1.20) 
NA 
0.69  
(0.60-0.80) 
NA 
0.80  
(0.71-0.91) 
0.47  
(0.41-0.55) 
NA 
p-value 0.31 0.003 NA 0.58 NA <0.001 NA <0.001 <0.001 NA 
ICH           
Event Rate (%/year) 0.32 0.23 0.76 0.5 0.7 0.33 0.80 0.39 0.26 0.85 
HR (95% CI) 
0.41 (0.28-
0.60) 
0.30 (0.19-
0.45) 
NA 
0.67  
(0.47-0.93) 
NA 
0.42  
(0.30-0.58) 
NA 
0.47  
(0.34-0.63) 
0.30  
(0.21-0.43) 
NA 
p-value <0.001 <0.001 NA 0.02 NA <0.001 NA <0.001 <0.001 NA 
GI Bleeding           
Event Rate (%/year) 1.56 1.15 1.07 2.0 1.24 0.76 0.86 1.51 0.82 1.23 
HR (95% CI) 
1.48 (1.18-
1.85) 
1.08 (0.85-
1.38) 
NA 
1.66 (1.34-
2.05) 
NA 
0.89  
(0.70-1.15) 
NA 
1.23  
(1.02-1.50) 
0.67  
(0.53-0.83) 
NA 
p-value 0.001 0.52 NA <0.001 NA 0.37 NA 0.03 <0.001 NA 
RE-LY: Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY); ROCKET AF: Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 1223 
Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; ARISTOTLE: Apixaban for Reduction in Stroke and 1224 
Other Thromboembolic Events in Atrial Fibrillation;  ENGAGE AF-TIMI 48: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - 1225 
Thrombolysis In Myocardial Infarction study 48. 1226 
 1227 
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NOACs vs. Aspirin  1228 
Apixaban is the only NOAC that has been compared with aspirin in AF patients. The Apixaban vs. 1229 
Acetylsalicyclic Acid to Prevent Strokes (AVERROES) trial compared apixaban 5 mg twice daily with 1230 
aspirin in AF patients who were not candidates for VKA therapy.
128
 The trial was stopped early for 1231 
benefit as apixaban significantly reduced the risk of stroke or systemic embolism compared with 1232 
aspirin (hazard ratio 0.45, 95% CI 0.32-0.62; p<0.001) (e-Table 16). There was no significant 1233 
difference in major bleeding (hazard ratio 1.13, 95% CI 0.74-1.75; p=0.57) between apixaban and 1234 
aspirin. 1235 
 1236 
Real World Observational Data  1237 
 1238 
With the availability of large health care system administrative data and the advent of quality 1239 
improvement and post-marketing anticoagulation registries, the number of observational outcome 1240 
studies on OAC in AF far outnumber randomized trials. Although these data have helped to 1241 
successfully identify treatment variation and gaps in care, the use of these data for comparative 1242 
effectiveness and safety studies of OACs must be interpreted with prudence. Despite the use of 1243 
sophisticated, high-quality methods to minimize confounding and bias and improve causal inference, 1244 
even very small amounts of residual confounding by treatment selection or measurement error can 1245 
attenuate or amplify the small absolute risk differences observed in the randomized trials.  1246 
 1247 
Similarly, definitive conclusions cannot be drawn from indirect comparisons such as network meta-1248 
analysess of NOACs to each other due to small absolute risk differences. Real-world or observational 1249 
data are generally insufficient to guide selection of individual anticoagulant drugs. Therefore, 1250 
observational data are best used to reaffirm that real-world effectiveness is in concordance with 1251 
clinical trial efficacy, based on both quality of care and generalizability.
129 2016
 1252 
 1253 
A meta-analysis of real-world observational studies of dabigatran was consistent with findings from 1254 
RE-LY. Compared to VKA, risk of stroke with dabigatran versus warfarin was 1.65 vs. 2.85 per 100 1255 
patients-years (HR 0.86, 95% CI 0.74-0.99).
130
 Dabigatran was also associated with a lower risk of 1256 
intracranial bleeding (HR 0.45, 95% CI 0.38-0.52) and lower risk of death (HR 0.73, 95% CI 0.61-0.87). 1257 
Risk of gastrointestinal bleeding was higher.  1258 
 1259 
One systematic review and meta-analysis provided comparative effectiveness and safety data for 1260 
rivaroxaban vs. dabigatran (n=3 trials), rivaroxaban vs. warfarin (n=11 trials) or both (n=3 trials) for 1261 
stroke prevention in AF
131
. Overall, the risk of stroke/systemic thromboembolism (TE) with 1262 
rivaroxaban were similar compared with dabigatran, but were significantly reduced when compared 1263 
to warfarin (HR 0.75, 0.64-0.85). Major bleeding risk was significantly higher with rivaroxaban vs. 1264 
dabigatran (HR 1.38, 1.27-1.49), but similar to warfarin (HR 0.99, 0.91-1.07). Rivaroxaban was 1265 
associated with increased all-cause mortality and gastrointestinal bleeding (GIB), but similar risk of 1266 
acute myocardial infarction (AMI) and intracranial hemorrhage (ICH) compared with dabigatran. 1267 
When compared with warfarin, rivaroxaban was associated with similar risk of any bleeding, 1268 
mortality and AMI, but a higher risk of GIB and lower risk of ICH.  1269 
 1270 
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Another large analysis of three Danish nationwide databases of 61,678 patients found that NOACs 1271 
were at least as safe and effective as warfarin, with small but significant differences in risk of stroke, 1272 
death, and bleeding across rivaroxaban, apixaban, and dabigatran.
132
  However, a new-user FDA 1273 
Medicare analysis of 118,891 patients found that rivaroxaban compared to dabigatran had a 1274 
statistical trend towards a decreased risk of stroke (HR 0.81, 95% CI 0.65-1.01) and significantly 1275 
increased risk of intracranial (HR 1.47, 95% CI 1.32-1.67) and major non-intracranial bleeding (HR 1276 
1.48, 95% CI 1.32-1.67).
133
  Absolute risk differences were small (2.0-2.1 per 1000 person-years) and 1277 
well within a range vulnerable to confounding.   1278 
 1279 
Different Ethnic Groups  1280 
Asian AF patients have a higher risk of intracranial hemorrhage compared with Caucasians when 1281 
VKAs are used.
134
 The higher risk of bleeding on VKA in Asians vs. non-Asians has also been observed 1282 
in major clinical trials of NOACs,
135
 even though Asians received a lower intensity of anticoagulation 1283 
with VKA.
136
  1284 
 1285 
In a recent meta-analysis comprising 5 NOAC trials (RE-LY, ROCKET AF, J-ROCKET AF, ARISTOTLE, and 1286 
ENGAGE AF), the effects of NOACs versus warfarin in Asians vs non-Asians were compared.
137
 For 1287 
standard-dose NOACs (dabigatran 150 mg, rivaroxaban 20 mg, apixaban 5 mg, and edoxaban 60 mg), 1288 
the effect sizes of the primary efficacy endpoint (stroke and SE) and the primary safety endpoint 1289 
(major bleeding) were greater in Asians versus non-Asians.  The risk reduction in hemorrhagic stroke 1290 
and GI bleeding was also greater in Asians vs. non-Asians. These data suggest that standard-dose 1291 
NOACs, when compared with warfarin, were more effective and safer in Asians than in non-Asians. 1292 
The efficacy and safety of low-dose NOACs (dabigatran 110 mg, rivaroxaban 15 mg, and edoxaban 30 1293 
mg), when compared with warfarin, appears similar among Asians and non-Asians.  1294 
 1295 
There are several real-world studies from Asia comparing NOACs with warfarin
138,139
.  Despite low-1296 
dose NOACs, such as dabigatran 110 mg or rivaroxaban 15 mg/10 mg being more commonly used 1297 
than standard-dose NOACs (dabigatran 150 mg or rivaroxaban 20 mg), the use of NOACs were 1298 
associated with reduced risk of ischemic stroke or systemic embolization, major bleeding, ICH, and 1299 
total mortality compared with warfarin.  Published data suggest that NOACs are preferentially 1300 
indicated for stroke prevention in Asians.
37
    1301 
 1302 
  1303 
Other Investigational Drugs  1304 
 1305 
Although NOACs are safer than VKAs, serious bleeding still occurs. The potential for bleeding often 1306 
discourages initiation of anticoagulant therapy in patients deemed to be at high risk of bleeding and 1307 
patients who experience a bleed frequently have permanent or prolonged discontinuation of their 1308 
anticoagulant. Therefore, continued interest remains in developing even safer anticoagulants than 1309 
thrombin and factor Xa inhibitors. Current investigation has focused on the upstream targets factor 1310 
XI and factor XII in the contact pathway as emerging research has elucidated their critical role in 1311 
thrombosis with minimal or no role in hemostasis.
140-142
 Strategies to target FXII or FXI include 1312 
antisense oligonucleotides that reduce hepatic synthesis of the clotting proteins, monoclonal 1313 
antibodies that block activation or activity, aptamers, small molecules that block the active site or 1314 
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induce allosteric modulation, and polyanion antagonists that attenuate contact activation by 1315 
nullifying stimulators of the pathway.
7
 1316 
 1317 
Human data are limited. The factor XI-directed antisense oligonucleotide IONIS-416858 was 1318 
compared with enoxaparin in 300 patients undergoing elective knee arthroplasty. Patients were 1319 
randomized to IONIS-416858 at doses of 200 or 300 mg starting 35 days prior to surgery, or 1320 
enoxaparin at a dose of 40 mg starting after the surgery. The 200 mg IONIS-416858 regimen was 1321 
non-inferior and the 300 mg IONIS-416858 regimen was superior compared with enoxaparin in 1322 
preventing the composite endpoint of asymptomatic deep venous thrombosis (DVT), symptomatic 1323 
DVT or pulmonary embolism, or venous thromboembolism related mortality.
143
 The rates of major 1324 
or clinically relevant non-major bleeding were 3% in both IONIS-416858 groups and 8% in the 1325 
enoxaparin group. With respect to patients with AF, potential unmet needs addressed by these 1326 
agents include patients at high risk for bleeding, such as those with end stage renal disease who are 1327 
on hemodialysis (phase 2 study ongoing https://clinicaltrials.gov/ct2/show/NCT02553889.  Another 1328 
area of interest is in patients with mechanical heart valves. Data from a phase II trial of dabigatran in 1329 
patients with mechanical heart valves (RE-ALIGN) demonstrated inferior efficacy and more bleeding, 1330 
compared to warfarin.
144
 FXI-directed strategies may be very effective in this setting because FXI 1331 
depletion abolished mechanical valve induced thrombin generation in vitro.
143
  1332 
Recommendations  1333 
6. For patients with AF, we recommend against antiplatelet therapy alone (monotherapy or 1334 
aspirin in combination with clopidogrel) for stroke prevention alone, regardless of stroke risk 1335 
(Strong recommendation, moderate quality evidence). 1336 
Remark: Patients with AF might have other indications for antiplatelet drugs (e.g. acute coronary 1337 
syndrome, stents) 1338 
 1339 
7. In patients with AF who are eligible for OAC, we recommend NOACs over VKA (strong 1340 
recommendation, moderate quality evidence). 1341 
Remark: Patient and caregiver preferences, cost, formulary considerations, anticipated 1342 
medication adherence or compliance with INR testing and dose adjustment should be 1343 
incorporated into clinical-decision making. 1344 
 1345 
8. In patients on VKAs with consistently low time in INR therapeutic range (eg. TTR<65%), we 1346 
recommend considering interventions to improve TTR or switching to NOACs (strong 1347 
recommendation, moderate quality evidence) 1348 
Remark:  Action required if TTR <65% - implement additional measures (more regular INR tests; 1349 
review medication adherence; address other factors known to influence INR control; 1350 
education/counselling) to improve INR control. 1351 
 1352 
 1353 
9. In patients with prior unprovoked bleeding, warfarin-associated bleeding, or at high risk of 1354 
bleeding, we suggest using apixaban, edoxaban, or dabigatran 110 mg (where available) as all 1355 
demonstrate significantly less major bleeding compared with warfarin (Weak 1356 
recommendation, very low quality evidence).  1357 
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Remark: In patients with prior gastrointestinal bleeding apixaban or dabigatran 110mg bid may 1358 
be preferable as they are the only NOACs not associated with an increased risk of 1359 
gastrointestinal bleeding compared with warfarin. 1360 
Remark: Dabigatran 150 mg twice daily recommended in patients at high risk of ischemic stroke 1361 
as only agent/dose with superior efficacy compared with warfarin. However, bleeding risk would 1362 
need to be assessed and patients monitored. 1363 
 1364 
ADJUSTED-DOSE ORAL VITAMIN K ANTAGONIST THERAPY 1365 
The vitamin K antagonists (VKA) are a class of oral anticoagulants; the most commonly used are the 1366 
4-hydroxycoumarins, and include warfarin, phenprocoumon and acenocoumarol.
145
 Less commonly 1367 
used VKAs are phenindione and fluindione which are 1,3-indandione derivatives.  Geographical 1368 
variation in VKA popularity is evident, with warfarin commonly used worldwide, but acenocoumarol 1369 
being popular in Spain and phenprocoumon in Germany. In randomized clinical trials, most have 1370 
used warfarin.   1371 
Optimal INR target range in AF 1372 
 1373 
For stroke prevention in patients with AF receiving a VKA the optimal INR target range is 2.0 to 1374 
3.0,
146
 aiming for an INR value of 2.5 to maximize the proportion of time spent in the therapeutic INR 1375 
range.  Numerous observational studies of AF patients have demonstrated that the risk of 1376 
thromboembolism/ischemic stroke is greater when INR is <2.0
81,83,85,147-149
 whereas INR levels >3.0 1377 
are associated with a greater incidence of major bleeding, especially intracranial hemorrhage when 1378 
the INR rises above 3.5.
81-86
 All the phase III NOAC trials employed an INR target of 2.0-3.0 among 1379 
patients receiving warfarin;
73,76,126,128
 J-ROCKET employed a lower INR target of 1.6-2.6 for the 1380 
Japanese population.
150
  1381 
 1382 
In some Asian countries, there is the perception that a lower target INR range e.g., 1.6-2.6 should be 1383 
used, especially in the elderly.  Only one small prospective randomized trial allocated 115 secondary 1384 
prevention AF patients to conventional-intensity group (INR 2.2 to 3.5) or a low-intensity group (INR 1385 
1.5 to 2.1).
151
 Major hemorrhagic complications occurred in 6 patients in the conventional-1386 
intensity group (6.6% per year) compared to the low-intensity group (0% per year, P=0.01).   Other 1387 
Asian registries have suggested that low intensity (INR 1.5-2.5) was associated with less bleeding, 1388 
but no information on quality of INR control was reported. There is currently no robust evidence for 1389 
implementing a target INR range of 1.6-2.6, and therefore the conventional, evidence-based INR 1390 
target of 2.0-3.0 should be employed globally. 1391 
 1392 
Importance of time in therapeutic INR range 1393 
 1394 
The proportion of time spent within the therapeutic INR range (INR 2.0 to 3.0) is intrinsically linked 1395 
to the risk of adverse events. The temporal pattern of INR control is most commonly calculated using 1396 
the Rosendaal method of linear interpolation between two consecutive INR values,
152
 known as the 1397 
time in therapeutic range (TTR) or by the percentage of INRs within therapeutic range (PINRR).
153
 1398 
However, a limitation of the Rosendaal method of interpolation is that INRs more than 42 days apart 1399 
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have generally not been interpolated in studies due to large uncertainties in fluctuation. Although 1400 
TTR and PINRR are highly correlated
154,155
 they are not equivalent and should not be used 1401 
interchangeably. TTR is a widely accepted and validated measure of anticoagulation control and 1402 
predicts adverse events in patients receiving VKA
155-157
 and is the quality and performance measure 1403 
of choice for specialized anticoagulation clinics. 1404 
 1405 
Numerous studies have demonstrated that the risk of thromboembolism, major bleeding, and death 1406 
is lower when the proportion of TTR is higher, at least ≥65%. 
127,155-157
  Indeed, random ‘one off’ INR 1407 
values give little insight into the degree of anticoagulation control, and many adverse outcomes 1408 
(e.g., bleeding) occur even within the therapeutic INR range of 2.0-3.0.
158
 Thus, when VKAs are used 1409 
attention should be focused on the average individual TTR as a measure of the quality of 1410 
anticoagulation control. 1411 
 1412 
Clinical guidelines on the management of AF advocate an individual TTR of at least ≥65%
159,160
 to 1413 
maximize efficacy and safety and this should be the treatment target, although in clinical practice 1414 
this may be more difficult to achieve.
155-158,161
  An analysis of anticoagulation control in the 1415 
GARFIELD-AF registry (n=9934), a global observational study, revealed that only 41.1% had TTR ≥65% 1416 
and of all the INR values only 51.4% were in the therapeutic range (INR 2.0 to 3.0), with one-third 1417 
being sub-therapeutic.
157
 After adjustment, the risk of stroke/systemic embolism (HR 2.55. 95% 1.61 1418 
to 4.03), all-cause mortality (HR 2.39, 95% CI 1.87 to 3.06) and major bleeding (1.54, 95% CI 1.04 to 1419 
2.26) was greater with TTR <65%, when compared to TTR ≥65%.
157
  1420 
 1421 
TTR varies widely by geographical region (TTR≥65% Asia 16.7%, North America 45.9%, Europe 1422 
49.4%).
157
 An analysis of individual TTR from Swedish registries (n=40,449) revealed an overall mean 1423 
individual TTR (iTTR) of 68.6% and significantly lower annual rates of thromboembolism (2.37% vs. 1424 
4.41%), all-cause mortality (1.29% vs. 4.35%) and major bleeding (1.61% vs. 3.81%) when iTTR was 1425 
≥70% compared to iTTR<70%, respectively.
156
   1426 
 1427 
Recommendation 1428 
 1429 
10. For patients with non-valvular AF, when VKAs are used, we suggest the target should be INR 1430 
2.0-3.0, with attention to individual TTR, ideally ≥70% (ungraded consensus-based statement). 1431 
Remark:  Action required if TTR sub-optimal (<65-70%) - implement additional measures (more 1432 
regular INR tests; review medication adherence; address other factors known to influence INR 1433 
control; education/counselling) to improve INR control or consider a NOAC. 1434 
Remark: When possible, experienced specialized anticoagulation clinics should be utilized for 1435 
VKA and INR management. 1436 
 1437 
 1438 
Factors affecting INR control 1439 
 1440 
Many factors affect TTR, including patient-related aspects (such as age, sex, socioeconomic status, 1441 
diet, ethnicity, hospitalization, length of time on VKA, medical and psychiatric co-morbidities, non-1442 
adherence, polypharmacy, genetic factors, etc.)
145,158,162
 and healthcare system-related factors, 1443 
particularly how VKA is managed (by country, setting of OAC management eg. anticoagulation clinic 1444 
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vs. physician/community-based practices),
90,163,164
 distant to OAC clinic,
163,164
 self-monitoring/self-1445 
management,
91
 frequency of INR monitoring etc.
158
  It is also important to note that site level 1446 
variation in VKA management has also been demonstrated in RCTs
165-169
 and for NOACs.
170
  The value 1447 
of dietary measures to improve anticoagulation control is debatable, and it is perhaps more relevant 1448 
to maintain a stable dietary habit, avoiding wide changes in the intake of vitamin K
171
. Amongst 1449 
patients initiating VKA, the ‘Time to achieve Therapeutic Range’ (TtTR) has also been related to the 1450 
likelihood of achieving a subsequently good Time in Therapeutic Range (TTR)
172,173
. 1451 
 1452 
The more common clinical factors influencing TTR have been used to formulate the SAMe-TT2R2 1453 
score
174,175
 (Table 5).  This clinical score is based on routine clinical parameters which can be used to 1454 
identify patients who may be able to attain good anticoagulation control (e.g. TTR≥65%) with a VKA 1455 
and those who probably will not, where a NOAC may be preferred or where other interventions (eg. 1456 
more frequent INR monitoring, patient education/counselling etc.) may need to be implemented to 1457 
ensure good INR control. Many of the factors included in the SAMe-TT2R2 score have been 1458 
associated with decreased adherence with NOACs and in the absence of trial data is not clear if 1459 
these patients would do substantially better on a NOAC or if they would do poorly anyway.    1460 
 1461 
Table 5: The SAMe-TT2R2 score
174,175
 1462 
 1463 
 1464 
 1465 
 1466 
 1467 
 1468 
 1469 
 1470 
 1471 
 1472 
 1473 
 1474 
 1475 
 1476 
 1477 
The SAMe-TT2R2 score has been assessed in 15 exclusively AF cohorts,
176-187
 with six
177,179,181,182,185,188
 1478 
reporting its predictive ability to forecast good or poor anticoagulation control, with c-statistics 1479 
ranging from 0.56
182
 to 0.72.
174
 However, these cohorts were predominantly elderly, Western 1480 
(white) populations and its predictive ability in non-Western populations has relatively limited data 1481 
as only three studies have assessed it,
176,177
, with only one reporting c-statistics (c-statistic 0.54, 95% 1482 
CI 0.52 to 0.57).
177
  In the multi-ethnic non-Caucasian Singaporean population by Bernaitis et al
176
 1483 
the SAMe-TT2R2 score was able to dichotomize the patients likely to do well on VKA, compared to 1484 
those (score >2) more likely to achieve poor TTR.  In the Loire Valley AF project, the SAMe-TT2R2 1485 
score was predictive of labile INR in AF patients who were VKA users, and was significantly 1486 
associated with the adverse consequences of labile INR, including stroke, serious bleeding and 1487 
death; the score was non-predictive in non-VKA users
189
.  The score has also been tested in some 1488 
VTE populations, where it similarly identifies patients likely to achieve a good TTR.
190,191
 1489 
 1490 
Acronym Risk factors Points 
S Sex (female) 1 
A Age (<60 years) 1 
Me Medical history (≥2 from: hypertension, diabetes mellitus, 
coronary artery disease/myocardial infarction, peripheral 
arterial disease, congestive heart failure, previous stroke, 
pulmonary disease, and hepatic or renal disease) 
 
1 
T Treatment (interacting drugs, e.g., amiodarone) 1 
T Tobacco use (within 2 years) 2 
R Race (non-Caucasian) 2 
Maximum score 8 
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Patients with AF who require OAC should not have to fail with a VKA before they are offered a 1491 
NOAC; the most appropriate OAC based on the patient’s individual risk profile and patient 1492 
preference, should be offered from the beginning of OAC therapy.  However, in some healthcare 1493 
systems where the patient has to have a period on VKA and their TTR determined, before a decision 1494 
to use a NOAC is approved, the SAMe-TT2R2 score could be used to aid decision-making
175
. 1495 
 1496 
Recommendation 1497 
11. For patients with AF, we suggest the SAMe-TT2R2score to aid decision making to help identify 1498 
patients likely to do well on VKA (ungraded consensus-based statement). 1499 
Remark: Those with score 0-2 are likely to achieve a good TTR.  Those with score >2 are less 1500 
likely to achieve a good TTR and would require more regular INR checks, education/counselling 1501 
and frequent follow-up, or alternatively, a NOAC should be considered as a better management 1502 
option if high medication adherence can be expected. 1503 
 1504 
 1505 
Monitoring anticoagulant therapy 1506 
 1507 
Point-of-care testing 1508 
There is an increasing demand for oral anticoagulation among AF patients
192
 and not all patients are 1509 
suitable for NOACs, therefore a large proportion requires VKA which necessitates INR monitoring. 1510 
Point-of-care (POC) testing using a coagulometer (INR monitor) is more convenient and time-1511 
efficient, particularly where patient’s self-monitor and/or self-manage. Home or clinic POC 1512 
monitoring is an increasingly standard method of INR monitoring associated with an appropriate 1513 
degree of precision and accuracy for clinical practice,
193
 however routine calibration is warranted 1514 
and quality control systems should adhere with the FDA Medical devices regulation guidance
194
.  1515 
 1516 
Patient self-monitoring and self-management 1517 
A recent Cochrane review
91
 evaluating the effect of self-monitoring or self-management of OAC 1518 
therapy compared to standard OAC monitoring on thromboembolic events, major bleeding and 1519 
death revealed a significant decrease in thromboembolic events overall (RR 0.58, 95% CI 0.45 to 1520 
0.75; 7594 participants in 18 studies) and with both self-monitoring (RR 0.69, 95% CI 0.49 to 0.97; 1521 
4097 participants in 7 studies) and self-management (RR 0.47, 95% CI 0.31 to 0.70; 3497 participants 1522 
in 11 studies), although not all patients were AF. There was no overall reduction in the risk of death 1523 
(RR 0.85, 95% CI 0.71 to 1.01, 6358 participants in 11 studies), however self-management did reduce 1524 
all-cause mortality (0.55, 95% CI 0.36 to 0.84; 3058 participants in 8 studies). Neither self-monitoring 1525 
nor self-management reduced the risk of major bleeding compared to standard OAC monitoring (RR 1526 
0.95, 95% CI 0.80 to 1.12; 8018 participants in 20 studies).  Rating of the quality of evidence was low 1527 
to moderate and the findings should be interpreted accordingly. 1528 
 1529 
The advantages of self-monitoring and self-management include convenience and freedom for the 1530 
patient, patient empowerment/control over their condition and treatment, increased patient 1531 
satisfaction, all of which may improve quality of life. However, this approach may not be a viable 1532 
option for all patients requiring VKA therapy as it is initially expensive, requires mastery of the point-1533 
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of-care device and for those self-managing, the knowledge and ability to dose-adjust, plus the 1534 
appropriate healthcare system infrastructure and patient support which may not be feasible 1535 
globally.  For many AF patients, a NOAC might be a more suitable alternative. 1536 
 1537 
PRACTICAL PATIENT MANAGEMENT ALGORITHM 1538 
The approach to stroke prevention in patients with AF can be simplified into a simple 3-step 1539 
algorithm (Figure 4).  The initial step is to determine the risk of stroke.  As noted in the Stroke Risk 1540 
section, risk scores for stroke in patients with AF lack specificity, and are therefore not clinically 1541 
useful in identifying and categorizing high-risk patients.  As noted in the stroke risk section, we 1542 
recommend the use of the CHA2DS2-VASc score given its superior sensitivity and ability to accurately 1543 
and safely identify patients at low risk of stroke.  Patients that are low risk (a score of 0 in males, 1 in 1544 
females) do not require antithrombotic treatment. 1545 
 1546 
All AF patients with ≥ 1 stroke risk factors are candidates for stroke prevention with oral 1547 
anticoagulation.  At this point it is important to assess the bleeding risk.  Although the benefit of 1548 
stroke prevention outweighs the risk of bleeding in almost all patients, calculation of the bleeding 1549 
risk allows the practitioner to identify potentially modifiable factors that elevate the bleeding risk 1550 
(uncontrolled hypertension, concomitant use of antiplatelet or nonsteroidal agents, excessive 1551 
alcohol intake; poor INR control (TTR<65%) in VKA patients).  In addition, patients identified as high 1552 
risk for bleeding should be scheduled for more frequent follow-up and monitoring.  As noted in the 1553 
bleeding risk section, we make a consensus suggestion that the HAS-BLED score be used for this 1554 
purpose, so those with a HAS-BLED score ≥3 can be flagged up for this reason. 1555 
 1556 
The final decision point is to decide which oral anticoagulant to use for stroke prevention.  As noted 1557 
in AT therapy and other approaches to stroke prevention, we recommend one of the NOACs 1558 
(dabigatran, apixaban, edoxaban, or rivaroxaban) as first line in patients with AF.  These agents have 1559 
not been compared head to head, and we therefore do not recommend one over the other.  Local 1560 
availability, cost, and patient co-morbidities might be considerations in choosing an agent (see Table 1561 
6) for comparative information.  The vitamin K antagonists are still widely used and are an 1562 
acceptable alternative with target TTR≥70%.  As outlined in the section ‘Factors affecting INR 1563 
control’, we recommend that the SAMe-TT2R2 score be used to help identify patients likely to do well 1564 
on VKA therapy. 1565 
 1566 
 1567 
 1568 
 1569 
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Table 6. A simplified schema to assist physician choice of anticoagulant (VKA or individual NOAC) according to patient characteristics.  1570 
 1571 
A= apixaban. BID=twice daily. CrCl=creatinine clearance. D= dabigatran. E=edoxaban. GI=gastro-intestinal. ICH= intracranial hemorrhage. INR= international normalised 1572 
ratio. NOAC=non-vitamin K antagonist oral anticoagulant. R=rivaroxaban. SE= systemic embolism. TIA= transient ischemic attack. TTR=time in therapeutic range. 1573 
Patient characteristic Possible OAC 
choice 
References to 
RCT subgroup 
data 
References 
to real world 
data or 
indirect 
evidence 
Comments 
• Recurrent ischemic stroke/SE/TIA despite good anticoagulation 
control (TTR≥70%).  Consider agent with superior efficacy for 
preventing both ischemic and hemorrhagic stroke   
 
D150 
 
127
 
130
 In general, any NOAC would be 
recommended, esp. where warfarin 
control suboptimal (TTR<65%). Ensure 
good adherence and avoid under-dosing 
• Moderate-severe renal impairment CrCl 15-49 ml/min 
 
A* D† E30 R15 
127
 
195
 All RCTs excluded patients with Cockroft-
Gault CrCl <30ml/min (<25mls/min, for 
apixaban) 
• High risk of GI bleeding 
 
A D110 
127
 
130,196
  
• Major GI symptoms or dyspepsia.  Also consider increased risk 
of bleeding  
 
A R E  
197
 
198,199
  
• High risk of bleeding (HAS-BLED ≥3).  Consider agent with the 
lowest bleeding risk  
 
A D110 E 
127
 
130,131,196,200,201
  
• Once daily dosing or preference to have lower pill burden 
 
E R VKA  # 
202,203
  
• Asian patients.  Consider agents with reduced risk of ICH and 
major bleed in Asian populations 
 
A D E 
137
 
138,139,204
  
• Less likely to do well on VKA (SAMe-TT2R2 score >2).   Avoid any 
potential ‘trial’ of VKA if possible 
 
NOAC preferred  
(A D E R) 
… 
176,185,189
 VKA with additional education, more 
regular follow-up and frequent INR checks 
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VKA=vitamin K antagonist.  *Reduced to 2·5 mg BID with two of three criteria from age ≥80 years, bodyweight ≤60 kg, or serum creatinine concentration ≥133 μmol/L. †110 1574 
mg BID for patients with a CrCl 30–49 mL/min (most countries, but not in the USA); in the USA only, 75 mg BID (available in the USA only) for patients with CrCl 15–29 1575 
mL/min (and only 150 mg BID dose available in the USA for CrCl >30 mL/min). ‡30 mg with CrCl 15–49 mL/min, P-glycoprotein inhibitors, or weight <60 kg. §110 mg BID 1576 
dose not available in the USA for atrial fibrillation. ¶Reduced to 15 mg if CrCl 15–49 mL/min.  1577 
||Dose to be halved if the patient has any of the following: CrCl 15–49 mL/min, bodyweight ≤60 kg, or concomitant use of P-glycoprotein inhibitors. # not available 1578 
 1579 
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 1580 
MANAGING BLEEDING ON OAC 1581 
 1582 
Bleeding on VKA 1583 
 1584 
Management of active bleeding on a VKA depends on the severity (Figure 6). For all bleed events, the 1585 
site of bleeding should be assessed, with mechanical compression where appropriate, the time-point of 1586 
the last dose of VKA should be obtained, with factors affecting bleeding risk documented (other 1587 
medications, kidney function, alcohol abuse, other comorbidities) and hemodynamic status assessed 1588 
(blood pressure, pulse etc.).  Assessment of INR, prothrombin time and activated partial thromboplastin 1589 
time is essential; other laboratory tests should include renal function, hemoglobin, hematocrit and 1590 
platelet count. For minor bleeding, VKA administration should be withheld until INR<2.0. Management 1591 
of moderate bleeding requires prompt identification and intervention to treat the cause and may also 1592 
necessitate fluid replacement and/or blood transfusion. Where bleeding is severe or life-threatening, 1593 
immediate reversal of the anticoagulant effect is required and administration of IV vitamin K, fresh 1594 
frozen plasma and prothrombin complex concentrates should be considered to restore coagulation. 1595 
PCCs are preferred over FFP for reversal due to a higher concentration of clotting factors and less 1596 
volume. 1597 
 1598 
Bleeding on NOAC 1599 
 1600 
Many physicians and patients have been reluctant to embrace NOACs due to their perception that they 1601 
are not able to effectively manage patients who present with bleeding, particularly without a specific 1602 
reversal agent or antidote.205 A helpful framework to consider when managing NOAC related bleeding 1603 
includes: (1) prevention of bleeding, (2) general principles and supportive measures, (3) non-specific 1604 
hemostatic agents, and (4) NOAC-specific reversal agents.
206
 1605 
 1606 
Minimize the Risk of Bleeding 1607 
Selecting the right dose of the NOAC is the most important step to minimize bleeding risk. Prescribing 1608 
information for all NOACS includes dose reduction criteria to avoid increased drug exposure (primarily 1609 
due to impaired renal function). Concomitant administration of antiplatelet drugs and non-steroidal 1610 
anti-inflammatory drugs should be avoided when possible as concomitant administration substantially 1611 
increases bleeding risk.  Blood pressure should be well-controlled. 1612 
 1613 
General Supportive Measures 1614 
Given the short half-lives of these medications, minor bleeds may only require temporary 1615 
discontinuation of anticoagulation for several doses. More significant bleeds may require additional 1616 
supportive measures that include: local management (mechanical/surgical); volume resuscitation; and 1617 
consideration of red blood cell and platelet transfusion, if appropriate.
207-209
 In cases of overdose or in 1618 
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patients who took their last NOAC dose within 2 to 4 hours, oral activated charcoal may attenuate 1619 
absorption of drug.
210-213
  1620 
 1621 
Laboratory Measurements 1622 
With respect to common coagulation tests, a prolonged activated partial thromboplastin time (aPTT) 1623 
indicates an anticoagulant effect of dabigatran, and a prolonged prothromin time (PT) indicates an 1624 
anticoagulant effect of the FXa inhibitors.
208
 However, the clinical utility of these common tests is limited 1625 
due to the fact that a normal aPTT or PT does not exclude clinically relevant plasma levels of dabigatran 1626 
and FXa inhibitors, respectively. The thrombin time (TT) is the most sensitive test for dabigatran; even 1627 
low levels of dabigatran will prolong the TT so a normal TT excludes clinically relevant dabigatran 1628 
concentrations. The dilute thrombin time (dTT) can be used to quantify dabigatran drug levels as it has 1629 
good correlation across a wide range of dabigatran concentrations.
214
 Chromogenic anti-FXa assays are 1630 
recommended for rivaroxaban, apixaban, and edoxaban with calibration for the specific agent.
208
 1631 
However, validation of these specialized coagulation tests is required, they are not universally available, 1632 
and often have delayed turn-around time which diminishes their usefulness in emergent situations. 1633 
Asking patients when they took their last dose of NOAC is often the most practical method for quickly 1634 
assessing residual anticoagulant activity. 1635 
 1636 
Non-Specific Hemostatic Agents 1637 
Hemostatic factors that have been studied as potential non-specific NOAC reversal agents including 1638 
prothrombic complex concentrates (PCC), activated PCC (aPCC), recombinant activated factor VII 1639 
(rFVIIa), and fresh-frozen plasma (FFP). PCCs are the preferred non-specific hemostatic agent for NOAC 1640 
reversal. PCCs are plasma-derived products that contain 3 (factors II, IX, and X) or 4 (addition of factor 1641 
VII) clotting factors in addition to variable amounts of heparin and the natural coagulation inhibitors 1642 
protein C and protein S. Animal studies have demonstrated that PCC have variable ability to normalize 1643 
anticoagulation parameters and prevent or attenuate bleeding across the NOACs.
209,215-221
 The limited 1644 
data in humans are restricted to healthy volunteers. In three small (12-93 patients) randomized, 1645 
placebo-controlled studies, PCC reversed the anticoagulant effect of rivaroxaban and edoxaban but not 1646 
dabigatran.
210,222-224
 There was a dose-dependent relationship with complete reversal with 50 U/kg and 1647 
partial reversal with 25 U/kg.  1648 
 1649 
It is unclear whether normalizing coagulation parameters in healthy volunteers translates to improved 1650 
outcomes in patients who are actively bleeding. Furthermore, the use of these agents in managing 1651 
bleeding caused by VKA or in hemophiliac patients has been associated with an increased risk of 1652 
thrombotic complications, especially when activated factors are used.
225-227
    1653 
 1654 
Specific Reversal Agents 1655 
Idarucizumab 1656 
Idarucizumab is a humanized monoclonal antibody fragment developed as a specific reversal agent for 1657 
dabigatran (Table 7). It binds with high affinity (350 times higher than thrombin) to free and thrombin-1658 
bound dabigatran228 and binding is effectively irreversible.229 The Reversal Effects of Idarucizumab on 1659 
Active Dabigatran (RE-VERSE AD) study was a phase 3, global, prospective, cohort study investigating the 1660 
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safety and efficacy of 5g idarucizumab (administered as two rapid 2.5g intravenous boluses) in 1661 
dabigatran-treated patients who present with uncontrolled or life-threatening bleeding (Group A) or 1662 
non-bleeding patients who require emergent surgery or intervention (Group B).
230
 Idarucizumab 1663 
resulted in immediate, complete, and sustained reversal of dabigatran. Median time to cessation of 1664 
bleeding in Group A was between 2.5 hours after reversal and in Group B, median time to surgery after 1665 
reversal was 1.6 hours with intraoperative hemostasis deemed “normal” by investigators in 93.4% of 1666 
patients. Idarucizumab has worldwide approval and availability. 1667 
 1668 
Andexanet Alfa 1669 
Andexanet alfa (andexanet) is a specific reversal agent for direct (apixaban, rivaroxaban and edoxaban) 1670 
and indirect (low molecular weight heparins and fondaparinux) FXa inhibitors that act through 1671 
antithrombin. It is a modified human recombinant FXa decoy protein that is catalytically inactive due to 1672 
replacement of an active-site serine with alanine and with deletion of the membrane binding domain, 1673 
which eliminates the ability to assemble the prothrombinase complex. Andexanet retains the ability to 1674 
bind to NOACs with high affinity and a 1:1 stoichiometric ratio and by sequestering FXa inhibitors within 1675 
the vascular space, endogenous FXa activity is restored.
231
 Due to its pharmacodynamic half-life of 1-1676 
hour, andexanet is administered as a bolus followed by an infusion. 1677 
 1678 
The ongoing ANNEXA-4 phase 3b–4 study (http://www.clinicaltrials.gov, NCT02329327) is evaluating the 1679 
efficacy and safety of andexanet in patients taking FXa inhibitors with acute major bleeding. Unlike RE-1680 
VERSE AD, this study does not include patients without bleeding but who require emergency or urgent 1681 
procedures. A preliminary interim analysis of 67 patients demonstrated that an initial bolus and 1682 
subsequent 2-hour infusion of andexanet substantially reduced anti-factor Xa activity with clinically 1683 
adjudicated effective hemostasis occuring in 79% of patients.
232
 Andexanet is in late stage review by 1684 
regulatory authorities. 1685 
 1686 
Ciraparantag (PER977) 1687 
Ciraparantag is a small synthetic water-soluble molecule developed as a reversal agent for 1688 
unfractionated heparin, low molecular weight heparins, fondaparinux, and the oral direct Xa and IIa 1689 
inhibitors. It binds to targets through non-covalent hydrogen bonding and charge-charge interactions 1690 
thereby preventing the anticoagulants from binding to their endogenous targets.
233
 Ciraparantag is 1691 
earlier in it development program as compared with other specific reversal agents.  1692 
 1693 
 1694 
Management approach to bleeding on NOACs 1695 
The vast majority of bleeds can be managed conservatively with temporary discontinuation of NOACs 1696 
and supportive measures.  Reversal agents should be used sparingly in the cases of severe and life-1697 
threatening bleeding which includes bleeding causing hemodynamic compromise, intracranial 1698 
hemorrhage, bleeding into a critical organ or closed space, persistent bleeding despite general 1699 
supportive measures and local hemostatic support, or risk of recurrent bleeding due to excess NOAC 1700 
drug exposure due to delayed clearance of NOAC (e.g., acute renal failure) or overdose.  1701 
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 1702 
In a patient with serious bleeding, a specific reversal agent (where available) should be used instead. 1703 
General hemostatic agents as non-specific agents are less effective in reversing coagulation 1704 
abnormalities, have not been shown to improve outcomes, and are potentially prothrombotic.  1705 
 1706 
Although coagulation testing will identify those patients with therapeutic levels of anticoagulation who 1707 
will likely benefit from specific reversal agents, and helps physicians to monitor the response to reversal, 1708 
it is reasonable to administer specific reversal agents immediately without waiting for a laboratory test 1709 
confirming therapeutic levels of anticoagulation in patients who present with life-threatening bleeding 1710 
presumed to be on a NOAC.  1711 
 1712 
 1713 
  1714 
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Table 7: Comparison of specific NOAC reversal agents [adapted from Ruff CT, Giugliano RP, Antman EM. 1715 
Circulation. 2016; 134(3)248-61] 1716 
 1717 
 Idaracizumab Andexanet alfa Ciraparantag 
Company Boehringer Ingelheim Portola 
Pharmaceuticals 
Perosphere Inc. 
Chemical 
structure 
Humanized 
monoclonal antibody 
fragment 
Recombinant 
truncated human 
factor Xa variant 
(decoy) 
Synthetic water-soluble cationic small 
molecule consisting of two L-arginine 
units connected with a piperazine 
containing linker chain 
Binding  Noncompetitive 
binding to dabigatran 
Competitive binding 
to direct factor Xa 
inhibitors or to 
indirect factor Xa 
inhibitor-activated 
antithrombin 
Covalent hydrogen bonding 
Target affinity ~350x greater affinity 
for dabigatran than 
factor IIa 
Affinity for direct 
factor Xa inhibitors 
similar to that of 
native factor Xa 
Not reported 
Onset <5 minutes 2 minutes 5-10 minutes 
Half-life Initial: 47 minutes 
Terminal: 10.3 hours 
 
Terminal: ~6 hours 
 
Duration of action 24 hours 
Elimination Kidney (protein 
catabolism) 
Not reported Not reported 
Anticoagulant(s) 
reversed 
Dabigatran Direct and indirect 
factor Xa inhibitors* 
- Dabigatran 
- Argatroban  
- Low-molecular weight heparins 
- Unfractionated heparin 
- Oral and parenteral factor Xa 
inhibitors 
Route and dose 
in clinical studies 
5 g administered as 2 
doses of 2.5 g IV over 
5-10 minutes, 15 
minutes apart (repeat 
dosing can be 
considered if 
recurrent bleeding or 
require second 
emergent procedure if 
elevated coagulation 
parameters) 
400-800 mg 
intravenous bolus (30 
mg/min) followed by 
infusion of 4-8 
mg/min
#
 
100-300 mg intravenous bolus 
Storage Refrigerated Refrigerated Room temperature 
* For the indirect factor Xa inhibitors, andexanet alfa likely to completely reverse fondaparinux which only 1718 
inhibits factor Xa but not low-molecular weight heparins which also inhibit factor IIa. 1719 
#
Lower dose to reverse apixaban, higher dose to reverse rivaroxaban 1720 
 1721 
 1722 
 1723 
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PRACTICAL ISSUES WITH VKA AND NOAC  1724 
CARDIOVERSION 1725 
Antithrombotic therapy for patients with AF undergoing cardioversion 1726 
  1727 
In AF of documented short duration (i.e.≤48 h), urgent cardioversion commonly occurs without prolonged 1728 
pre-cardioversion anticoagulation. In the context of elective cardioversion, whether electrical or chemical, 1729 
therapeutic anticoagulation either with adjusted-dose VKAs, or NOACs is currently recommended for a 1730 
minimum of 3 weeks before, and for a minimum of 4 weeks after the procedure. In AF of >48 h duration or 1731 
unknown duration, a TEE-guided approach provides an alternative strategy to guide anticoagulation 1732 
management before cardioversion. In this section, we appraise and summarize the evidence and give 1733 
recommendations for the use of antithrombotic therapy in patients undergoing electrical or pharmacologic 1734 
cardioversion for AF (or atrial flutter). In particular, the option of NOACs in the setting of cardioversion is 1735 
reviewed. 1736 
Cardioversion of AF of more than 48 h or unknown duration 1737 
VKA 1738 
Observational data support the use of VKA in the context of elective cardioversion, whether electrical or 1739 
pharmacologic. A systematic review of 18 observational studies provides moderate-quality evidence for a 1740 
lower risk of stroke or thromboembolism (TE) with peri-cardioversion anticoagulation (with VKA) versus no 1741 
anticoagulation (0.3% vs 2.0%; relative risk, RR, 0.16, 95% CI, 0.05-0.48), but did not report major bleeding 1742 
events
234
.  1743 
 1744 
The recommended duration of a minimum of 3 weeks’ therapeutic anticoagulation with VKA before 1745 
cardioversion and a minimum 4 weeks subsequently is arbitrary and has no trial basis, being based on 1746 
indirect pathophysiologic and observational data. The rationale for maintenance of a therapeutic INR in the 1747 
peri-cardioversion period is from observational data, showing that thromboembolism is significantly more 1748 
common at INR of 1.5-2.4 before cardioversion than INR of 2.5 (0.93% vs 0%, P 0.012)
235
. Retrospective 1749 
observational studies suggest that, after cardioversion, the highest risk of stroke and thromboembolism is 1750 
in the first 72 hours. In addition, most thromboembolic complications are within 10 days of 1751 
cardioversion
236
. However, even if sinus rhythm is restored on ECG, transoesophageal echocardiography 1752 
(TEE) studies have shown that atrial mechanical dysfunction can persist for several weeks following 1753 
cardioversion
237
. Recent Finnish registry data suggest that most post-cardioversion strokes are associated 1754 
with not using anticoagulation
238
. Although data relating to the impact of long-term anticoagulation post-1755 
cardioversion are lacking, relevant Swedish observational data suggest that discontinuation of warfarin 1756 
after catheter ablation is not safe in high-risk patients, especially those individuals with history of ischemic 1757 
stroke
239
. It is also worth noting that although the risk of ischemic stroke/TE is higher with non-paroxysmal 1758 
vs. paroxysmal AF (multivariable adjusted hazard ratio 1.38, 95% CI: 1.19-1.61, p<0.001), pattern of AF does 1759 
not affect the decision regarding long-term OAC. 1760 
 1761 
NOACs 1762 
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Evidence is available for all four currently available NOACs: dabigatran, apixaban, rivaroxaban and 1763 
edoxaban.  An existing systematic review from Renda et al. compared the use of NOAC versus VKA in the 1764 
setting of cardioversion in six studies.
240
  Reported pooled risk ratios (RRR) were 0.82 (0.38-1.75) for 1765 
stroke/systemic embolism, 0.72 (0.27-1.90) for mortality and 0.72 (0.19-2.71) for MI respectively, 1766 
suggesting at least comparable efficacy of NOACs with VKA in the setting of cardioversion (e-Table 17). It 1767 
should be noted that despite these reassuring data, the included trials were under-powered for safety and 1768 
efficacy, and judged to be of poor quality.  1769 
 1770 
The need for consensus guidance is illustrated by the current wide variation in VKA and NOAC use in the 1771 
setting of elective cardioversion 
241,242
. Available data support use of rivaroxaban
243
 
244
, dabigatran
245
, 1772 
apixaban
246
 and edoxaban
247
 in patients to be continued on these NOACs if scheduled for cardioversion.  1773 
Similar observations were found in a randomized trial of apixaban vs. warfarin (EMANATE) 
248
. 1774 
 1775 
A TEE-guided approach with abbreviated anticoagulation before cardioversion has been recommended as 1776 
an alternative to the conventional approach of using a minimum of 3 weeks therapeutic pre-cardioversion 1777 
anticoagulation as outlined above
249
. In the TEE--guided strategy, patients receive VKA and once 1778 
therapeutic, undergo a screening TEE. If the TEE identifies thrombus in either the atrial appendage or 1779 
atrium, cardioversion is postponed, given the presumed high risk of thromboembolism. In the absence of 1780 
thrombus, cardioversion is immediately performed. Given the need for accurate visualization of thrombus, 1781 
the TEE-guided strategy requires an experienced echocardiographer. The best data for the use of VKA in the 1782 
TEE-guided approach is from the Assessment of Cardioversion Using Transesophageal Echocardiography 1783 
(ACUTE) RCT, which compared a TEE-guided strategy of abbreviated therapeutic anticoagulation with IV 1784 
unfractionated heparin (started 24 h before cardioversion) or warfarin (INR 2.0-3.0) (started 5 days before 1785 
cardioversion) to a strategy of therapeutic anticoagulation for at least 3 weeks before cardioversion
250
.   1786 
 1787 
Overall, the evidence is of low quality, and therefore the results are not conclusive with respect to either a 1788 
benefit or harm with the TEE-guided strategy versus the conventional approach of 3 weeks of 1789 
anticoagulation pre-cardioversion. 1790 
 1791 
For NOACs vs. warfarin in the TEE-guided approach, our review found an existing systematic review and 1792 
meta-analysis.
251
  An updated search of this systematic review identified one additional study.  Pooled 1793 
results found the relative risk ratio for stroke/TE was 0.33 (0.06-1.68) for NOACs versus warfarin (e-Figure 1794 
3, e-table 18). Although these data indicate safety and probable equivalence of NOACs in the TEE-guided 1795 
approach versus VKA, the trials were under-powered to show efficacy, and therefore the evidence is of low 1796 
quality (e-Table 18). The advantage of NOACs is that their mode of action is quicker than VKA and therefore 1797 
there is no delay in waiting for a therapeutic INR. However, the need for strict adherence to the NOAC 1798 
therapy must be emphasized to patients, particularly in the post-cardioversion period.  1799 
 1800 
 1801 
Individuals who are very symptomatic due to AF may gain greatest benefit from the TEE-guided approach 1802 
since cardioversion can be expedited by a thrombus-negative TEE. In addition, a TEE-guided approach can 1803 
be used to avoid prolonged VKA before cardioversion, which is a particular consideration in patients at 1804 
increased risk for bleeding. The NOACs now offer an alternative to prolonged anticoagulation before 1805 
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cardioversion. However, a “risk-based approach” to anticoagulation should be used, and avoiding 1806 
anticoagulation with a TEE-guided strategy should only be considered in the absence of stroke risk factors 1807 
and a low risk of recurrent AF. 1808 
 1809 
For patients undergoing a TEE-guided approach, low-molecular-weight heparin at full VTE treatment doses 1810 
or IV unfractionated heparin (to maintain an activated partial thromboplastin time prolongation that 1811 
corresponds to plasma heparin levels of 0.3-0.7 International Units/mL anti-factor Xa activity) should be 1812 
started at the time of TEE and cardioversion performed within 24 hours of the TEE if no thrombus is seen. 1813 
Observational data and one RCT show that low-molecular-weight heparin has similar efficacy compared 1814 
with heparin or warfarin for immediate anticoagulation before TEE
252-256
. In the outpatient setting, a TEE-1815 
guided approach should involve initiation of VKA (INR 2.5; range, 2.0-3.0) followed by the TEE and 1816 
subsequent cardioversion scheduled 5 days later (if the INR is in therapeutic range at that time). The NOACs 1817 
again offer an alternative in outpatient treatment before TEE-guided cardioversion, with no bridging 1818 
therapy necessary. 1819 
 1820 
Among AF patients undergoing TEE, 10% have left atrial appendage thrombus with a 3.5-fold increased risk 1821 
of stroke/TE
257
, but no specific data are available in the context of cardioversion. If atrial thrombus is seen 1822 
on TEE, then there is heterogeneity in current clinical practice regarding both when or whether to perform 1823 
the TEE again, as well as subsequent management of anticoagulation. There is no evidence to support re-1824 
imaging, although it is a reasonable strategy. Although, current practice favors not performing 1825 
cardioversion if re-imaging shows thrombus due to the presumed high risk of TE, there is a lack of direct 1826 
data about the safety of cardioversion in the presence of thrombus. Taken together, a risk-based approach 1827 
to anticoagulation can be recommended and with respect to TEE, individualization of therapy on a case-by-1828 
case basis is proposed. It should be noted that in a multicenter registry of AF patients undergoing catheter 1829 
ablation, TEE-guided cardioversion did not show a benefit compared with uninterrupted NOAC therapy
258
. 1830 
 1831 
Although there is no direct evidence to guide decision-making about long-term management of 1832 
anticoagulation in patients who appear to be in sinus rhythm at 4 weeks after cardioversion, but indirect 1833 
evidence suggests strongly that long-term anticoagulation should be based on the risk of stroke rather than 1834 
the apparent success of the cardioversion procedure. First, recurrence of AF at 1 year after cardioversion 1835 
occurs in approximately one-half of patients and therefore long-term stroke risk is significant
259-262
. Second, 1836 
the AFFIRM study, in which many patients stopped anticoagulation after initial (apparently) successful 1837 
restoration of sinus rhythm, demonstrated similar rates of thromboembolism with a rhythm control 1838 
strategy compared with a rate control strategy
263
. Thirdly, patients with paroxysmal AF are often 1839 
asymptomatic during episodes of AF recurrence, with one series suggesting that only one in every 12 1840 
paroxysms are symptomatic
264
.  1841 
Recommendation 1842 
12. For patients with AF of greater than 48 hours or unknown duration undergoing elective electrical or 1843 
pharmacologic cardioversion, we recommend therapeutic anticoagulation with well-managed VKA 1844 
(INR 2-3) or a NOAC using dabigatran, rivaroxaban, edoxaban or apixaban for at least 3 weeks before 1845 
cardioversion or a transesophageal echocardiography (TEE)-guided approach with abbreviated 1846 
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anticoagulation before cardioversion rather than no anticoagulation (Strong recommendation, 1847 
moderate quality evidence). 1848 
Remark: With NOACs adherence and persistence should be strongly emphasized 1849 
 1850 
13. For patients with AF of greater than 48 hours or unknown duration undergoing elective electrical or 1851 
pharmacologic cardioversion, we recommend therapeutic anticoagulation (with VKA or NOAC) for at 1852 
least 4 weeks after succesful cardioversion to sinus rhythm rather than no anticoagulation, regardless 1853 
of the baseline risk of stroke (strong recommendation, moderate quality evidence) 1854 
Remark: Decisions about anticoagulation beyond 4 weeks should be made in accordance with our risk-1855 
based recommendations for long-term antithrombotic therapy in recommednations 1 and 2, and not 1856 
on the basis of successful cardioversion  1857 
 1858 
14.  In patients in which LAA thrombus is detected on TEE, cardioversion postponed, and OAC continued 1859 
for another 4-12 weeks, to allow thrombus resolution or endothelisation, we suggest that a decision 1860 
on whether a repeat TEE is performed should be individualized (ungraded consensus-based 1861 
statement). 1862 
 1863 
 1864 
Cardioversion of AF of 48 h duration or less: 1865 
 1866 
The duration of AF necessary for development of thrombus is not clear. Therefore, the threshold of AF 1867 
duration below which pre-cardioversion anticoagulation can be safely avoided is not known. It is common 1868 
practice to cardiovert without TEE or prolonged pre-cardioversion anticoagulation if AF is of short duration 1869 
(<48 hours). The problem with this approach is the presence of left atrial thrombus on TEE in up to 14% of 1870 
patients with AF of short duration in observational studies
265,266
. In addition, the high prevalence of 1871 
asymptomatic AF makes determining the exact duration of AF difficult
267
.  If there is uncertainty about 1872 
precise time of AF onset, then such patients should be managed as if AF >48 hours. 1873 
 1874 
A recent Finnish observational study of 5,116 successful cardioversions in 2,481 patients with acute (<48 h) 1875 
AF showed low incidence of stroke/TE during the 30 days following cardioversion, even without 1876 
perioperative anticoagulation (0.7%)
268
. These results concur with low rates of stroke/TE in observational 1877 
studies (Table 8). However, there is lower incidence of stroke/TE with cardioversions performed during 1878 
anticoagulation (0.1% vs 0.7%, p=0.001), and with anticoagulation versus no anticoagulation in patients 1879 
with a CHA2DS2VASc score of ≥2 (0.2% vs 1.1%, p=0.001). It should also be noted that there is a high risk of 1880 
recurrence of the composite of cardioversion failure and recurrence of AF within 30 days (40%) in acute 1881 
AF
269
. Overall, the evidence suggests that peri-cardioversion anticoagulation is beneficial and that the 1882 
decision regarding peri- and post-cardioversion anticoagulation should be based on risk of stroke/TE
268
, 1883 
even if an individual is presenting for the first time with AF.  1884 
 1885 
Table 8.  Thromboembolic Complications in Patients With No Anticoagulation After Cardioversion of 1886 
Acute (<48 h) Atrial Fibrillation in Previous Studies (from Airaksinen et al. 2013
268
) 1887 
First Author (Ref. #) n 
Mean Age, 
yrs 
Male 
Success 
Rate 
Thromboembolism 
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Weigner et al.
270
 224 68 NA 95% 0.9%∗ 
Michael et al. 
271
 217 64 54 86% 0.5%∗ 
Burton et al. 
272
 314 61 55 86% 0
†
 
Gallagher et al. 
235
 198 63 68 100% 0.5%
‡
 
Stiell et al. 
273
 414 65 56 92% 0
†
 
Xavier Scheuermeyer et al. 
274
 104 57 92 96% 0 
∗All 3 thromboembolic events after spontaneous cardioversion and in elderly (>75 years) women. 1888 
†Follow-up of 7 days. 1889 
‡Plus 1 probable thromboembolic event.  NA, not available 1890 
  1891 
 1892 
Recommendations 1893 
15. For patients with AF of documented duration of 48 hours or less undergoing elective cardioversion 1894 
(electrical or pharmacologic), we suggest starting anticoagulation at presentation (low-molecular-1895 
weight heparin or unfractionated heparin at full venous thromboembolism treatment doses) and 1896 
proceeding to cardioversion rather than delaying cardioversion for 3 weeks of therapeutic 1897 
anticoagulation or a TEE-guided approach (weak recommendation, low quality evidence).   1898 
 1899 
16. For patients with AF and hemodynamic instability undergoing urgent cardioversion (electrical or 1900 
pharmacologic), after successful cardioversion to sinus rhythm, we recommend therapeutic 1901 
anticoagulation (with VKA or full adherence to NOAC therapy) for at least 4 weeks rather than no 1902 
anticoagulation, regardless of baseline stroke risk (weak recommendation, low quality evidence). 1903 
Remark: Decisions about long-term anticoagulation after cardioversion should be made in accordance 1904 
with our risk-based recommendations for long-term antithrombotic therapy in recommendations 1 and 1905 
2 1906 
 1907 
Patients undergoing urgent cardioversion for hemodynamically unstable AF 1908 
 1909 
Our systematic review of anticoagulation versus no anticoagulation in patients with AF undergoing urgent 1910 
found no published data regarding the optimal anticoagulation strategy to use before or during urgent 1911 
cardioversion for patients with AF and hemodynamic instability. On the basis of the above evidence for 1912 
anticoagulation in elective cardioversion, initiation of anticoagulation immediately before urgent 1913 
cardioversion (e.g., with IV unfractionated heparin or low-molecular weight heparin) would be expected to 1914 
reduce the risk of stroke/TE based on studies of elective cardioversion. Initiation of anticoagulation therapy 1915 
should not delay any emergency interventions required in order to stabilize the patient. 1916 
Recommendation 1917 
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17. For patients with AF and hemodynamic instability undergoing urgent cardioversion (electrical or 1918 
pharmacologic), we suggest that therapeutic-dose parenteral anticoagulation be started before 1919 
cardioversion, if possible, but that initiation of anticoagulation must not delay any emergency 1920 
intervention (weak recommendation, low quality evidence). 1921 
 1922 
18.  For patients with AF and hemodynamic instability undergoing urgent cardioversion (electrical or 1923 
pharmacologic), after successful cardioversion to sinus rhythm, we suggest therapeutic 1924 
anticoagulation for at least 4 weeks after successful cardioversion to sinus rhythm rather than no 1925 
anticoagulation, regardless of baseline stroke risk (weak recommendation, low quality evidence). 1926 
Remark: Decisions about anticoagulation beyond 4 weeks should be made in accordance with our risk-1927 
based recommendations for long-term antithrombotic therapy in recommendations 1 and 2. 1928 
 1929 
Patients Undergoing Elective or Urgent Cardioversion for Atrial Flutter 1930 
 1931 
There are no specific trials which have considered electrical cardioversion in the context of atrial flutter and 1932 
associated anticoagulation. Despite the low risk of TE after cardioversion for atrial flutter, which has been 1933 
suggested by some observational studies, even in absence of anticoagulation, other studies have shown a 1934 
similar risk of TE in patients after cardioversion for atrial flutter and AF
235,275,276
, perhaps due to co-existence 1935 
of AF and atrial flutter. Adults with congenital heart disease represent a growing, important population 1936 
with atrial flutter where long-term studies of outcomes with anticoagulation are required. 1937 
Recommendation 1938 
19. For patients with atrial flutter undergoing elective or urgent pharmacologic or electrical 1939 
cardioversion, we suggest that the same approach to thromboprophylaxis be used as for patients 1940 
with atrial fibrillation undergoing cardioversion. (ungraded consensus-based statement). 1941 
 1942 
 1943 
PATIENTS WITH AF WITH CORONARY ARTERY DISEASE 1944 
ACS and/or PCI 1945 
AF commonly coexists with vascular disease, whether coronary, carotid or peripheral artery disease
277,278
.  1946 
Some AF patients with coronary disease may present with an acute coronary syndrome (ACS).  Whether 1947 
stable or acute, such patients may undergo percutaneous intervention with stent deployment.  This section 1948 
deals with the antithrombotic therapy management of this group of patients. 1949 
 1950 
There are 4 considerations when managing these patients, as follows
277,279
: 1951 
• Stroke prevention, necessitating OAC, whether with VKA or NOAC 1952 
• Prevention of stent thrombosis, necessitating antiplatelet therapy (APT).  There is evidence for 1953 
using DAPT for up to 12 months in non-AF patients. 1954 
• Prevention of recurrent cardiac ischemia in an ACS patient, necessitating APT.  There is some 1955 
evidence for using DAPT for beyond 12 months in non-AF patients from the DAPT and PEGASUS 1956 
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trials, to reduce non-stent related ischemic and stroke events, but at the risk of more bleeding 1957 
events
280
. 1958 
• Serious bleeding risks (e.g., ICH) with the combination of OAC and one or more antiplatelet drug 1959 
 1960 
Additional considerations are the duration of treatment, acute or stable setting, type of APT, stent type, 1961 
OAC type, bleeding risks, etc.  Bleeding risk can be assessed by various bleeding risk scores, with the focus 1962 
on modifiable bleeding risk factors; however, the HAS-BLED score is predictive of bleeding in the setting of 1963 
ACS and/or PCI-stenting
110
.  Coronary stent technology has also evolved, with small strut sizes necessitating 1964 
shorter duration of dual APT (DAPT, i.e. aspirin plus P2Y12 inhibitor such as clopidogrel).  We are also in the 1965 
era of NOACs, which may offer a better safety profile compared to VKA based therapy.  Nonetheless the 1966 
latter may be relatively safe in the presence of well managed anticoagulation control with high TTR
281
. 1967 
 1968 
AF patients undergoing percutaneous coronary intervention 1969 
Various case series and cohort studies of AF patients undergoing PCI/stenting have been reported.  These 1970 
have been systematically reviewed as part of the 2014 and 2018 joint European consensus documents, 1971 
endorsed by HRS and APHRS, which provides consensus recommendations on optimal management of such 1972 
patients
277,279
.  A similar North American expert consensus document has been published
282
. 1973 
 1974 
In a systematic review and meta-analysis (18 studies with 20,456 patients with AF; 7,203 patients received 1975 
DAPT + VKA and 13,253 patients received DAPT after PCI-S) Chaudhary et al
283
, showed that DAPT  and VKA 1976 
was associated with significantly lower risk of stroke, stent thrombosis, and all-cause mortality, but the risk 1977 
of major bleeding was significantly higher in the DAPT and VKA group.  1978 
Broadly similar conclusions were drawn from the systematic review and meta-analysis (17 studies, 104,639 1979 
patients) by Zhu et al
284
 where triple therapy (DAPT+OAC) was associated with an increased risk of bleeding 1980 
compared with DAPT alone, with no differences observed between triple therapy and the dual therapy for 1981 
all-cause death, cardiovascular death, or thrombotic complications (i.e., acute coronary syndrome, stent 1982 
thrombosis, thromboembolism/stroke, and major adverse cardiac and cerebrovascular events). In both 1983 
systematic reviews, there was marked heterogeneity in study size, patient population, intervention types, 1984 
stent use, etc. 1985 
 1986 
Bennaghmouch et al
285
 reported a meta-analysis restricted to the subgroups of patients on aspirin therapy 1987 
(n=21,722) from the four RCTs comparing VKA and NOACs (N=71,681) in AF patients. NOACs were more 1988 
effective (outcome stroke or systemic embolism HR: 0.78 [95% CI, 0.67-0.91] and vascular death HR 0.85 1989 
[0.76-0.93]) and as safe as VKA with respect to major bleeding (HR: 0.83 [95% CI, 0.69-1.01]). NOACs were 1990 
safer with respect to the reduction of intracranial hemorrhage (HR: 0.38 [0.26-0.56]). Thus, it may be both 1991 
safer and more effective to use NOACs as compared with VKA to treat patients with non-valvular AF and 1992 
concomitant aspirin therapy. 1993 
 1994 
The largest observational cohort was reported by Lamberts et al
286
, which included a total of 12,165 AF 1995 
patients (60.7% male; mean age 75.6 years) hospitalized with MI and/or undergoing PCI between 2001 and 1996 
2009. Relative to triple therapy (OAC plus DAPT, i.e. aspirin plus clopidogrel), no increased risk of recurrent 1997 
coronary events was seen for OAC plus clopidogrel (hazard ratio [HR]: 0.69, 95% CI: 0.48 to 1.00), OAC plus 1998 
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aspirin (HR: 0.96, 95% CI: 0.77 to 1.19), or aspirin plus clopidogrel (HR: 1.17, 95% CI: 0.96 to 1.42), but 1999 
aspirin plus clopidogrel was associated with a higher risk of ischemic stroke (HR: 1.50, 95% CI: 1.03 to 2.20). 2000 
OAC plus aspirin and aspirin plus clopidogrel were associated with a significant increased risk of all-cause 2001 
death (HR: 1.52, 95% CI: 1.17 to 1.99 and HR: 1.60, 95% CI: 1.25 to 2.05, respectively). When compared to 2002 
triple therapy, bleeding risk was non-significantly lower for OAC plus clopidogrel (HR: 0.78, 95% CI: 0.55 to 2003 
1.12) and significantly lower for OAC plus aspirin and aspirin plus clopidogrel.  Thus, OAC and clopidogrel 2004 
was equal or better for both benefit and safety outcomes compared to triple therapy. However, this 2005 
analysis provides limited information on the duration of therapies, quality of INR control, stent type, 2006 
underlying bleeding risk profile, etc. 2007 
 2008 
Randomized trials 2009 
Prospective RCTs in AF patients presenting with ACS and/or undergoing PCI/stenting are limited. The first 2010 
trial was the WOEST trial
287
, which randomized 573 adults receiving oral anticoagulants (65% with AF) and 2011 
undergoing PCI to clopidogrel alone (double therapy) or clopidogrel plus aspirin (triple therapy). The 2012 
primary endpoint of ‘any bleeding’ was seen in 19·4% receiving double therapy and 44·4% receiving triple 2013 
therapy (HR 0·36, 95% CI 0·26-0·50, p<0·0001).  Of the secondary endpoints, there was no increase in the 2014 
rate of thrombotic events, but all-cause mortality was higher in the triple therapy arm.  This trial was 2015 
underpowered for efficacy and safety endpoints, and the primary endpoint of ‘any bleeding’ was driven by 2016 
minor bleeds given that triple therapy was mandated for 12 months.    2017 
 2018 
The duration of triple therapy was also addressed by the ISAR-TRIPLE trial
288
, a RCT in 614 patients receiving 2019 
OAC plus aspirin, randomized to either 6-weeks of clopidogrel therapy (n=307) or 6-months of clopidogrel 2020 
therapy (n=307). The primary endpoint (composite of death, myocardial infarction (MI), definite stent 2021 
thrombosis, stroke, or Thrombolysis In Myocardial Infarction (TIMI) major bleeding at 9 months) occurred 2022 
in 30 patients (9.8%) in the 6-week group compared with 27 patients (8.8%) in the 6-month group (HR: 2023 
1.14; 95% CI: 0.68 to 1.91; p=0.63). There were no significant differences for the secondary combined 2024 
ischemic endpoint of cardiac death, MI, definite stent thrombosis, and ischemic stroke (12 [4.0%] vs. 13 2025 
[4.3%]; HR: 0.93; 95% CI: 0.43 to 2.05; p=0.87) or the secondary bleeding endpoint of TIMI major bleeding 2026 
(16 [5.3%] vs. 12 [4.0%]; HR: 1.35; 95% CI: 0.64 to 2.84; p=0.44). Thus, 6 weeks of triple therapy was not 2027 
superior to 6 months of therapy with respect to net clinical outcomes, suggesting that physicians should 2028 
weigh the trade-off between ischemic and bleeding risk when choosing a shorter or longer duration of 2029 
triple therapy.  2030 
 2031 
In the PIONEER AF-PCI trial
289
, 2,124 patients with AF undergoing PCI with stenting were randomized to 2032 
low-dose rivaroxaban (15 mg once daily, reduced to 10mg with moderate renal impairment) plus a P2Y12 2033 
inhibitor for 12 months (group 1), very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 2034 
months (group 2), or standard VKA (once daily) plus DAPT for 1, 6, or 12 months (group 3). The rates of 2035 
clinically significant bleeding were lower in the two groups receiving rivaroxaban than in the VKA group 2036 
(16.8% in group 1, 18.0% in group 2, and 26.7% in group 3; hazard ratio for group 1 vs. group 3, 0.59; 95% CI 2037 
0.47 to 0.76; P<0.001; hazard ratio for group 2 vs. group 3, 0.63; 95% CI, 0.50 to 0.80; P<0.001). The rates of 2038 
death from cardiovascular causes, myocardial infarction, or stroke were similar in the three groups but the 2039 
trial was underpowered for efficacy endpoints.  There was only a minority of newer P2Y12 inhibitors used 2040 
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as APT.  There was an associated reduction in hospitalizations in the 2 rivaroxaban arms, compared to 2041 
VKA
290
. 2042 
 2043 
In the RE-DUAL PCI trial
291
, randomized 2,725 patients with AF who had undergone PCI to triple therapy 2044 
with warfarin plus a P2Y12 inhibitor (clopidogrel or ticagrelor) and aspirin (for 1 to 3 months) (triple-therapy 2045 
group) or dual therapy with dabigatran (110 mg or 150 mg twice daily) plus a P2Y12 inhibitor (clopidogrel or 2046 
ticagrelor) and no aspirin (110-mg and 150-mg dual-therapy groups). Outside the United States, elderly 2047 
patients (≥80 years of age; ≥70 years of age in Japan) were randomly assigned to the 110-mg dual-therapy 2048 
group or the triple-therapy group.  The incidence of the primary end point (major or clinically relevant non-2049 
major bleeding) was 15.4% in the 110-mg dual-therapy group compared with 26.9% in the triple-therapy 2050 
group (HR 0.52; 95%CI 0.42 to 0.63; P<0.001 for non-inferiority; P<0.001 for superiority) and 20.2% in the 2051 
150-mg dual-therapy group as compared with 25.7% in the corresponding triple-therapy group, which did 2052 
not include elderly patients outside the United States (HR 0.72; 95%CI 0.58 to 0.88; P<0.001 for non-2053 
inferiority). The incidence of the composite efficacy end point of thromboembolic events (myocardial 2054 
infarction, stroke, or systemic embolism), death, or unplanned revascularization was 13.7% in the two dual-2055 
therapy groups combined as compared with 13.4% in the triple-therapy group (hazard ratio, 1.04; 95% CI, 2056 
0.84 to 1.29; P=0.005 for non-inferiority).  Thus, the risk of bleeding was lower among those who received 2057 
dual therapy with dabigatran and a P2Y12 inhibitor than among those who received triple therapy with 2058 
warfarin, a P2Y12 inhibitor, and aspirin. Dual therapy was non-inferior to triple therapy with respect to the 2059 
risk of thromboembolic events.  In contrast to the PIONEER-AF trial, the REDUAL PCI trial tested dabigatran 2060 
doses (110mg and 150mg bid) which are licensed for stroke prevention in AF. 2061 
 2062 
There are limited data on use of the newer P2Y12 inhibitors (ticagrelor, prasugrel) with OAC.  Observational 2063 
cohorts in AF patients report a higher bleeding rate where these newer APT agents are used as part of a 2064 
triple therapy regime, compared to when clopidogrel is used as part of the triple therapy regime
292
.  Only a 2065 
minority of patients in PIONEER AF-PCI had newer P2Y12 agents, whereas the largest experience in AF 2066 
patients was in the RE-DUAL PCI trial, which allowed ticagrelor in combination with dabigatran 110mg or 2067 
150mg bid.   2068 
 2069 
In the GEMINI-ACS-1 trial
293
, 3037 patients with ACS (i.e. essentially a non-AF population) were randomly 2070 
assigned to either aspirin 100mg or rivaroxaban 2.5mg bid, and the subsequent choice of clopidogrel (44%) 2071 
or ticagrelor (in 56%) during trial conduct was non-randomized.  Low-dose rivaroxaban with a P2Y12 2072 
inhibitor for the treatment of ACS patients had similar risks of clinically significant bleeding (5%) as aspirin 2073 
and a P2Y12 inhibitor [HR 1·09 [95% CI 0·80-1·50]; p=0·5840)]. 2074 
 2075 
Stable vascular disease 2076 
 2077 
The presence of vascular disease adds to stroke risk in patients with AF. In the Danish registries, AF patients 2078 
with vascular disease (prior myocardial infarction, prior peripheral artery disease, or aortic plaque) as a 2079 
single risk factor have a high stroke rate of 4.85 per 100 person-years
294
. This corresponds to CHA2DS2-2080 
VASc=1 for males and a CHA2DS2-VASc=2 for females, with rates of 4.53 and 5.69, respectively.  Contrasting 2081 
low risk CHA2DS2-VASc (that is, score 0 (male) or 1 (female)) as a reference population vs. those with ≥1 2082 
additional stroke risk factors (i.e. CHA2DS2-VASc score =1 (male) or =2 (females)), the risk attributable to 2083 
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vascular disease had a crude HR of 2.7 (95%CI 1.7-4.2).  In Asian countries
295
, PAD may confer an ischemic 2084 
stroke risk that is much higher than that seen in Western populations
296
. 2085 
 2086 
In AF patients with stable CAD there is no evidence that adding APT to OAC reduces stroke/SE, death, or MI.  2087 
However, the risk of major bleeding and ICH is substantially increased with the addition of APT to OAC.   2088 
The largest cohort was reported by Lamberts et al
297
 where 8700 AF patients (mean age, 74.2 years; 38% 2089 
women) with stable CAD (defined as 12 months from an acute coronary event) followed-up for a mean 3.3 2090 
years, found the risk of myocardial infarction/coronary death was similar for VKA plus aspirin (HR 1.12; 95% 2091 
CI 0.94-1.34]) and VKA plus clopidogrel (HR 1.53; 95% CI 0.93-2.52]), relative to VKA monotherapy,  2092 
However, the risk of bleeding increased >50% when aspirin (HR 1.50; 95% CI 1.23-1.82]) or clopidogrel (HR 2093 
1.84; 95% CI 1.11-3.06]) was added to VKA. 2094 
 2095 
In the RCTs of NOACs compared to warfarin, aspirin at <100mg daily was allowed. Ancillary analyses show  2096 
no added benefit of adding aspirin on stroke or mortality rates; however, absolute bleeding rates were 2097 
higher with combination therapy, but the relative efficacy and safety with NOAC vs. warfarin use was 2098 
maintained irrespective of aspirin use
298
.  Only the RELY trial showed data for combination of dabigatran 2099 
with aspirin and/or clopidogrel, and as expected, major bleeding risks were increased with a single APT and 2100 
further increased where 2 APTs were used
299
. 2101 
Less data are evident for OAC use in AF patients with stable isolated PAD or carotid disease, in relation to 2102 
OAC use.  However, it is reasonable to assume that data for CAD would be generally applicable to PAD or 2103 
carotid disease. One post-hoc ancillary analysis
300
 from the ROCKET-AF trial reported that the efficacy of 2104 
rivaroxaban when compared with warfarin for the prevention of stroke or systemic embolism was similar in 2105 
patients with PAD (HR: 1.19, 95% CI: 0.63-2.22) and without PAD (HR: 0.86, 95% CI: 0.73-1.02; interaction P 2106 
= 0.34).  However, there was a higher risk of major bleeding or NMCR bleeding with rivaroxaban when 2107 
compared with warfarin in AF patients with PAD  (HR: 1.40, 95% CI: 1.06-1.86) compared with those 2108 
without PAD (HR: 1.03, 95% CI: 0.95-1.11; interaction P = 0.037).   2109 
Recommendations 2110 
20. In AF patients presenting with an ACS and/or undergoing PCI/stenting, we recommend assessment of 2111 
stroke risk using the CHA2DS2-VASc score (Strong recommendation, moderate quality evidence) 2112 
Remark: All such patients are not ‘low risk’ and should be considered for concomitant OAC. 2113 
 2114 
21. In AF patients presenting with an ACS and/or undergoing PCI/stenting, we suggest attention to 2115 
modifiable bleeding risk factors at every patient contact, and assessment of bleeding risk using the 2116 
HAS-BLED score (weak recommendation, low quality evidence). 2117 
Remark: Where bleeding risk is high (HAS-BLED ≥3), there should be more regular review and follow-up. 2118 
 2119 
22. In AF patients requiring OAC undergoing elective PCI/stenting, where bleeding risk is low (HAS-BLED 2120 
0-2) relative to risk for recurrent ACS and/or stent thrombosis, we suggest triple therapy for one 2121 
month, followed by dual therapy with OAC plus single antiplatelet (preferably clopidogrel) until 12 2122 
months, following which OAC monotherapy can be used (weak recommendation, low quality 2123 
evidence). 2124 
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 2125 
23. In AF patients requiring OAC undergoing elective PCI/stenting, where bleeding risk is high (HAS-BLED 2126 
≥3), we suggest triple therapy for one month, followed by dual therapy with OAC plus single 2127 
antiplatelet (preferably clopidogrel) for 6 months, following which OAC monotherapy can be used 2128 
(weak recommendation, low quality evidence) 2129 
 2130 
24. In AF patients requiring OAC undergoing elective PCI/stenting , where bleeding risk is unusually high 2131 
and thrombotic risk relatively low, we suggest use of OAC plus single antiplatelet (preferably 2132 
clopidogrel) for 6 months, following which OAC monotherapy can be used (weak recommendation, 2133 
low quality evidence) 2134 
 2135 
Remark: Patients at unusually high bleeding risk may include patients with HAS-BLED ≥3 and recent 2136 
acute bleeding event. High thrombotic risk may include those with left main stent, multivessel 2137 
PCI/stenting, etc. 2138 
 2139 
 2140 
25. In AF patients requiring OAC presenting with an ACS, undergoing PCI/stenting, where bleeding risk is 2141 
low (HAS-BLED 0-2) relative to risk for ACS or stent thrombosis, we suggest triple therapy for 6 2142 
months, followed by dual therapy with OAC plus single antiplatelet (preferably clopidogrel) until 12 2143 
months, following which OAC monotherapy can be used (weak recommendation, low quality 2144 
evidence) 2145 
 2146 
26. In AF patients requiring OAC presenting with an ACS, undergoing PCI/stenting, where bleeding risk is 2147 
high (HAS-BLED ≥3), we suggest triple therapy for 1-3 months, followed by dual therapy with OAC 2148 
plus single antiplatelet (preferably clopidogrel) up to 12 months, following which OAC monotherapy 2149 
can be used (weak recommendation, low quality evidence). 2150 
 2151 
27. In AF patients requiring OAC presenting with an ACS, undergoing PCI/stenting where bleeding risk is 2152 
unusually high and thrombotic risk low, we suggest OAC plus single antiplatelet (preferably 2153 
clopidogrel) for 6-9 months may be considered, following which OAC monotherapy can be used. 2154 
(weak recommendation, low quality evidence). 2155 
Remark: Patients at unusually high bleeding risk may include patients with HAS-BLED ≥3 and recent 2156 
acute bleeding event. High thrombotic risk may include those with left main stent, multivessel 2157 
PCI/stenting, etc. 2158 
 2159 
28. In AF patients with ACS or undergoing PCI in whom OAC is recommended, we suggest using VKA with 2160 
TTR>65-70% (INR range 2.0-3.0), or to use a NOAC at a dose licensed for stroke prevention in AF 2161 
(weak recommendation, low quality evidence).  2162 
Remark: Only Dabigatran 150mg bid or (not licensed in USA) 110mg bid or Rivaroxaban 15mg qd are 2163 
currently supported by clinical trial evidence. A NOAC based strategy has lower bleeding risk compared 2164 
to a VKA-based strategy. 2165 
 2166 
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29. In AF patients in which aspirin is concomitantly used with OAC, we suggest a dose of 75-100mg qd 2167 
with concomitant use of PPI to minimize gastrointestinal bleeding (Weak recommendation, low 2168 
quality evidence) 2169 
 2170 
30. In AF Patients in which a P2Y12 inhibitor is concomitantly used with OAC, we suggest the use of 2171 
clopidogrel (Weak recommendation, low quality evidence) 2172 
Remark: Newer agents (eg. Ticagrelor) can be considered where bleeding risk is low. Data on the 2173 
combination of ticagrelor with either dabigatran 110mg bid or 150 bid (without concomitant aspirin 2174 
use) are available from the RE-DUAL PCI trial. 2175 
31. For patients with AF and stable coronary artery disease (eg, no acute coronary syndrome within the 2176 
previous year) and who choose oral anticoagulation, we suggest OAC with either a NOAC or adjusted-2177 
dose VKA therapy alone (target international normalized ratio [INR] range, 2.0-3.0) rather than the 2178 
combination of OAC  and aspirin (Weak recommendation, low quality evidence) 2179 
 2180 
 2181 
 2182 
 2183 
CATHETER OR SURGICAL ABLATION, ELECTROPHYSIOLOGICAL PROCEDURES  2184 
 2185 
Periprocedural anticoagulation for catheter ablation and implantable devices 2186 
 2187 
Randomized trials have shown that uninterrupted warfarin is safe and superior to warfarin 2188 
interruption for implantation of cardiac implantable electronic devices.
7
  2189 
 2190 
For catheter ablation, anticoagulation guidelines pertinent to cardioversion generally apply to 2191 
periprocedural anticoagulation and are detailed in a recent professional society expert consensus 2192 
statement
301
.  In a randomized trial of 1584 patients, uninterrupted warfarin, compared to 2193 
interruption with heparin bridging, has been shown to have a lower risk of periprocedural stroke and 2194 
bleeding
302
.  A randomized trial of uninterrupted rivaroxaban vs. uninterrupted VKA in AF ablation 2195 
demonstrated similar event rates in both arms
303
.  A similar randomized trial of uninterrupted 2196 
dabigatran found that dabigatran was associated with fewer bleeding complications than 2197 
uninterrupted warfarin
304
. Although these studies were open-label, they strongly support the use of 2198 
uninterrupted anticoagulation for electrophysiology procedures (Table 9). Two recent systematic 2199 
reviews with meta-analyses that include these studies found consistent with results
305,306
.  2200 
 2201 
Long-term anticoagulation after restoration of sinus rhythm 2202 
Clinical observations indicate that AF and stroke are often temporally discordant, with stroke 2203 
occurring during periods of sinus rhythm in the majority of patients with paroxysmal AF
307,308
.    2204 
 2205 
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After catheter ablation, discontinuation of OAC is associated with an increased risk of stroke
301
.   2206 
Similarly, post-operative AF may confer a long-term risk of stroke. In a U.S. claims analysis of 1.7 2207 
million patients hospitalized for surgery, perioperative atrial fibrillation was associated with an 2208 
increased long-term risk of ischemic stroke, especially following non-cardiac surgery
309
. It is not 2209 
known to what extent the risk was mediated by AF recurrence (often asymptomatic) or was 2210 
independent of rhythm.  Thus, patients should be anticoagulated according to their thromboembolic 2211 
risk profile based on CHA2DS2-VASc, regardless of whether sinus rhythm has been restored via 2212 
ablation, cardioversion, or other means. 2213 
Recommendations 2214 
32. In patients with AF in whom catheter ablation of AF or implantation of cardiac electronic 2215 
implantable devices is planned, we suggest performing the procedure on uninterrupted VKA in 2216 
the INR therapeutic range, dabigatran or rivaroxaban (weak recommendation, low quality 2217 
evidence). 2218 
 2219 
 2220 
33. In patients in whom sinus rhythm has been restored, we suggest that long-term 2221 
anticoagulation should be based on the patient’s CHA2DS2-VASc thromboembolic risk profile, 2222 
regardless of whether sinus rhythm has been restored via ablation, cardioversion (even 2223 
spontaneous), or other means (Weak recommendation, low quality evidence). 2224 
 2225 
 2226 
Table 9: Summary of Studies of Periprocedural Anticoagulation for Catheter Ablation of Atrial 2227 
Fibrillation and Implantation of Cardiac Electronic Implantable Devices: 2228 
 2229 
Trial Population Interventions Results 
COMPARE
302
 Catheter ablation of AF 
N=1584 
Uninterrupted 
warfarin vs. 
interrupted warfarin 
with low-molecular 
weight bridging 
Significant reduction 
in stroke (0.25% vs 
3.7%), TIA (0% vs. 
1.3%), and minor 
bleeding with 
uninterrupted 
warfarin 
VENTURE-AF
303
 Catheter ablation of AF 
N = 248 
Uninterrupted 
rivaroxaban vs. 
uninterrupted VKA 
No difference in 
overall low incidence 
of major bleeding 
(0.4%) or 
thromboembolic 
events (0.8%) 
RE-CIRCUIT
304
. Catheter ablation of AF 
N = 704 
Uninterrupted 
dabigatran vs. 
uninterrupted 
warfarin 
Significant reduction 
in major bleeding 
events with 
dabigatran (1.6% vs. 
6.9%) 
BRUISE-CONTROL
310
 Pacemaker or 
defibrillator 
Uninterrupted 
warfarin vs. 
Significant reduction 
in pocket hematoma 
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implantation 
N = 343 
interrupted warfarin 
with heparin bridging 
(3.5% vs. 16%) 
  2230 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 63
 2231 
CEREBROVASCULAR DISEASE 2232 
 2233 
AF patients presenting with an acute ischemic stroke or TIA 2234 
 2235 
In AF-associated acute ischemic stroke, the risk of early recurrence is high: for example, the 2236 
International Stroke Trial reported a 4.8% risk of recurrent stroke in those with AF within the first 2 2237 
days
311
, while other studies suggest a recurrence risk of between 0.4% and 1.3% per day in the first 2238 
7-14 days 
311-315
. AF-related ischemic strokes are more often disabling or fatal than other types, with 2239 
longer hospital stays and higher costs
316
, so preventing early recurrence is a key clinical challenge.  2240 
 2241 
The safety and benefit of OAC in acute stroke have not been established. Early anticoagulation (i.e. 2242 
in the first few days) might increase the risk of symptomatic intracranial hemorrhage, including 2243 
hemorrhagic transformation of the infarct (estimated at ~1% per day
317
), leading to clinical 2244 
uncertainty about when to start anticoagulation. Recent studies reported an 8-10% risk of recurrent 2245 
ischemic stroke and a 2-4% risk of symptomatic intracranial hemorrhage within 90 days of AF-related 2246 
ischemic stroke
318,319
.   2247 
 2248 
Current uncertainty regarding optimal timing of anticoagulation 2249 
Current guidelines do not provide clear recommendations on the timing of OAC after acute AF-2250 
related stroke. US guidelines suggest that commencing OAC within 14 days is reasonable 
320
 while 2251 
recent European Society of Cardiology guidelines recommend starting anticoagulation - according to 2252 
infarct size – at 1, 3, 6, or 12 days
321
 based only on expert consensus.  Current UK guidelines 2253 
recommend delaying anticoagulation for 14 days for “disabling” stroke (Intercollegiate Stroke 2254 
Working Party. National Clinical Guideline for Stroke 2016. (https://www.strokeaudit.org).  2255 
 2256 
A recent observational study (n=1029) suggested that anticoagulation at 4-14 days after 2257 
cardioembolic stroke had the best outcome, but did not have statistical power to determine benefit 2258 
of earlier anticoagulation 
322
. Increasing cerebral infarct size is associated with increased risk of both 2259 
symptomatic hemorrhagic transformation and early recurrent ischemia 
317
 2260 
 2261 
A systematic review and meta-analysis of 7 randomized trials of unfractionated heparin (UFH), low-2262 
molecular-weight heparin (LMWH) or heparinoids (n=4624) started <48 hours, vs. aspirin or placebo, 2263 
found that early anticoagulation was associated with non-significantly reduced recurrent ischemic 2264 
stroke, but with increased intracranial bleeding, and no reduction in death or disability (e-Table 2265 
19).
314
 In contrast, other small studies suggested fewer ischemic strokes without an increase in 2266 
intracranial bleeding, as well as reduced mortality and disability with early initiation of vitamin K 2267 
antagonists (to achieve therapeutic levels by day 7) 
319,323-325
. Observational data suggest that the use 2268 
of low molecular weight heparin (as a “bridging” strategy) together with oral anticoagulation is 2269 
associated with a higher risk of symptomatic hemorrhage.
318,326-328
 2270 
 2271 
Observational studies suggest early (<14 days) anticoagulation with NOACs might be safe 
318
 
319,322
 2272 
329
.  One study reported improved outcomes and no early ICH with NOAC started at a median of 4 2273 
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days post-stroke (n=1192)
330,331
.  The Pre-TIMING observational study of 249 patients with AF-2274 
associated acute ischemic stroke treated with OAC (<5 days) reported in-hospital recurrent ischemic 2275 
stroke in 4.4%, and symptomatic ICH in 3.1% 
332
.    There are no large trials of NOACs including 2276 
patients within 7-14 days of a stroke, but one small study (Triple AXEL) randomized 195 patients with 2277 
AF-related acute ischemic stroke to rivaroxaban or warfarin <5 days and found similar rates of 2278 
symptomatic/asymptomatic MRI-defined recurrent ischemia (~30%) or intracranial bleeding (~30%) 2279 
at 4 weeks, with reduced hospital stay for rivaroxaban
333
.    2280 
Recommendations   2281 
34. In AF patients with acute ischaemic stroke, we suggest that very early anticoagulation (<48h) 2282 
using heparinoids or VKA should not be used (ungraded consensus-based statement). 2283 
Remark: Heparinoids should not be used as bridging therapy in the acute phase of ischaemic 2284 
stroke because they appear to increase the risk of symptomatic intracranial haemorrhage 2285 
without net benefit. The optimal timing of anticoagulation after acute ischaemic stroke is 2286 
unknown.   2287 
 2288 
35. In AF patients with acute stroke without contraindications, we recommend that long term oral 2289 
anticoagulation is indicated as secondary prevention (Strong recommendation, high quality 2290 
evidence).   2291 
Remark: The optimal timing of anticoagulation early after acute ischaemic stroke is unknown. 2292 
Early use of NOACs shows promise but requires testing in randomised controlled trials. 2293 
 2294 
36. In AF patients with acute ischaemic stroke, We suggest that oral anticoagulation should 2295 
usually be started within 2 weeks of acute ischaemic stroke, but the optimal timing within this 2296 
period is not known (ungraded consensus-based statement). 2297 
Remark: Although infarct size is clinically used to guide timing of anticoagulation, it is predictive 2298 
of a higher risk of early recurrent ischaemia, haemorrhagic transformation of the infarct, and 2299 
poor outcome, so might not be helpful in determining the net benefit of early treatment. 2300 
Remark: Anticoagulation with NOACs soon after stroke (earlier than 1 week) has not been tested 2301 
in randomised trials, but shows promise in observational studies. 2302 
 2303 
AF patients with intracerebral hemorrhage (ICH) 2304 
 2305 
Spontaneous (non-traumatic) intracerebral hemorrhage (ICH) causes about 1 in 10 strokes, and is 2306 
caused by the rupture of a cerebral artery or arteriole, most often a small vessel affected by either 2307 
hypertensive arteriopathy or cerebral amyloid angiopathy. ICH is the most feared, often lethal, 2308 
complication of antithrombotic (anticoagulant and antiplatelet) therapy. Recent data indicate that 2309 
about 50% of people with ICH are taking an antithrombotic agent at the time of ICH.
334
 In a recent 2310 
hospital ICH cohort study, 25% of patients had AF
335
 2311 
 2312 
Risk of ischemic stroke  2313 
Survivors of ICH with AF are at risk of further brain ischemia but also recurrent ICH.  The use of 2314 
antithrombotic therapy (antiplatelet agents and anticoagulants) following ICH thus presents a major 2315 
clinical dilemma. The risk of ischemic stroke with and without antithrombotic treatment must be 2316 
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weighed carefully against the possible increase in ICH risk associated with antithrombotic therapy. 2317 
The risk of ischemic stroke in people with AF is typically estimated using instruments such as the 2318 
CHA2DS2VASC score and it seems reasonable to use this score in populations of ICH survivors
336
.  2319 
 2320 
Risk of recurrent ICH  2321 
The future risk of ICH is highly variable; the annual recurrence risk was between 1.8% and 7.4% in 2322 
one recent systematic review of observational studies
337
. Computed tomography is a highly sensitive 2323 
test for ICH and can classify the location as “lobar” (originating in the lobes of the brain) or “deep” 2324 
(originating in the basal ganglia or brainstem).
338
  The risk of recurrence has been reported to be 2325 
higher for lobar ICH than after deep ICH,
337
 a finding which is probably related to different 2326 
underlying small vessel diseases that cause ICH in the different locations. Although CT can define ICH 2327 
location, it cannot reliably identify the underlying type of causal small vessel disease. Magnetic 2328 
resonance imaging (MRI) can identify biomarkers of small vessel disease including cerebral 2329 
microbleeds (CMBs), whose distribution can be used to diagnose cerebral amyloid angiopathy (CAA) 2330 
with high specificity in ICH cohorts
339
.   In a recent pooled analysis of observational studies, patients 2331 
with ICH classified using CMBs as due to CAA had a ~7% annual recurrence risk, compared with ~1% 2332 
for those not fulfilling criteria for CAA
340
. 2333 
 2334 
Since oral anticoagulants increase the risk of ICH, some experts have recommended avoiding them in 2335 
patients with ICH attributed to CAA. In survivors of ischemic stroke and TIA, CMBs are also 2336 
associated with increased risk of ischemic stroke, although as the number of CMBs increases, the risk 2337 
of future ICH increases more steeply than that of ischemic stroke.
341
 In ICH survivors the number of 2338 
CMBs is also associated with the risk of recurrent ICH.
342
  2339 
 2340 
Balancing the risks of ischemic stroke and recurrent ICH  2341 
A decision analysis which modelled warfarin for AF in an ICH survivor suggested that in lobar ICH 2342 
avoiding warfarin increased quality-adjusted life (QOL) years by 1.9, compared with 0.3 for deep ICH; 2343 
the authors concluded that anticoagulation for AF should not be offered to patients with lobar ICH 2344 
and only to survivors of deep ICH if the risk of ischemic events was high (>7% per year)
343
. However, 2345 
CMBs were not considered in this analysis. In contrast, recent “real-world” observational 2346 
studies(including some very large registry datasets) from ICH survivors with AF suggest that 2347 
anticoagulation might reduce mortality and ischemic complications, without an unacceptable 2348 
increase in ICH.  2349 
 2350 
A recent systematic review and meta-analysis of observational studies suggested that restarting 2351 
anticoagulation was associated with a significantly lower risk of thromboembolic complications 2352 
(pooled RR 0.34; 95% CI 0.25–0.45; Q=5.12, P for heterogeneity=0.28) with no increased risk of 2353 
recurrent ICH (pooled RR 1.01; 95% CI 0.58–1.77; Q=24.68, P for heterogeneity <0.001).
344
 However, 2354 
none of the real world studies stratified ICH by location, nor by CMB burden or distribution. Two 2355 
small randomized studies of early anticoagulation after ICH were not able to confirm benefit or 2356 
harm.
345,346
 There are no reliable randomized trial data to guide the timing of anticoagulation after 2357 
ICH. In acute ICH, hematoma expansion is common, and is aggravated by anticoagulation. 2358 
Anticoagulants should therefore be reversed and avoided in acute ICH (<24-48 hours).  2359 
 2360 
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A survival model based on observational data indicated that the total stroke risk (both ischemic and 2361 
ICH) was lowest when anticoagulation was restarted after about 10 weeks, and a delay of at least 4 2362 
weeks after ICH was suggested.
347
 There are no large scale randomized controlled trials to answer 2363 
the question of whether long-term anticoagulation has net benefit in ICH survivors with AF.  NOACs 2364 
have a ~50% lower ICH risk than VKA
127
, and are therefore preferred in most ICH survivors, except 2365 
where warfarin is indicated (e.g. in those with metallic mechanical heart valves). Observational data 2366 
suggest that ICH occurring on OAC are of similar size and with similar clinical outcome in patients 2367 
taking VKA or NOACs.
348
 2368 
 2369 
There are two ongoing randomized trials of antithrombotic use after ICH: APACHE-AF 2370 
(http://apache-af.nl –aspirin vs. apixaban vs. no antithrombotics for the treatment of AF in patients 2371 
after ICH) and RESTART (www.restarttrial.org –antiplatlets vs, no antiplatelets in patients with ICH 2372 
with an indication for antiplatelets). 2373 
 2374 
Left atrial appendage occlusion in ICH survivors  2375 
Randomized trials indicate that left atrial appendage occlusion (LAAO) has similar efficacy to oral 2376 
anticoagulation in patients with AF; thus, in ICH survivors with AF and high ischemic stroke risk, 2377 
LAAO is a potentially attractive option to reduce ischemic stroke and systemic embolism from AF 2378 
without the need to expose patients to a long-term risk of oral anticoagulation.
349
 Observational 2379 
data from 1025 patients suggest that LAAO might be safe and effective in patients with a contra-2380 
indication to long term oral anticoagulation, but only a minority of patients (15%) in this study had 2381 
suffered ICH.
350
 Small studies of ICH survivors suggest that LAAO, using antiplatelet treatment as 2382 
periprocedural antithrombotic treatment, is safe and effective in this population, including those 2383 
with CAA 
351,352
 Randomized trials of LAAO, ideally In comparison to NOACs, are needed to 2384 
definitively determine the safety and efficacy of each approach in ICH survivors.  2385 
Recommendations   2386 
37. In patients with AF and high ischaemic stroke risk, we suggest anticoagulation with a NOAC 2387 
after acute spontaneous ICH (which includes subdural, subarachnoid and intracerebral 2388 
haemorrhages) after careful consideration of the risks and benefits (ungraded consensus-2389 
based statement). 2390 
Remark: The balance of net benefit from long term oral anticoagulation might be more 2391 
favourable in those with deep ICH or without neuroimaging evidence of cerebral amyloid 2392 
angiopathy. 2393 
Remark: In ICH survivors with AF, clinicians should aim to estimate the risk of recurrent ICH 2394 
(using ICH location and, where available, MRI biomarkers including cerebral microbleeds) and 2395 
the risk of ischaemic stroke 2396 
Remark: The optimal timing of anticoagulation after ICH is not known, but should be delayed 2397 
beyond the acute phase (~48 hours) and probably for at least ~4 weeks. Randomised trials of 2398 
NOACs and left atrial appendage occlusion are ongoing. 2399 
 2400 
38. In ICH survivors at high risk of recurrent ICH (e.g. those with probable cerebral amyloid 2401 
angiopathy), we suggest left atrial appendage occlusion (ungraded consensus-based 2402 
statement).  2403 
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Remark: Cerebral amyloid angiopathy should be diagnosed using validated clinico-radiological 2404 
criteria. 2405 
 2406 
AF patients with carotid disease 2407 
 2408 
Carotid stenosis is present in about 8% of people over the age of 60.
353
 A recent multicenter 2409 
retrospective study found >50% carotid stenosis in 18.3% of patients with AF, which was associated 2410 
with a doubling of stroke risk.
354
 Thus in patients with both carotid stenosis and AF there are 2411 
indications for both anticoagulation and antiplatelet therapy, yet this combination, at least in the 2412 
long term, is associated with high bleeding risk and is thus generally not recommended.   2413 
 2414 
Randomized trials show superiority for carotid endarterectomy over stenting in patients with 2415 
symptomatic stenosis (>50%) of the internal carotid artery.
355
 This could reduce the need for 2416 
combination therapy with OAC and antiplatelet drugs in those with AF. Current practice is to treat all 2417 
potential stroke risk factors including AF and carotid stenosis. Those who have had successful carotid 2418 
revascularization are typically managed with OAC alone. In patients with carotid stenosis not treated 2419 
by revascularization (including those with asymptomatic disease) as well as AF, the optimal 2420 
management is not known and requires further randomized data; meanwhile, decisions need to be 2421 
tailored to the individual patient.   2422 
Recommendations 2423 
39. In patients with AF and symptomatic carotid stenosis (>50%), we suggest carotid 2424 
revascularisation with endarterectomy or stenting in addition to OAC as indicated (Weak 2425 
recommendation, moderate quality evidence). 2426 
 2427 
40. In patients with AF and carotid stenosis treated with revascularisation, we suggest OAC 2428 
therapy, without long-term antiplatelet therapy (ungraded consensus-based statement). 2429 
Remark: There is limited evidence to guide the optimal treatment of patients with AF and carotid 2430 
stenosis not requiring revascularisation. Remark: Short-term concomitant antiplatelet therapy 2431 
(dual or mono) is generally used in the immediate post-revascularisation period (e.g. 1-3 2432 
months) 2433 
 2434 
Patients presenting with Embolic Stroke of Undetermined Source (ESUS) 2435 
 2436 
In North America and Europe, about 1 in 4 ischemic strokes remain of uncertain etiology (i.e. not 2437 
attributable to definite cardiac embolism, large artery atherosclerosis, or small artery disease), 2438 
despite adequate investigation, and are termed “cryptogenic”.
320,356
  2439 
 2440 
Because most cryptogenic strokes are embolic, a more recent concept of embolic stroke of 2441 
undetermined source (ESUS) has been developed, defined as ischemic stroke detected by CT or MRI 2442 
that, after a standardized and adequate diagnostic pathway including brain imaging, 2443 
echocardiography, cardiac rhythm monitoring for at least 24 hours, and imaging of the intracranial 2444 
and extracranial arteries supplying the affected brain area: is not lacunar (subcortical, less than 2445 
15mm diameter); where there is absence of extracranial or intracranial atherosclerosis causing ≥50% 2446 
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luminal stenosis in the arteries supplying the area of ischemia; no major-risk cardioembolic source of 2447 
embolism (permanent or paroxysmal atrial fibrillation, sustained atrial flutter, intra-cardiac 2448 
thrombus, prosthetic cardiac valve, atrial myxoma or other cardiac tumours, mitral stenosis, recent 2449 
(<4 weeks) myocardial infarction, left ventricular ejection fraction less than 30%, valvular 2450 
vegetations, or infective endocarditis); and no other specific cause of stroke identified (e.g. arteritis, 2451 
dissection, migraine/vasospasm, drug misuse)
357
.  2452 
Thus, ESUS is a sub-category of cryptogenic stroke, accounting for about 1 in 6 ischemic strokes.
358
 A 2453 
careful and systematic diagnostic work up in patients with ESUS is needed as there might be 2454 
important management differences between underlying embolic sources if detected, such as aortic 2455 
arch atheroma, patent foramen ovale, and paroxysmal AF.   This brief section only refers to the 2456 
latter. 2457 
 2458 
As a general principle, AF can be detected in a high proportion of ESUS patients, if we ‘look harder, 2459 
look longer and look with more sophisticated monitoring’ (Table 10). Screening consecutive patients 2460 
with ischemic stroke with routine Holter or event loop recorder monitoring will identify new 2461 
AF/atrial flutter in approximately 1 in 20 patients
359
.  2462 
 2463 
Two randomized controlled trials clearly showed that prolonged cardiac monitoring increases the 2464 
detection of occult AF in patients with TIA or acute ischemic stroke presenting in sinus rhythm. In 2465 
CRYSTAL AF, 441 patients randomly assigned to prolonged ambulatory cardiac monitoring with a 2466 
subcutaneous implantable loop recorder or to a control group with conventional follow-up, detected 2467 
more AF in the monitored group (8.9% vs. 1.4% in the control group; HR 6.4, 95% CI 1.9-21.7); 
360
 2468 
while in EMBRACE, 572 patients randomly assigned to additional ambulatory monitoring with a 30-2469 
day external loop recorder (intervention group) or a 24-hour Holter monitor (control group) found 2470 
more AF in the intervention group (16.1% vs. 3.2% in the control group; absolute difference, 12.9 % 2471 
95% CI 8.0-17.6).
361
  2472 
 2473 
In a systematic review and meta-analysis, Sposato et al
362
 described a much higher rate of AF 2474 
detection after multi-phase sequential cardiac monitoring, at 23.7% (Table 10). Despite this, one 2475 
recent analysis only found that 2.6% and 9.7% of stroke patients had ambulatory ECG monitoring in 2476 
the 7 days and 12 months post-stroke leading to underdiagnosis.
363
 2477 
 2478 
 2479 
Table 10: Phases of screening for AF in cryptogenic stroke patients, methods and incidence of AF 2480 
diagnosed 
362
 2481 
 2482 
4 sequential phases of screening  Cardiac monitoring methods  
 
% (95% CI) diagnosed with post
Phase 1 (emergency room)-  admission electrocardiogram (ECG) 7·7% (5·0–10·8) 
Phase 2 (in hospital)  serial ECG, continuous inpatient ECG monitoring, 
continuous inpatient cardiac telemetry, and in-
hospital Holter monitoring 
5·1%  
(3·8–6·5)  
Phase 3 (first ambulatory period)  ambulatory Holter;  10·7%  
(5·6–17·2)  
Phase 4 (second ambulatory 
period)  
mobile cardiac outpatient telemetry, external loop 
recording, and implantable loop recording 
16·9%  
(13·0–21·2) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 69
 2483 
 2484 
Unsurprisingly, AF is more likely to be detected in elderly patients with more prolonged monitoring, 2485 
especially if there is evidence of prior embolic cortical or cerebellar infarction
364,365
.   In a 2486 
retrospective analysis, newly detected atrial tachycardia (AT) or AF (NDAF; AT/AF >5 minutes on any 2487 
day) was identified in 30% patients with implantable cardiac rhythm devices and ≥1 stroke risk 2488 
factors during a follow-up of 1.1 years
366
. The presence of AT/AF >6 hours on ≥1 day increased 2489 
significantly with increased CHADS2 scores.  Similarly, the ASSERT-II study reported that subclinical 2490 
AF lasting ≥5 minutes was present in 34.4% per year, in a prospective cohort of elderly patients with 2491 
risk factors but no prior stroke
367
.   2492 
 2493 
Of note, data from the Athens Stroke Registry show that the CHADS2 and CHA2DS2-VASc scores are 2494 
independently associated with the risk of ischemic stroke/TIA recurrence and death in ESUS patients, 2495 
with the risk of stroke recurrence and death in patients with a CHA2DS2-VASc score ≥2 being 2496 
approximately 3-fold and 15-fold higher compared with that in patients with a score of 0, 2497 
respectively
368
.  If ESUS is phenotypically different from AF-associated stroke, we should see 2498 
differences in stroke severity and outcomes; however, no difference in NIHSS score was evident in 2499 
ESUS where AF was detected on follow-up, compared to where no AF was evident
369
. Nevertheless, 2500 
it remains possible that within ESUS there is a spectrum of underlying proximal embolic sources, 2501 
suggested by the strong effect of age on recurrence risk and mortality
370
. 2502 
 2503 
Current guidelines recommend use of antiplatelet agents including aspirin in ESUS patients
320
 unless 2504 
AF is detected (often requiring prolonged work up, as above), when such patients would be 2505 
managed with oral anticoagulation. The available data (mainly from retrospective observational 2506 
studies) suggest a sizeable rate of stroke recurrence (more than 4% per year) despite the frequent 2507 
use of antiplatelet agents in clinical practice.
358
 Thus, there is an important clinical need for more 2508 
effective antithrombotic therapy for ESUS. Since a large proportion of ESUS are likely to be due to 2509 
undetected AF, oral anticoagulation is a theoretically attractive option.  2510 
 2511 
Ongoing randomized trials comparing NOACs to aspirin in ESUS patients are in progress. Prior to data 2512 
from these trials, physicians might, in the meantime, consider the use of anticoagulation in parallel 2513 
with continued cardiac evaluation (e.g. prolonged rhythm monitoring) after discussion and 2514 
consideration of patient preference.  2515 
 2516 
ATRIAL HIGH-RATE EPISODES DETECTED BY CARDIAC IMPLANTED 2517 
ELECTRONIC DEVICES 2518 
Cardiac implanted electrical devices (CIEDs) with an atrial lead or with capability of rhythm 2519 
discrimination (i.e. implantable cardiac monitors) allow continuous monitoring of the cardiac rhythm 2520 
and  appropriate detection of  atrial tachyarrhythmias,  including AF,  as atrial high-rate episodes 2521 
(AHREs) as well as storing arrhythmia electrograms in the device’s memory for review and specific 2522 
diagnosis. AHREs, currently defined as episodes of at least 5 min of atrial tachyarrhythmias/AF with 2523 
an atrial rate >180 bpm, are usually asymptomatic, discovered during routine device follow-up and 2524 
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classified in terms of duration of the single episode or time spent in atrial tachyarrhythmias during a 2525 
day (from minutes to hours) 
371-377
. 2526 
 2527 
Although temporal cut-offs for detection and storage of AHRE data as short as 30-60 seconds have 2528 
been used, the diagnostic accuracy is reliable when episodes ≥5 minutes in duration are considered, 2529 
since, using this cut-off, the appropriateness in AF detection is 95%, minimizing the risk of over-2530 
sensing due to detection of artefacts caused by myopotentials or other sources of electrical 2531 
interference 
378,379
. Individual patient analysis of electrograms corresponding to AHREs is clinically 2532 
indicated to exclude artifacts or other causes of inappropriate detection of atrial tachyarrhythmias 2533 
or AF. Electrograms of AHREs correspond to intracardiac electrograms recorded from right atrial 2534 
appendage or right atrium so a diagnosis of tachyarrhythmias can be easily made through analysis of 2535 
tracings recorded in the device’s memory 
159
.  After detection of AHREs by CIEDs, conventional 2536 
Holter or other ECG long-term recordings (i.e., patient operated devices) can be considered in 2537 
specific cases (e.g. unavailable electrograms or unclear diagnosis at device electrograms analysis).  2538 
 2539 
The possibility of continuous monitoring of AF through implanted devices has led to new terms, such 2540 
as “AF burden”, defined as the overall time spent in AF during a specified period of time 
372,380
 
381
 
382
), 2541 
and “subclinical AF”, corresponding to episodes of atrial tachyarrhythmias  with duration between 5 2542 
min and 24 h, detected by a CIED in patients without clinical history or clinical symptoms of AF 2543 
371,375,376,383,384
.  2544 
 2545 
The prevalence of AHRE, often reported as AF burden, among patients implanted with CIEDs varies, 2546 
depending on underlying heart disease, periods of observation, and above all previous history of 2547 
clinically overt atrial tachyarrhythmias, including AF. In the ASSERT study, subclinical atrial 2548 
tachyarrhythmias with at least 6 min duration were detected within 3 months in around 10% of 2549 
patients implanted with a CIED 
375
. During a follow-up period of 2.5 years, additional subclinical atrial 2550 
tachyarrhythmias occurred in approximately 25% of patients, and around 16% of those who had 2551 
subclinical atrial tachyarrhythmias developed symptomatic AF
375
. Considering these findings, as well 2552 
as data from the literature reported in e-Table 20, there is evidence that AHREs with a duration >5-6 2553 
min are common in patients implanted with CIEDs. 2554 
 2555 
In patients implanted with CIEDs for conventional indications, AHREs, with a short duration,  ranging 2556 
from three atrial premature complexes to 15–20 s, are currently considered of no specific clinical 2557 
significance since this type of AHRE was found not to be significantly associated with  episodes of 2558 
longer duration, or with an increased risk of stroke or systemic thromboembolism 
385
 .  For this 2559 
reason most of the interest is patient with CIEDs is focused on AHRE with a duration ≥5–6 min,  a 2560 
finding associated  with a substantial risk of subsequently presenting clinical  AF (HR 5.5–6.0), 2561 
initially reported by the ancillary MOST analysis 
386
 and then by  the ASSERT study 
375
,  where a CIED-2562 
detected AHREs  >6 min were  followed by clinical AF detected by a surface ECG in approximately 2563 
16% of patients at 2.5 years of follow-up (e-Table 21). 2564 
 2565 
The association between CIED-detected atrial tachyarrhythmias of variable durations and stroke or 2566 
systemic thromboembolism has been evaluated by several studies that overall collected data on 2567 
>22,000 patients, taking into account the maximum duration of AHRE episode, or the maximum daily 2568 
AF  burden (that is, the maximum time spent in adjudicated AF in one day of the follow-up 2569 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 71
period)
375,385-393
. The studies show that AHRE burden with a duration ≥5–6 min are significantly 2570 
associated with an increase in the risk of stroke or systemic thromboembolism (HR 2–9). In a re-2571 
analysis of the ASSERT study 
394
, the increase in the risk of stroke occurred only when the longest 2572 
duration of the various episodes of detected AHREs was >24 h. The largest dataset of patients with 2573 
CIED-detected AHREs was analysed in the SOS AF project, with a pooling of three prospective studies 2574 
(PANORAMA, Italian Clinical Services Project, and TRENDS) resulting in 10,016 patients 
391
. During a 2575 
median follow-up of 24 months, 43% of an unselected cohort of patients with implanted devices 2576 
experienced ≥1 day with ≥5 min of AHRE burden and a 1-h threshold of AHRE burden was associated 2577 
with a hazard ratio for ischemic stroke of 2.11 (95% CI 1.22–3.64, P = 0.008), although the absolute 2578 
risk of ischemic stroke in patients with AHREs was low (0.39% annual rate in the whole cohort). 2579 
Similarly, the TRENDS study 
389
 found that an AHRE burden of 5.5 h in a day, in a 30-day period, was 2580 
associated with a two-fold increase in the adjusted risk of stroke (absolute risk of thromboembolism 2581 
around 1.8% per year)
389
. Integration of AHRE presence, duration, or burden (≥5 min or ≥24 h) into 2582 
risk scores for thromboembolism may modestly improve c-statistics of both the CHADS2 and 2583 
CHA2DS2-VASc scores for predicting stroke 
395
.  2584 
 2585 
The clinical significance of AHRE is presumably different from that of clinically identified AF since the 2586 
latter, detected using conventional surface ECG methods corresponds to a much higher AF burden as 2587 
compared to patients with AHRE detected by continuous monitoring via a CIED 
374,376
.  The actual 2588 
rates of stroke or systemic embolic events reported in studies evaluating CIED-detected AHREs are 2589 
often lower than what would be predicted by CHADS2 and CHA2DS2-VASc scores and this may be 2590 
related to concurrent treatment with oral anticoagulants in each study, risk of under-reporting and 2591 
confounding.  Also, the temporal relationship between ischemic stroke and AF is less strict than 2592 
expected, since stroke may occur without the concurrent presence of atrial tachyarrhythmias or AF 2593 
at the time of stroke or in the days before. These findings suggest that the relationship between AF 2594 
and stroke can be complex, with AF involved but not always in a causative role (mediated by a left 2595 
atrial thrombus), but also simply representing a marker of increased vascular risk
372,376
.  2596 
 2597 
Two randomized controlled trials are ongoing evaluating the efficacy and risk-benefit ratio of oral 2598 
anticoagulation to no oral anticoagulation (aspirin only) in patients with CIED-detected AHRE 2599 
(ARTESiA (NCT01938248)
396
 and NOAH – AFNET 6 (NCT02618577).
397
   2600 
 2601 
In the absence of the results of these on-going trials, management of patients with CIEDs-detected 2602 
AHREs  requires cardiological clinical evaluation, clinical decision making and follow up (Figure 7). 2603 
Oral anticoagulants could be considered as a result of an individualized clinical assessment taking 2604 
into account overall AHRE burden (in the range of multiple hours rather than few minutes) and 2605 
specifically presence of AHRE > 24 hours, individual stroke risk (CHA2DS2-VASc), predicted risk benefit 2606 
of oral anticoagulation (specifically risk of major bleeding) and informed patient preferences. 2607 
Recommendations 2608 
41. For patients that present with a clinically documented episode of AF (12-lead ECG or other 2609 
means, eg. external devices with validated rhythm detection), we suggest that the presence or 2610 
absence of symptoms must not influence the process of decision making with regard to the 2611 
need for anticoagulation based on risk stratification (ungraded consensus-based statement). 2612 
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 2613 
42. In cases of AHRE (atrial high rate episodes) detected by a CIED of at least 5 min duration, we 2614 
suggest that direct analysis of electrograms corresponding to AHRE is clinically indicated to 2615 
exclude artifacts or other causes of inappropriate detection of atrial tachyarrhythmias or AF 2616 
(ungraded consensus-based statement). 2617 
Remark: In patients with CIED detected AHRE a complete cardiological evaluation is indicated, 2618 
with 12-lead ECG, general assessment of clinical conditions and clinical risk stratification for 2619 
stroke using CHA2DS2VASc score. 2620 
Remark: There is no evidence in support or against prescription of oral anticoagulants in patients 2621 
at risk of stroke (intermediate to high risk according to CHA2DS2VASc) who present with AHREs, 2622 
corresponding to atrial tachyarrhythmias/AF at electrograms assessment of less than 24 hours 2623 
duration. 2624 
 2625 
43. In patients with AF, we suggest that prescription of oral anticoagulants could be considered as 2626 
a result of an individualized clinical assessment taking into account overall AHRE burden (in 2627 
the range of hours rather than minutes) and specifically, the presence of AHRE > 24 hours, 2628 
individual stroke risk (using CHA2DS2VASc), predicted risk benefit of oral anticoagulation and 2629 
informed patient preferences (ungraded consensus-based statement).   2630 
Remark: In patients with CIED detected AHRE continued patient follow-up is recommended, 2631 
preferentially combining clinical follow up with remote monitoring of the CIED or else more 2632 
frequent device interrogation than standard for CIED follow-up, to detect the development of 2633 
clinical AF (symptomatic or asymptomatic), to monitor the evolution of AHRE or AF burden and 2634 
specifically the transition to AHRE lasting more than 24 hours,onset or worsening of heart 2635 
failure, or any clinical change that might suggest a change in clinical profile or clinical conditions. 2636 
 2637 
ATRIAL FLUTTER 2638 
The risk of thromboembolism and stroke in patients with atrial flutter has been evaluated in 2639 
relatively few studies compared to AF. However, patients with atrial flutter frequently present 2640 
phases of AF alternated with phases of classical flutter or regular atrial rhythm 
398-400
.  A systematic 2641 
review on the thromboembolic risk associated with atrial flutter, including 52 articles, found that 2642 
thromboembolic event rates after  cardioversion, varied from 0% to 6% with a follow-up from 1 2643 
week to 6 years.
235,273,275,276,401-411
 Echocardiographic studies reported prevalence of intra-atrial 2644 
thrombi from 0% to 38% and a prevalence of spontaneous echo contrast up to 28%. 
398,399,409,412-421
 2645 
One ablation study in non-anticoagulated patients with atrial flutter reported thromboembolic 2646 
events in 13.9% of cases. 
422
 The differences in patient selection, type of study and, importantly, use 2647 
of oral anticoagulation explain the heterogeneity of reported data with regard to echo findings and 2648 
thromboembolic complications. Observational studies demonstrated an increased risk of stroke (risk 2649 
ratio 1.4, 95% CI 1.35 to 1.46) and death (HR 1.9, 95% CI 1.2 to 3.1)
401
 compared to controls at long-2650 
term follow-up. 2651 
 2652 
A report from the Danish nationwide registry on patients undergoing an atrial flutter ablation or an 2653 
AF ablation procedure between 2000–2013, found that the rate of thromboembolic events for atrial 2654 
flutter patients was 0.46 per 100 persons-years,  not significantly different from that  of patients 2655 
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presenting with AF (HR adjusted for several variables including anticoagulation = 1.22 [0.62–2656 
2.41]).
401
  2657 
 2658 
The role of anticoagulant therapy for patients with atrial flutter has not been evaluated in large 2659 
randomized clinical trials, but because these patients often have concomitant AF or are at increased 2660 
risk of developing AF, it is reasonable to base decisions regarding antithrombotic therapy on the 2661 
same risk stratification schemes and scores used for AF. 
423
 2662 
Recommendation.  2663 
44. For patients with atrial flutter, we suggest that antithrombotic therapy decisions follow the 2664 
same risk-based recommendations as for AF. (ungraded consensus-based statement).  2665 
 2666 
PREGNANCY 2667 
Atrial fibrillation (AF) and atrial ﬂutter are very rare during pregnancy, unless when there is an 2668 
underlying structural heart disease or hyperthyroidism. 
424
  Lone AF is uncommon in pregnancy and 2669 
is associated with older age and late pregnancy. 
425
  In countries where the prevalence of rheumatic 2670 
heart disease is still high or among immigrants from these areas to Western countries the 2671 
prevalence of AF in pregnancy may be commonly related to rheumatic heart disease. 
425
 Peri-partum 2672 
cardiomyopathy AF is common, with a prevalence that may reach 10%,  and may severely impair 2673 
hemodynamic status. 
426
 2674 
 2675 
In a registry of >250, 000 pregnancies in Southern California 
427
 AF was evident  in 0.6 per 1000, 2676 
more frequently in white women (1,1 per 1000 pregnancies), and was associated with more 2677 
advanced age, higher BMI, hypertension, hyperlipidemia, and diabetes. Decision-making on 2678 
antithrombotic therapy during pregnancy has been reviewed in detail in the 9
th
 Edition of the 2679 
Antithrombotic Therapy and Prevention Guidelines; here we provide an update with 2680 
recommendations focused on AF.
428
 2681 
 2682 
The use of anticoagulant therapy during pregnancy is challenging because of the potential  for both 2683 
fetal and maternal complications. Pregnancy-induced changes in hemostasis lead to a state of 2684 
hypercoagulability, so in a women with AF at risk of stroke/thromboembolism in the non-pregnant 2685 
state, pregnancy will increase this risk 3- to 4- fold.
428,429
 2686 
 2687 
Vitamin K antagonists cross the placenta and have the potential to cause fetal wastage, bleeding in 2688 
the fetus, and teratogenicity. The most common fetal anomaly developing as a consequence of fetal 2689 
exposure to warfarin consists of midfacial hypoplasia and stippled epiphyses and typically occurs 2690 
after in utero exposure to vitamin K antagonists during the first trimester of pregnancy 
428
. Vitamin K 2691 
antagonists have also been associated with central nervous system abnormalities after exposure 2692 
during any trimester, but these complications are uncommon. 
428
 There is general consensus that in 2693 
order to minimize the risk of warfarin embryopathy it is reasonable to avoid warfarin between 2694 
weeks 6 and 12 of gestation because of the high risk of fetal defects, especially if the dose of 2695 
warfarin is higher than 5 mg per day. 
424
 2696 
 2697 
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LMWH does not cross the placenta and there is no evidence that LMWH causes teratogenicity or 2698 
increases fetal bleeding. Because of accelerated clearance, LMWH has a shorter half-life and lower 2699 
peak plasma concentration during pregnancy thus potentially requiring higher doses. For this reason, 2700 
use of LMWH (such as between weeks 6 and 12) has to be managed with dose adjustment according 2701 
to weight and target anti-Xa level (4–6 hours post-dose 0.8–1.2 U/mL). 2702 
 2703 
Unfractionated heparin (UFH) does not cross the placenta and therefore can be safely used in 2704 
pregnancy. However, it carries some risk of heparin-induced thrombocytopenia and osteopenia, 2705 
which may lead to symptomatic vertebral fracture in approximately 2% of women 
428
. Moreover, the 2706 
pharmacokinetic changes of pregnancy result in a shorter half-life and lower peak plasma 2707 
concentration of heparin compounds, with the need to titrate doses in order to keep the mid-2708 
interval aPTT (6 hours post dose  ≥ twice control values.  Since both the risk of heparin-induced 2709 
thrombocytopenia and the risk of osteoporosis are lower with LMWH than with UFH, the former is 2710 
preferred as subcutaneous treatment during pregnancy. 2711 
  2712 
Pregnant women were excluded from participating in clinical trials evaluating NOACs. Given the 2713 
rather low molecular weight of NOACs and data on placental transfer in rats, all NOACs  are 2714 
expected to cross the placenta. 
430
  Hence, use of NOACs in pregnancy should be avoided. Limited 2715 
data are available on the consequences of exposure to NOACs but women inadvertently exposed to 2716 
a NOAC in early pregnancy before diagnosis of pregnancy) can be reassured, since the risk of 2717 
embryopathy seems low. In case of planned pregnancy, avoidance of NOACs should be considered 2718 
(with switching to LMWH).  2719 
 2720 
With regard to breast-feeding, warfarin, in view of its characteristics (polar, non-lipophilic, and 2721 
highly protein bound) can be considered safe since two reports showed that warfarin is not detected 2722 
in breast milk and does not induce an anticoagulant effect in the breast-fed infant when nursing 2723 
mothers consume the drug. 
431,432
  Acenocoumarol, which is commonly used in Europe, has similar 2724 
properties. 
433,434
  Use of UFH and LMWH in breast-feeding women appears safe. No clinical data on 2725 
the effect of NOACs on breast-fed infants are available and therefore the recommendation is against 2726 
use these medications in breast-feeding women. 2727 
 2728 
A flow chart on how to manage women with AF during pregnancy is shown in Figure 8 2729 
  2730 
Recommendations  2731 
45. For women receiving OAC for prevention of stroke/TE in AF who become pregnant, we suggest 2732 
discontinuation of OAC with a VKA between weeks 6 and 12 and replacement by LMWH twice 2733 
daily (with dose adjustment according to weight and target anti-Xa level 4-6 hours post-dose 2734 
0.8-1.2 U/mL), especially in patients with a warfarin dose required of >5 mg/day (or 2735 
phenprocoumon >3 mg/day or acenocoumarol >2mg/day). OAC should then be discontinued 2736 
and replaced by adjusted-dose LMWH (target anti-Xa level 4-6 hours post-dose 0.8-1.2 U/mL) 2737 
in the 36th week of gestation (ungraded consensus-based statement). 2738 
 2739 
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46. For women on treatment with long-term vitamin K antagonists who are attempting pregnancy 2740 
and are candidates for LMWH substitution, we suggest performing frequent pregnancy tests 2741 
and use LMWH instead of VKA when pregnancy is achieved rather than switching to LMWH 2742 
while attempting pregnancy (ungraded consensus-based statement). 2743 
 2744 
47. For pregnant women, we suggest avoiding the use of NOACs (ungraded consensus-based 2745 
statement) . 2746 
Remark: For women on treatment with a NOAC we suggest switching to vitamin K antagonists, 2747 
rather than switching to LMWH while ahemp\ng pregnancy.¬† 2748 
 2749 
48. For lactating women using warfarin, acenocoumarol, or UFH who wish to breastfeed, we 2750 
suggest continuing the use of warfarin, acenocoumarol, LMWH or UFH (ungraded consensus-2751 
based statement) 2752 
 2753 
49. For breast-feeding women, we suggest alternative anticoagulants rather than NOACs 2754 
(ungraded consensus-based statement). 2755 
 2756 
 2757 
ATRIAL FIBRILLATION AND CHRONIC KIDNEY DISEASE 2758 
 2759 
Chronic kidney disease (CKD) is frequently present in patients with AF and has significant 2760 
implications on the trajectory of AF, risk of stroke, and bleeding risk of anticoagulation. The presence 2761 
of CKD or AF bi-directionally affects the incident risk of the other. Among patients with CKD, the 2762 
prevalence of AF is substantially higher than in the general population, ranging from 16-21% in non-2763 
dialysis dependent CKD and 15-40% in patients on dialysis
435
.    2764 
 2765 
Among patients with AF, CKD is present in one-third of patients at the time of AF diagnosis
51
 
436
  2766 
although this may be substantially higher among cohorts of prevalent AF subjects. The impact of AF 2767 
is illustrated in the systematic review by Odutayo et al
51
 whereby the presence of AF increased 2768 
chronic kidney disease (1.64, 1.41 to 1.91),  as well as all-cause mortality (relative risk 1.46, 95% CI 2769 
1.39 to 1.54), cardiovascular mortality (2.03, 1.79 to 2.30), major cardiovascular events (1.96, 1.53 to 2770 
2.51), stroke (2.42, 2.17 to 2.71), ischemic stroke (2.33, 1.84 to 2.94), ischemic heart disease (1.61, 2771 
1.38 to 1.87), sudden cardiac death (1.88, 1.36 to 2.60), heart failure (4.99, 3.04 to 8.22), and 2772 
peripheral arterial disease (1.31, 1.19 to 1.45).   2773 
 2774 
AF, CKD and stroke 2775 
CKD increases the baseline risk of ischemic stroke in patients with AF
435
.  The pathophysiological 2776 
mechanisms responsible for stroke and systemic embolism in these patients are multifactorial. The 2777 
precise attributable risk of AF as a causal agent of cardioembolic stroke is therefore unclear, 2778 
particularly where patients have substantially higher risk of atherothrombotic ischemic stroke due to 2779 
hypertension, intracranial and carotid atherosclerosis, heart failure, and CAD.  2780 
 2781 
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Second, CKD increases the competing risk of death from causes unrelated to AF-associated stroke 2782 
and may attenuate expected benefit of stroke prevention therapy. In a recent analysis of seven risk 2783 
stratification scores, all had substantially poorer discrimination in CKD patients than those without 2784 
CKD (c-statistics 0.50-59 vs. 0.69-0.70, respectively), and inclusion of CKD stage did not improve 2785 
calibration or discrimination
437
. One study from Taiwan showed that the CHA2DS2-VASc score could 2786 
adequately risk stratify for ischemic stroke amongst a haemodialysis population (c-index 0.682, 2787 
superior to CHADS2) 
438
. 2788 
 2789 
Third, moderate to severe CKD increases the risk of major and intracranial bleeding through a 2790 
number of mechanisms, and the risk may be further increased by the use of oral anticoagulation or 2791 
antiplatelet therapy. The clinical bleeding risk scores (e.g., HAS-BLED, ORBIT, ATRIA) all include CKD 2792 
measures as part of their score calculation
104
. Therefore, CKD is both a marker of risk of disease and 2793 
of its therapy, and there is significant controversy as to the net clinical benefit of oral anticoagulation 2794 
in severe CKD despite encouraging observational studies 
439
. 2795 
 2796 
Fourth, there are virtually no randomized trial data of oral anticoagulation in severe CKD (creatinine 2797 
clearance < 25-30 ml/min).  Some observational data suggest that warfarin may be harmful in end 2798 
stage renal disease (ESRD) patients on haemodialysis, with no reduction (or an increase) in stroke 2799 
and an excess of major bleeding; however, many of these studies (largely from North America) do 2800 
not report quality of anticoagulation control, as reflected by time in therapeutic range (TTR)
440-442
..  2801 
In contrast, European data suggest that there is a beneficial reduction in ischemic stroke which 2802 
outweighs the increase in severe bleeding, where TTR is good >65-70%
440-442
. 2803 
 2804 
The latest systematic review and meta-analysis by Harel et al
443
 of 14 observational studies (20,398 2805 
participants) among hemodialysis with AF, found that the use of warfarin was not associated with 2806 
ischemic stroke (14 studies; 20,398 participants; HR, 0.85; 95% CI, 0.55- 1.07), or intracranial 2807 
hemorrhage (hemorrhagic stroke; 4 studies; 15,726 participants; aHR, 1.93; 95% CI, 0.93-4.00) (e-2808 
Table 23). They concluded that warfarin was not associated with a clear benefit or harm among 2809 
patients who have AF and receive dialysis.  However, there was marked study heterogeneity 2810 
including the inability to account for major confounders such as the quality of anticoagulation 2811 
control (TTR). One study reported that in AF patients on peritoneal dialysis, warfarin reduced stroke 2812 
and thromboembolism compared to aspirin or no antithrombotic therapy, with no excess in serious 2813 
bleeds (ICH) 
247
. 2814 
The lack of clinical trial data in severe CKD is a major evidence gap with the NOACs, even though 2815 
some regulatory agencies such as the Food and Drug Administration have approved reduced-dosed 2816 
NOACs for severe CKD and dialysis on the basis of pharmacokinetic data
444
. Fortunately, the pivotal 2817 
NOAC randomized trials have demonstrated non-inferiority of NOACs to warfarin among patients 2818 
with creatinine clearance of 30-50 ml/min (and for apixaban 25-50 ml/min)
246
.  2819 
 2820 
All the NOACs have some degree of renal elimination, Cmax, and half-life, with the greatest renal 2821 
dependency for excretion with dabigatran (80%) and the least with renal dependency for apixaban 2822 
(27%). However, there are no head-to-head NOAC trials and therefore insufficient evidence to 2823 
recommend one agent over another. Given these limitations, treatment should be individualized and 2824 
the dose adapted on the basis of creatine-clearance according to licensed indications [see Figure 9].  2825 
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 2826 
Recommendations 2827 
50. For mild CKD (Stage II, CrCl 60-89 ml/min), we suggest that oral anticoagulation clinical 2828 
decision making and treatment recommendations match that of patients without CKD (weak 2829 
recommendation, very low quality evidence). 2830 
 2831 
51. For moderate CKD (Stage III, CrCl 30-59 ml/min), we suggest oral anticoagulation in patients 2832 
with a CHA2DS2-VASc ≥2 with label-adjusted NOACs or dose adjusted vitamin K antagonists 2833 
(Weak recommendation, very low quality evidence). 2834 
Remark: With VKA, good quality anticoagulation control (TTR>65-70%) is recommended. 2835 
 2836 
52. In severe non-dialysis CKD (Stage IV CrCl 15-30), we suggest using VKAs and selected NOACs 2837 
(rivaroxaban 15mg QD, apixaban 2.5mg bid, edoxaban 30mg QD and (in USA only) dabigatran 2838 
75mg bid) with caution, based on pharmacokinetic data (ungraded consensus-based 2839 
statement). 2840 
 2841 
53. In end-stage renal disease (CrCl < 15 or dialysis-dependent), we suggest that individualized 2842 
decision-making is appropriate (ungraded consensus-based statement). 2843 
 2844 
54. In end-stage renal disease (CrCl < 15 or dialysis-dependent , we suggest using well managed 2845 
VKA with TTR>65-70% (ungraded consensus-based statement). 2846 
 2847 
Remark: NOACs should generally not be used, although in USA, apixaban 5mg bid is approved for 2848 
use in AF patients receiving hemodialysis 2849 
 2850 
Remark: In patients with CKD who initiate OAC, concomitant antiplatelet therapy including low-2851 
dose aspirin is likely to substantially elevate bleeding risk and should be used very judiciously. 2852 
 2853 
AF WITH ASSOCIATED VALVULAR HEART DISEASE 2854 
A recent physician survey
445
 reported marked heterogeneity in the definition of valvular and non-2855 
valvular AF and variable management strategies, including NOACs in patients with valvular heart 2856 
disease (VHD) other than prosthetic heart valves or hemodynamically significant mitral stenosis. 2857 
Whilst hypertrophic cardiomyopathy is sometimes discussed in association with valvular AF, this will 2858 
not be addressed in this section;  specific guidelines on this condition are available
446
. 2859 
 2860 
The use of the term non-valvular AF is unfortunate and misleading as patients with a wide range of 2861 
valvular pathology and severity were enrolled in all of the phase 3 NOAC trials. The only VHD 2862 
uniformly excluded from all the NOAC trials were significant (moderate or severe) mitral stenosis 2863 
and mechanical heart valves.  2864 
 2865 
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A meta-analysis of the four phase 3 AF trials comparing NOAC with warfarin found that although 2866 
patients with VHD at higher risk compared with those without valvular disease, the efficacy and 2867 
safety of NOACs versus warfarin is consistent in regardless of the presence or absence of VHD
240
.  2868 
 2869 
AF patients with mechanical heart valves should only be prescribed VKAs.  Data from the only phase 2870 
II trial of a NOAC, dabigatran, in patients with mechanical heart valves (RE-ALIGN trial) demonstrated 2871 
inferior efficacy and more bleeding
447
. However,patients with bioprosthetic valves were included in 2872 
the ARISTOTLE trial
448
 (apixban) the ENGAGE AF-TIMI 48 trial
449
 (edoxaban) and the relative efficacy 2873 
and safety of NOACs compared with warfarin was consistent in these patients, although the number 2874 
of patients with bioprosthetic valves was limited (<300). 2875 
 2876 
In keeping with a recent European consensus document, with endorsement by international learned 2877 
societies, we propose that the term ‘valvular AF’ is outdated.  Given that any definition ultimately 2878 
relates to the evaluated practical use of oral anticoagulation (OAC) type, we propose a functional 2879 
EHRA (Evaluated Heart valves, Rheumatic or Artificial) categorization in relation to the type of oral 2880 
anticoagulation (OAC) use in patients with AF [see Summary Box]. This classification would have the 2881 
advantage that it may easily evolve or be updated (type 1 may become type 2 or vice versa) when 2882 
there are new results. For example, transcatheter mitral valve interventions (TMVI, e.g., to include 2883 
both MitraClip and Mitral valve replacement) are emerging as a possible therapeutic options
450
, but 2884 
more data are awaited especially in relation to OAC use. Also, EHRA Type I is broadly similar to the 2885 
previously described MARM-AF
451
. 2886 
 2887 
Table 11. Summary box: Evaluated Heart valves, Rheumatic or Artificial) categorization in relation to 2888 
the type of oral anticoagulation (OAC) use in patients with AF 2889 
 2890 
Definition  
EHRA  Type 1 VHD  
 
AF patients with ‘VHD needing 
therapy with a Vitamin K 
antagonist (VKA)’  
 
• Mitral stenosis (moderate-severe, of rheumatic origin) 
• Mechanical prosthetic valve replacement 
 
 
EHRA Type 2 VHD,  
 
AF patients with ‘VHD needing 
therapy with a VKA or a NOAC’, 
also taking into consideration 
CHA2DS2VASc score risk factor 
components:  
 
• Mitral regurgitation 
• Mitral valve repair 
• Aortic stenosis 
• Aortic regurgitation 
• Tricuspid regurgitation 
• Tricuspid stenosis 
• Pulmonary regurgitation 
• Pulmonic stenosis 
• Bioprosthetic valve replacements 
• Trans-aortic valve intervention (TAVI) 
 
EHRA, Evaluated Heart valves, Rheumatic or Artificial; NOAC, non-vitamin K antagonist oral 2891 
anticoagulant; VHD, Valvular heart disease; VKA, vitamin K antagonist 2892 
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 2893 
Non-drug alternatives and perioperative considerations   2894 
Occlusion of the left atrial appendage with devices or surgical techniques 2895 
Approximately 90% of the thrombi found in patients with non-valvular AF and 57% of the thrombi 2896 
found in valvular AF are located in the LAA 
452
.   2897 
 2898 
Left atrial appendage occlusion using specific percutaneous devices (WATCHMAN, Amplatzer Cardiac 2899 
Plug, or WaveCrest device or the Lariat endocardial and epicardial ligation technique) or occlusion 2900 
during a cardiac surgery procedure with either LAA amputation and closure or a  stapler  device have 2901 
been proposed and tested for patients with AF at high risk of stroke in the presence of an high risk of 2902 
bleeding or in the presence of  contraindications to  OACs. 2903 
 2904 
Two randomized studies evaluated the WATCHMAN (Atritech, Inc) device versus warfarin, the 2905 
PROTECT-AF and the PREVAIL AF trials 
453-459
.   In the PROTECT AF trial the efficacy of LAA closure 2906 
with the device met the pre-specified criteria for non-inferiority vs. warfarin, but the rate of adverse 2907 
safety events in the intervention group was 4.4% with evidence of harmful periprocedural 2908 
complications (pericardial effusion and procedure-related ischemic stroke). For acute complications 2909 
a “learning curve” appeared to be present, with serious pericardial effusions (requiring drainage) in 2910 
7.1% of the first 3 implant patients at each site compared with 4.4%  of subsequent patients 
460
. The 2911 
serious complication rate of around 7%, has been reported also for first or second generation 2912 
Amplatzer occluders 
461,462
.   A recent systematic review network meta-analysis on the use of oral 2913 
anticoagulants and Watchman device showed that the use of VKA, NOAC and the Watchman device 2914 
significantly reduce the risk of any stroke and systemic embolism as compared to placebo/control 2915 
(Watchman Device OR, 95% CI: 0.35, 0.16-0.80).
463
 Data on the use of the WATCHMAN device in 2916 
patients with contraindications to anticoagulation are very limited and DAPT is needed for at least 6 2917 
weeks after the procedure, potentially exposing the patient to increased risk of bleeding,  
460
.  2918 
 2919 
The Lariat device is based on an epicardial snare that requires positioning using a percutaneous 2920 
approach to the epicardium through a pericardial access and in combination a percutaneous 2921 
endocardial approach. In inexperienced operators incomplete occlusion of the LAA after LARIAT 2922 
ligation was relatively common (20% of cases) and was associated with risk of thromboembolic 2923 
events 
464
. No randomized controlled study comparing this device with oral anticoagulation is 2924 
currently available.  2925 
 2926 
In addition,  the role of LAAO devices in AF patients has also to consider that no trials are available 2927 
comparing these devices with NOACs.  Thrombus formation on LAAO devices is also not uncommon 2928 
(as high as 7.2%/year) and are associated with a risk of ischemic stroke during follow-up
465,466
. 2929 
 2930 
Different surgical techniques have been applied for surgical exclusion of LAA (simple suture ligation, 2931 
over-sewing of the LAA base without excision, appendage excision or amputation, surgical stapling) 2932 
but data on TEE during follow-up suggest incomplete occlusion in up to 60% of subjects 
467,468
. These 2933 
observations and the lack of a clear benefit on stroke prevention evident from  a RCT indicate that in 2934 
patients with AF these surgical techniques do not currently allow avoidance or interruption of oral 2935 
anticoagulation in patients at risk of stroke 
469,470
. 2936 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 80
Recommendations 2937 
55. In patients with AF at high risk of ischaemic stroke who have absolute contraindications for 2938 
OAC, we suggest using LAA occlusion (Weak recommendation, low quality evidence). 2939 
Remark: When taking into account LAAO as a potential option, the risk of bleeding related to 2940 
antiplatelets agents that need to be prescribed in the first months has to be considered and the 2941 
possibility to use NOACs. 2942 
 2943 
56. In AF patients at risk of ischaemic stroke undergoing cardiac surgery, we suggest considering 2944 
surgical exclusion of the LAA for stroke prevention, but the need for long term OAC is 2945 
unchanged (Weak recommendation, low quality evidence). 2946 
 2947 
 2948 
Surgical procedures and interventions-   2949 
 2950 
Patients with AF on long-term prophylaxis with oral anticoagulants may need surgical or 2951 
interventional procedures that require appropriate management.  Since bleeding risk may obviously 2952 
be increased by the anticoagulant effect, interrupting anticoagulation for an intervention or a 2953 
procedure transiently exposes the patient to increased risk of thromboembolism. Appropriate 2954 
management requires balancing reducing the risk of thromboembolism and preventing excessive 2955 
procedure-related bleeding. 2956 
 2957 
In the NOAC RCTs surgical or other invasive procedures were required during a follow up of around 2 2958 
years in one-quarter of patients in RE-LY and one-third of patients in ROCKET AF and ARISTOTLE 
471-
2959 
473
. 2960 
 2961 
General principles of management can be considered, to be combined with individual clinical 2962 
judgment, but they are derived from consensus of experts, since no data from RCTs are available to 2963 
guide clinical decision making. 2964 
 2965 
The following steps are important for appropriate management: 2966 
 2967 
- Estimation of the bleeding risk associated with a specific intervention/procedure. The risk 2968 
of bleeding can be predicted by the type of intervention and by its need, urgent or  elective.  2969 
e-Table 23 classifies surgical and interventional procedures according to bleeding risk as well 2970 
as thromboembolic risk 
474-476
. The direct consequence of this evaluation is that interventions 2971 
or procedure at very low bleeding risk, such as simple dental extractions or minor skin 2972 
excision can be planned and performed without interruption of oral anticoagulation.  2973 
If the bleeding risk is substantial then interruption of anticoagulation prior to the procedure 2974 
intervention is needed to minimize the hemorrhagic risk, both in the intra-operative and 2975 
immediate post-operative phase. 2976 
 2977 
- Estimation of patient thromboembolic risk. Calculate the CHA2DS2-VASc score (low risk if 0 2978 
or 1) but an additional transient increase in risk has to be considered in case of recent stroke 2979 
or recent pulmonary embolism. 2980 
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 2981 
- Planning of the timing of anticoagulation interruption.  The timing of interruption is strictly 2982 
dependent on the specific anticoagulant the patients is receiving and creatinine clearance.  2983 
Important differences exist between the management of patients treated with VKA or  2984 
NOACs
476,477
. The effect of warfarin can be monitored through INR, however, no standard 2985 
laboratory test exists to measure the effect of NOACs. Discontinuation of warfarin is usually 2986 
instituted 5 days before an elective surgical intervention, with INR checked the day before 2987 
surgery, with the usual indication that surgery can be regularly planned if the INR is ≤1.4 -1.5 2988 
the day before surgery or the same day of surgery
475
. For NOACs the planning of interruption 2989 
and resumption of therapy for surgical interventions/procedures is dependent on the type 2990 
of procedure/intervention, the specific agent used and renal function, estimated by Creatine 2991 
Clearance (using the Cockroft-Gault equation).  In case of urgent surgery reversal of 2992 
anticoagulation or specific measures may be required 
476,477
. 2993 
 2994 
- Evaluation of the need for bridging. Pre-operative bridging can be considered in patients 2995 
receiving VKA who are particularly high risk of TE (e.g., recent stroke, mechanical heart 2996 
valve)
475
. In these cases, LMWH at therapeutic doses is usually prescribed starting 3 days 2997 
before the procedure/intervention.  Post-operative bridging includes administration of a 2998 
LMWH when VKA is resumed in the post-operative period, with administration of both 2999 
agents until achievement of a therapeutic INR.   3000 
 3001 
The role of bridging has been tested in a randomized trial, the BRIDGE trial (Bridging 3002 
Anticoagulation in Patients who Require Temporary Interruption of Warfarin Therapy for an 3003 
Elective Invasive Procedure or Surgery) performed in patients on warfarin who were 3004 
candidate to an invasive procedure (patients with mechanical valves were excluded)
478
. The 3005 
risk of TE after the procedure was similar in patients with and without bridging, but the risk 3006 
of major bleeding was higher in those who were bridged. Thus, we suggest that preoperative 3007 
bridging is not required in AF patients treated with warfarin who do not have a particularly 3008 
high risk of thromboembolism and who do not have a mechanical valve.  3009 
 3010 
- In patients receiving NOACs, bridging is not required but bridging could be considered in the 3011 
post-operative phase if the patient cannot take oral medications for a prolonged period. 3012 
 3013 
Recommendations 3014 
57. In AF patients taking warfarin without high risk of thromboembolism or do not have a 3015 
mechanical valve, we suggest pre-operative management without bridging (Weak 3016 
recommendation, low quality evidence). 3017 
 3018 
58. In AF patients on antithrombotic prophylaxis with warfarin with a high risk of 3019 
thromboembolism or with a mechanical valve, we suggest pre-operative management with 3020 
bridging (Weak recommendation, low quality evidence). 3021 
 3022 
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59. In AF patients on antithrombotic prophylaxis with a NOAC, we suggest pre-operative 3023 
management without bridging (Weak recommendation, low quality evidence). 3024 
 3025 
 3026 
 3027 
THE PATIENT 3028 
Patient knowledge and understanding of the stroke risk associated with AF and the benefit of OAC to 3029 
prevent stroke is crucial to patient acceptance of anticoagulants, as well as adherence, and life-long 3030 
persistence (in most cases), to OAC.  However, research demonstrates that AF patients generally 3031 
have poor awareness and knowledge about their condition,
479-484
 medications used to treat AF, 3032 
particularly OAC, and do not clearly comprehend the benefit/risk associated with stroke prevention 3033 
regimens.
480-483,485-491
 Although there is increasing advocacy from clinical guidelines
159,160
 and expert 3034 
consensus
488,492,493
 to incorporate patient preferences for treatment into the decision-making 3035 
process, a patient’s ability to make an informed decision may be hindered by their lack of 3036 
understanding about the relationship between AF and stroke and the efficacy/safety of OAC for 3037 
stroke prevention, particularly at diagnosis, when these decisions are invariably addressed.  3038 
Assessment of patient’s knowledge (using the AF Knowledge questionnaire
494
 or Jessa Atrial 3039 
Fibrillation Knowledge questionnaire
495
), as well as their values and preferences, could be 3040 
undertaken to ascertain gaps to be filled; this may lead to better decision-making and improved 3041 
adherence and persistence.  3042 
Patient education is essential to provide patients with sufficient information to enable them to make 3043 
an informed decision about whether or not they wish to take OAC, and if they do, which OAC they 3044 
would prefer.
488,489,496
  Education needs to be tailored to the person’s desire for information and 3045 
their level of health literacy to promote patient understanding.  Recently a prospective survey of 499 3046 
AF patients (with and without previous stroke) in the US found that most (87%) desired more 3047 
information about AF and how to reduce their risk of AF-related stroke.
485
    AF patients perceive 3048 
greater satisfaction with treatment if they are engaged in treatment decisions and provided with 3049 
relevant information (verbal, visual, written, electronic/on-line resources, as appropriate , chosen by 3050 
the patient), which is well-communicated by their healthcare providers,
479,485,497
 and updated over 3051 
time. Full details on shared decision-making, patient preferences and patient education/counseling 3052 
are provided in the Online Supplement (e-Tables 24-26). 3053 
Recommendations 3054 
60. In AF patients who have previously refused OAC, we suggest reinforcing educational messages 3055 
at each contact with the patient and revisit OAC treatment decisions (ungraded consensus-3056 
based statement). 3057 
Remark: Patient and physician treatment objectives often differ significantly and it is important 3058 
to elicit from the patient what outcomes of OAC treatment are important to them. 3059 
Remark: Explain the risk of stroke and benefit/risks of treatment in terms the patient can 3060 
understand and signpost the patient to appropriate educational resources 3061 
 3062 
 3063 
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Table 1. PICO Questions  4560 
 4561 
 Section Question Patients Intervention Control Outcomes Methodology 
 Burden of stroke in atrial 
fibrillation (AF) 
      
1.2 • Established clinical 
risk factors for 
ischemic stroke in 
AF (including AF 
burden) 
• Echocardiographic 
risk factors for 
ischemic stroke in 
AF 
• Potential novel risk 
factors for ischemic 
stroke in AF 
•  
What are the risk 
factors for ischemic 
stroke and TE? 
Patients with AF 
- established clinical risk 
factors 
- risk factors on 
echocardiography 
- novel risk factors 
Patients with chronic 
atrial flutter 
 
N/A N/A Ischemic stroke 
 
Systemic 
thromboembolism 
(TE) 
 
Mortality 
Cohort studies 
 
Non-warfarin 
arms of RCTs 
1.3 Risk stratification for ischemic 
stroke and TE 
What risk 
stratification 
schemes most 
accurately predict 
ischemic stroke and 
TE, and mortality? 
 
Patients with AF N/A N/A c-statistic  
 
NRI. IDI, DCA 
 
Absolute rates of 
ischemic stroke and TE 
 
Cohort studies 
 
Clinical 
prediction rules 
 Antithrombotic therapy 
 
      
2.1 Patients with non-valvular AF  
 
What are the 
benefits and risks of 
different stroke 
prevention 
strategies?  
Patients with non-
rheumatic AF 
- low risk 
- intermediate risk 
- high risk (including 
prior stroke) 
Vitamin K 
antagonist (VKA) 
No VKA - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
SR 
RCTs 
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(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
2.1  Patients with non-rheumatic AF 
(cont’d) 
 As above Antiplatelet drug 
(aspirin or other) 
 
No antiplatelet drug - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
SR 
RCTs 
   As above 
 
VKA Antiplatelet drug 
(aspirin or other) 
 
- Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
SR 
RCTs 
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   As above Adjusted dose VKA Fixed minidose or 
low-intensity VKA ± 
aspirin 
 
- Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
 
   As above Clopidogrel + 
aspirin 
 
Aspirin - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
SR 
RCTs 
   As above NOACs 
 
VKA - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
SR 
RCTs 
Cohort studies 
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intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
   As above NOAC 
 
Aspirin - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
SR 
RCTs 
Cohort studies 
   As above Device therapy  
WATCHMAN, 
PLAATO) 
VKA - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
-cardiac tamponade 
SR 
RCTs 
Cohort studies 
   As above Non-
pharmacologic 
VKA - Death 
- All stroke 
SR 
RCTs 
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therapies 
- removal or 
ligation of left 
atrial appendage 
- surgical or 
catheter ablation 
- maze procedure 
 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
- procedural / surgical 
complications 
Cohort studies 
2.2 Patients with valvular AF What are the 
benefits and risks of 
different stroke 
prevention 
strategies?  
 
Patients with AF and 
rheumatic heart disease 
(i.e., mitral stenosis) 
Vitamin K 
antagonist (VKA) 
No VKA - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
SR 
RCTs 
Cohort studies 
2.3 Patients with prosthetic valves What are the 
benefits and risks of 
different stroke 
prevention 
strategies? 
Patients with AF and 
prosthetic valves 
Vitamin K 
antagonist (VKA) 
No VKA - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
SR 
RCTs 
Cohort studies 
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- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
4 Antithrombotic therapy for AF 
(or atrial flutter) patients 
undergoing cardioversion 
      
3.1 Urgent cardioversion 
 
What are the 
benefits and risks of 
antithrombotic 
therapy for AF 
patients undergoing 
urgent 
cardioversion? 
Patients with AF 
undergoing urgent 
cardioversion 
 
Anticoagulation No anticoagulation - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
SR 
RCTs 
Cohort studies 
3.2 Elective cardioversion What are the 
benefits and risks of 
antithrombotic 
therapy for AF 
patients undergoing 
elective 
cardioversion? 
Patients with AF 
undergoing elective 
cardioversion 
 
Anticoagulation No anticoagulation - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
 
SR 
RCTs 
Cohort studies 
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3.3 Transesophageal 
echocardiography (TEE)-guided 
cardioversion 
 
What are the 
benefits and risks of 
antithrombotic 
therapy when using 
TEE-guided 
cardioversion? 
 
Patients with AF 
undergoing TEE-guided 
cardioversion 
TEE-guided 
cardioversion 
Conventional 
anticoagulation 
- Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
SR 
RCTs 
Cohort studies 
5 Practical issues in the use of 
adjusted-dose VKA therapy 
      
5.1 Optimal target INR What target INR 
provides the 
optimal balance 
between stroke 
prevention and 
bleeding in AF? 
Patients with AF INR 2-3 Other - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
SR 
RCTs 
Cohort studies 
   Patients with AF and 
valvular heart disease/ 
prosthetic valves 
INR 2-3 Other - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
SR 
RCTs 
Cohort studies 
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intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
5.1 Time within therapeutic range 
(TTR) 
What is the 
association 
between TTR and 
outcomes in AF? 
Patients with AF Good TTR Poor TTR - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
SR 
RCTs 
Cohort studies 
5.1 Monitoring of VKA therapy What is the most 
effective way to 
monitor VKA 
therapy? 
 
 
 
 
Patients with AF on VKA 
therapy 
Point of care 
testing, patient self 
monitoring 
Usual care - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
SR 
RCTs 
Cohort studies 
5.2 NOACs 
 
      
 Special situations 
 
      
5.3a Patients with AF with stable What are the Patients with coronary OAC + aspirin OAC - Death  
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coronary artery disease or 
peripheral arterial disease 
 
benefits and risks of 
adding aspirin  
therapy to VKA 
therapy? 
 
artery disease or 
peripheral arterial 
disease 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
SR 
RCTs 
Cohort studies 
5.3b Patients with AF presenting 
with acute coronary syndrome?  
 
 
 
As above Patients with ACS OAC + aspirin + 
clopidogrel 
Aspirin + clopidogrel - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
SR 
RCTs 
Cohort studies 
5.3c Patients with AF undergoing 
percutaneous coronary 
intervention with stenting 
 
As above Patients undergoing PCI 
+ stenting 
OAC + aspirin + 
clopidogrel 
Aspirin + clopidogrel - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
SR 
RCTs 
Cohort studies 
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- MI 
- Vascular death 
5.4 Patients with AF being treated 
in a rhythm control strategy 
 
What are the 
benefits and risks of 
OAC therapy in 
patients treated 
with a rhythm 
control strategy? 
Patients being treated 
with a rhythm control 
strategy (e.g. maze 
procedure, catheter 
ablation, 
electrophysiology 
procedure, 
pharmacological) 
 
VKA, NOAC No OAC - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
SR 
RCTs 
Cohort studies 
5.5 Perioperative 
management of OACs 
(including devices) 
 
Atrial High Rate Episodes 
on devices or monitors  
How should VKA 
therapy be 
managed for AF 
patients undergoing 
surgery/invasive 
procedure? 
Patients with AF on OAC 
therapy 
“Bridging” therapy 
with LMWH or IV 
heparin 
No bridging therapy - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
Cohort studies 
5.6 Patients with AF presenting 
with an acute stroke 
 
AF patients with an ICH 
 
What is the optimal 
timing for initiation 
of anticoagulation? 
 
Patients with acute 
stroke 
Anticoagulation 
immediately 
Anticoagulation 
delayed 
- Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
SR 
RCTs 
Cohort studies 
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intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
5.7a Patients with AF who are 
pregnant 
 
What are the 
benefits and risks of 
VKA therapy in 
pregnancy? 
 
Patients with AF who 
are pregnant 
VKA No VKA - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
SR 
RCTs 
Cohort studies 
5.7b Patients with chronic atrial 
flutter 
 
What are the 
benefits and risks of 
different stroke 
prevention 
strategies? 
 
 
Patients with atrial 
flutter 
As in 2.1 As in 2.1 - Death 
- All stroke 
- Ischemic stroke 
- Systemic embolism 
- Intracranial 
hemorrhage 
(subdural, 
subarachnoid, and 
intracerebral) 
- Major extracranial 
hemorrhage 
- MI 
- Vascular death 
SR 
RCTs 
Cohort studies 
6 Bleeding 
 
      
6.1 Risk factors for bleeding on 
OAC therapy 
What are the risk 
factors for bleeding 
while on VKA 
Patients with AF on VKA 
therapy 
N/A N/A -Fatal hemorrhage 
-Intracranial 
hemorrhage 
Epidemiologic 
studies 
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therapy? 
 
(subdural, 
subarachnoid, 
intracerebral) 
-Major extracranial 
hemorrhage 
-Minor bleeding 
 
Cohort studies 
 
RCTs 
6.2 Bleeding risk assessment What risk 
stratification 
schemes most 
accurately predict 
the risk of bleeding? 
 
Patients with AF on OAC 
therapy 
N/A N/A c-statistic 
 
NRU, IDI, DCA 
 
Absolute rates of 
bleeding outcomes (as 
listed above) 
Clinical 
prediction rules 
7 The patient 
 
      
  What are the values 
and preferences of 
patients with AF 
regarding VKA 
therapy, risk of 
stroke, and risk of 
bleeding? 
Patients with AF N/A N/A Patient preferences 
 
Factors which affect 
patient preferences 
 
Quality of life 
 
RCTs 
Observational 
studies 
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Table 2. CHEST Grading System 4562 
 4563 
Grade of Recommendation Benefit vs Risk and 
Burdens 
Methodologic Strength of Supporting 
Evidence 
Implications 
Strong 
recommendation, 
High-quality evidence  
Benefits clearly 
outweigh risk and 
burdens, or vice versa  
We are very confident that the true 
effect lies close to that of the estimate of 
the effect. 
 
 
Recommendation can apply to most 
patients in most circumstances. Further 
research is very unlikely to change our 
confidence in the estimate of effect. 
 
 
Strong 
recommendation, 
Moderate-quality 
evidence  
Benefits clearly 
outweigh risk and 
burdens, or vice versa 
We are moderately confident in the 
effect estimate: The true effect is likely to 
be close to the estimate of the effect, but 
there is a possibility that it is substantially 
different 
 
 
Recommendation can apply to most 
patients in most circumstances. Higher 
quality research may well have an 
important impact on our confidence in 
the estimate of effect and may change 
the estimate. 
Strong 
recommendation, 
Low-quality evidence 
 
Benefits clearly 
outweigh risk and 
burdens, or vice versa  
Our confidence in the effect estimate is 
limited: The true effect may be 
substantially different from the estimate 
of the effect. 
 
Recommendation can apply to most 
patients in many circumstances. Higher 
quality research is likely to have an 
important impact on our confidence in 
the estimate of effect and may well 
change the estimate. 
Strong 
recommendation, very 
low quality evidence 
Benefits clearly 
outweigh risk and 
burdens, or vice versa 
We have very little confidence in the 
effect estimate: The true effect is likely to 
be substantially different from the 
estimate of effect 
 
 
Recommendation can apply to most 
patients in many circumstances. Higher 
quality research is likely to have an 
important impact on our confidence in 
the estimate of effect and may well 
change the estimate. 
Weak (conditional) 
recommendation, 
High-quality evidence  
Benefits closely 
balanced with risks 
and burden 
We are very confident that the true 
effect lies close to that of the estimate of 
the effect. 
 
 
The best action may differ depending on 
circumstances or patients’ or societal 
values. Further research is very unlikely 
to change our confidence in the estimate 
of effect. 
 
Weak (conditional) 
recommendation, 
Moderate-quality 
evidence  
Benefits closely 
balanced with risks 
and burden  
We are moderately confident in the 
effect estimate: The true effect is likely to 
be close to the estimate of the effect, but 
there is a possibility that it is substantially 
different 
 
 
Best action may differ depending on 
circumstances or patients’ or societal 
values. Higher quality research may well 
have an important impact on our 
confidence in the estimate of effect and 
may change the estimate. 
Weak (conditional) 
recommendation, 
Low-quality evidence 
 
Uncertainty in the 
estimates of benefits, 
risks, and burden; 
benefits, risk and 
burden may be closely 
balanced  
Our confidence in the effect estimate is 
limited: The true effect may be 
substantially different from the estimate 
of the effect. 
 
 
Other alternatives may be equally 
reasonable. Higher quality research is 
likely to have an important impact on our 
confidence in the estimate of effect and 
may well change the estimate. 
Weak (conditional) 
recommendation, 
very-low quality 
evidence 
Uncertainty in the 
estimates of benefits, 
risks, and burden; 
benefits, risk and 
burden may be closely 
balanced  
We have very little confidence in the 
effect estimate: The true effect is likely to 
be substantially different from the 
estimate of effect 
 
Other alternatives may be equally 
reasonable. Higher quality research is 
likely to have an important impact on our 
confidence in the estimate of effect and 
may well change the estimate. 
Ungraded Consensus-based Suggestions 
Ungraded Consensus-
Based Statement  
Uncertainty due to 
lack of evidence but 
expert opinion that 
benefits outweigh risk 
and burdens or vice 
versa 
Insufficient evidence for a graded 
recommendation 
Future research may well have an 
important impact on our confidence in 
the estimate of effect and may change 
the estimate. 
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ANTITHROMBOTIC THERAPY FOR ATRIAL FIBRILLATION
Recommendations or 
Suggestions
1. For patients with AF, including those with 
paroxysmal AF, stroke risk should be assessed 
using a risk factor based approach, rather than an 
categorisation into low, moderate/high risk 
strata. We recommend use of the CHA2DS2VASc 
as a simple clinical based stroke risk score to 
initially identify ‘low stroke risk’ patients that 
should not be offered antithrombotic therapy to 
prevent stroke and reduce mortality (Strong 
recommendation, moderate quality evidence). 
Remark: Low risk patients are generally those 
age<65 and ‘lone AF’ irrespective of sex (this 
includes those with a CHA2DS2VASc score=0 in 
males, or 1 in females). 
2. Subsequent to this initial step, for patients with 
AF, including those with paroxysmal AF, stroke 
prevention should be offered to those AF patients 
with one or more non-sex CHA2DS2VASc stroke 
risk factors (score of ≥1 in a male or ≥2 in a 
female)  (Strong recommendation, moderate 
quality evidence). 
Remark: Consideration of other less established 
clinical stroke risk factors, imaging (cardiac or 
cerebral) or biomarkers (urine, blood or genetics) 
may refine risk stratification based on simple 
clinical factors. A complex risk schema using a 
variety of such data that could accurately place 
more patients in the low risk stratum not 
requiring anticoagulants than current simple 
clinically-based scores (personalised medicine) 
should be the goal of future research, but it will 
be very difficult to find non-anticoagulated 
patient cohorts for prospective validation.
3. For patients with AF, bleeding risk assessment 
should be performed in all patients with AF at 
every patient contact and should initially focus on 
potentially modifiable bleeding risk factors 
(Strong recommendation, low quality evidence).
Remark: Modifiable risk factors may include: 
Uncontrolled blood pressure, Labile INRs (in a 
patient taking VKA), Alcohol excess, Concomitant 
use of NSAIDs or aspirin, in an anticoagulated AF 
patient, bleeding tendency or predisposition (e.g. 
treat gastric ulcer, optimise renal or liver function 
etc.).
4. For patients with AF, we recommend use of 
the HAS-BLED score to address modifiable 
bleeding risk factors in all AF patients and those 
potentially at high risk (HAS-BLED score ≥3) 
warrant more frequent and regular reviews or 
follow-up (Strong recommendation, moderate 
quality evidence).
Remark: Given that bleeding risk is highly 
dynamic, attention to modifiable bleeding risk 
factors should be prioritized during every patient 
encounter.
5. In VKA treated patients, we recommend use of the 
HAS-BLED score for bleeding risk assessment (Weak 
recommendation, low quality evidence)
Remark: A high HAS-BLED score (≥3) is rarely a 
reason to avoid anticoagulation. The individual 
modifiable components of the score, when reviewed 
with the patient, can serve to ameliorate bleed risk
6. For patients with AF, we recommend against 
antiplatelet therapy alone (monotherapy or 
aspirin in combination with clopidogrel) for stroke 
prevention alone, regardless of stroke risk (Strong 
recommendation, moderate quality evidence).
Remark: Patients with AF might have other 
indications for antiplatelet drugs (e.g. acute 
coronary syndrome, stents)
7. In patients with AF who are eligible for OAC, 
we recommend NOACs over VKA (strong 
recommendation, moderate quality evidence).
Remark: Patient and caregiver preferences, cost, 
formulary considerations, anticipated medication 
adherence or compliance with INR testing and 
dose adjustment should be incorporated into 
clinical-decision making.
8. In patients on VKAs with consistently low time 
in INR therapeutic range (eg. TTR<65%), we 
recommend considering interventions to improve 
TTR or switching to NOACs (strong 
recommendation, moderate quality evidence)
9. In patients with prior unprovoked bleeding, 
warfarin-associated bleeding, or at high risk of 
bleeding, we suggest apixaban, edoxaban, or 
dabigatran 110 mg (if available) may be 
considered as they demonstrated significantly 
less major bleeding compared with warfarin 
(Weak recommendation, very low quality 
evidence). 
Remark: In patients with prior gastrointestinal 
bleeding apixaban or dabigatran 110mg bid may 
be preferable as they are the only NOACs not 
associated with an increased risk of 
gastrointestinal bleeding compared with 
warfarin.
Remark: Dabigatran 150 mg twice daily 
recommended in patients at high risk of ischemic 
stroke as only agent/dose with superior efficacy 
compared with warfarin.¬† However, bleeding 
risk would need to be assessed and patients 
monitored.
10.In patients with prior unprovoked bleeding, 
warfarin-associated bleeding, or at high risk of 
bleeding, we suggest apixaban, edoxaban, or 
dabigatran 110 mg (if available) may be 
considered as all demonstrate significantly less 
major bleeding compared with warfarin (Weak 
recommendation, very low quality evidence). 
Remark: In patients with prior gastrointestinal 
bleeding apixaban or dabigatran 110mg bid may 
be preferable as they are the only NOACs not 
associated with an increased risk of 
gastrointestinal bleeding compared with 
warfarin.
Remark: Dabigatran 150 mg twice daily 
recommended in patients at high risk of ischemic 
stroke as only agent/dose with superior efficacy 
compared with warfarin. However, bleeding risk 
would need to be assessed and patients 
monitored.
11. For patients with non-valvular AF, when VKAs 
are used, we suggest the target should be INR 2.0-
3.0, with attention to individual TTR, ideally ≥70% 
(ungraded consensus-based statement).
Remark:  Action required if TTR <65% - 
implement additional measures (more regular 
INR tests; review medication adherence/other 
factors known to influence INR control; 
education/counselling) to improve INR control or 
consider a NOAC.
Remark: When possible, experienced specialized 
anticoagulation clinics should be utilized for VKA 
and INR management.
12. For patients with AF of greater than 48 hours 
or unknown duration undergoing elective 
electrical or pharmacologic cardioversion, we 
recommend therapeutic anticoagulation with 
well-managed VKA (INR 2-3) or a NOAC using 
dabigatran, rivaroxaban, edoxaban or apixaban 
for at least 3 weeks before cardioversion or a 
transesophageal echocardiography (TEE)-guided 
approach with abbreviated anticoagulation 
before cardioversion rather than no 
anticoagulation (Strong recommendation, 
moderate quality evidence).
Remark: With NOACs adherence and persistence 
should be strongly emphasized
13. In patients in which LAA thrombus is detected 
on TEE, cardioversion postponed, and OAC 
continued for another 4-12 weeks, to allow 
thrombus resolution or endothelisation, we 
suggest that a decision on whether a repeat TEE 
is performed should be individualized (ungraded 
consensus-based statement)
14. In AF patients presenting with an ACS and/or 
undergoing PCI/stenting, we recommend 
assessment of stroke risk using the CHA2DS2-
VASc score (Strong recommendation, moderate 
quality evidence)
Remark: All such patients are not ‘low risk’ and 
should be considered for concomitant OAC.
15. In AF patients presenting with an ACS and/or 
undergoing PCI/stenting, we recommend 
attention to modifiable bleeding risk factors, and 
assessment of bleeding risk using the HAS-BLED 
score is recommended (weak recommendation, 
low quality evidence).Remark: Where bleeding 
risk is high (HAS-BLED ‚â•3), there should be 
regular review and follow-up.
16. In AF patients presenting with an ACS and/or 
undergoing PCI/stenting, we suggest attention to 
modifiable bleeding risk factors at every patient 
contact, and assessment of bleeding risk using 
the HAS-BLED score is recommended (weak 
recommendation, low quality evidence).
Remark: Where bleeding risk is high (HAS-BLED 
≥3), there should be more regular review and 
follow-up.
17. In AF patients requiring OAC undergoing 
elective PCI/stenting, where bleeding risk is high 
(HAS-BLED ≥3), we suggest triple therapy for one 
month, followed by dual therapy with OAC plus 
single antiplatelet (preferably clopidogrel) for 6 
months, following which OAC monotherapy can 
be used (weak recommendation, low quality 
evidence)
18. In AF patients requiring OAC undergoing 
elective PCI/stenting , where bleeding risk is 
unusually high and thrombotic risk low, we 
suggest considering OAC plus single antiplatelet 
(preferably clopidogrel) for 6 months, following 
which OAC monotherapy can be used (weak 
recommendation, low quality evidence)
19. In AF patients requiring OAC presenting with 
an ACS, undergoing PCI/stenting, where bleeding 
risk is low (HAS-BLED 0-2) relative to risk for ACS 
or stent thrombosis, we suggest triple therapy for 
6 months, followed by dual therapy with OAC 
plus single antiplatelet (preferably clopidogrel) 
until 12 months, following which OAC 
monotherapy can be used (weak 
recommendation, low quality evidence)
20. In AF patients requiring OAC presenting with 
an ACS, undergoing PCI/stenting, where bleeding 
risk is high (HAS-BLED ≥3), we suggest triple 
therapy for 1-3 months, followed by dual therapy 
with OAC plus single antiplatelet (preferably 
clopidogrel) up to 12 months, following which 
OAC monotherapy can be used (weak 
recommendation, low quality evidence).
21. In AF patients requiring OAC presenting with 
an ACS, undergoing PCI/stenting where bleeding 
risk is unusually high and thrombotic risk low, we 
suggest OAC plus single antiplatelet (preferably 
clopidogrel) for 6-9 months may be considered, 
following which OAC monotherapy can be used. 
(weak recommendation, low quality evidence).
22. In AF patients with ACS or undergoing PCI in 
whom OAC is recommended, we suggest using 
VKA with TTR>65-70% (INR range 2.0-3.0), or to 
use a NOAC at a dose licensed for stroke 
prevention in AF (weak recommendation, low 
quality evidence). 
Remark: Only Dabigatran 150mg bid or (not 
licensed in USA) 110mg bid or Rivaroxaban 15mg 
od are currently supported by clinical trial 
evidence. A NOAC based strategy has lower 
bleeding risk compared to a VKA-based strategy.
23. In AF patients in which aspirin is 
concomitantly used with OAC, we suggest a dose 
of 75-100mg od with concomitant use of PPI to 
minimize gastrointestinal bleeding (Weak 
recommendation, low quality evidence)
24. In AF Patients in which a P2Y12 inhibitor is 
concomitantly used with OAC, we suggest the use 
of clopidogrel (Weak recommendation, low 
quality evidence)
Remark: Newer agents (eg. Ticagrelor) can be 
considered where bleeding risk is low. Data on 
the combination of ticagrelor with either 
dabigatran 110mg bid or 150 bid (without 
concomitant aspirin use) are available from the 
RE-DUAL PCI trial.
25. In patients in whom sinus rhythm has been 
restored, we suggest that long-term 
anticoagulation should be based on the patient’s 
CHA2DS2-VASc thromboembolic risk profile, 
regardless of whether sinus rhythm has been 
restored via ablation, cardioversion (even 
spontaneous), or other means (Weak 
recommendation, low quality evidence).
26. In AF patients with acute ischaemic stroke, we 
suggest that very early anticoagulation (<48h) 
using heparinoids or VKA should not be used 
(ungraded consensus-based statement).
Remark: Heparinoids should not be used as 
bridging therapy in the acute phase of ischaemic 
stroke because they appear to increase the risk of 
symptomatic intracranial haemorrhage without 
net benefit. The optimal timing of anticoagulation 
after acute ischaemic stroke is unknown.  
27. In AF patients with acute stroke without 
contraindications, we suggest that long term oral 
anticoagulation is indicated (Strong 
recommendation, high quality evidence).  
Remark: The optimal timing of anticoagulation 
early after acute ischaemic stroke is unknown. 
Early use of NOACs shows promise but requires 
testing in randomised controlled trials.
28. In AF patients with acute ischaemic stroke, 
We suggest that anticoagulation should usually 
be started within 2 weeks of acute ischaemic 
stroke, but the optimal timing within this period 
is not known (ungraded consensus-based 
statement).
Remark: Although infarct size is clinically used to 
guide timing of anticoagulation, it is predictive of 
a higher risk of early recurrent ischaemia, 
haemorrhagic transformation of the infarct, and 
poor outcome, so might not be helpful in 
determining the net benefit of early treatment.
Remark: Anticoagulation with NOACs soon after 
stroke (earlier than 1 week) has not been tested 
in randomised trials, but shows promise in 
observational studies.
29. In patients with AF and high ischaemic stroke 
risk, we suggest considering anticoagulation with 
a NOAC after acute spontaneous ICH (which 
includes subdural, subarachnoid and 
intracerebral haemorrhages) after careful 
consideration of the risks and benefits (ungraded 
consensus-based statement).
Remark: The balance of net benefit from long 
term oral anticoagulation might be more 
favourable in those with deep ICH or without 
neuroimaging evidence of cerebral amyloid 
angiopathy.
Remark: In ICH survivors with AF, clinicians 
should aim to estimate the risk of recurrent ICH 
(using ICH location and, if available, MRI 
biomarkers including cerebral microbleeds) and 
the risk of ischaemic stroke
Remark: The optimal timing of anticoagulation 
after ICH is not known, but should be delayed 
beyond the acute phase (~48 hours) and probably 
for at least ~4 weeks. Randomised trials of NOACs 
and left atrial appendage occlusion are ongoing.
30. In ICH survivors at high risk of recurrent ICH 
(e.g. those with probable cerebral amyloid 
angiopathy), we suggest considering left atrial 
appendage occlusion (ungraded consensus-based 
statement). 
Remark: Cerebral amyloid angiopathy should be 
diagnosed using validated clinico-radiological 
criteria.
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Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Received compensation for the following: 
Speaking Activities for Boehringer Ingelheim, 
Boston Scientific, Medtronic, St. Jude Medical; 
Advisory Committee for Biotronik.
Chern-En Chiang, MD, PhD
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: Speaking 
Activities for MSD, Novartis, Pfizer; Advisory 
Committees for Bayer, Boehringer-Ingelheim, Daiichi-
Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Received compensation for the following: 
Speaking Activities for MSD, Novartis, Pfizer; 
Advisory Committees for Bayer, Boehringer-
Ingelheim, Daiichi-Sankyo. 
Ramiz Fargo, MD none none none none none none none none none none none none none none none none none none none none none none none none none none none none none none
Ben Freedman, MBPhD
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: Speaking 
Activities for AstraZeneca, Bayer, BMS/Pfizer;  
Advisory Committees for AstraZeneca, Bayer, 
BMS/Pfizer, Gilead; Institution received grants from 
the following: Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Received compensation for the following: 
Speaking Activities for AstraZeneca, Bayer, 
BMS/Pfizer;  Advisory Committees for 
AstraZeneca, Bayer, BMS/Pfizer, Gilead; 
Institution received grants from the following: 
Bayer AG, BMS, Servier.
Deirdre Lane, PhD
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: Speaking 
Activities for Bayer Healthcare, Boehringer 
Ingelheim, Bristol-Myers Squibb, Pfizer; Advisory 
Committee for Bristol-Myers Squibb; Medical 
Consultancy for Boehringer Ingelheim; Institution 
received grants from the following: Boehringer 
Ingelheim, Bristol-Myers-Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Recieved compensation for the following: 
Speaking Activities for Bayer Healthcare, 
Boehringer Ingelheim, Bristol-Myers Squibb, 
Pfizer; Advisory Committee for Bristol-Myers 
Squibb; Medical Consultancy for Boehringer 
Ingelheim; Institution received grants from the 
following: Boehringer Ingelheim, Bristol-Myers-
Squibb.
Gregory Y.H. Lip, MD                                 
Received compensation for the following: 
Speaking Activities for Bayer/Jensen J&J, 
BMS/Pfizer Alliance, Daiichi-Sankyo, Boehringer 
Ingelheim; Advisory Committee for Bayer/Jensen 
J&J, BMS/Pfizer Alliance, Daiichi-Sankyo, 
Boehringer Ingelheim.
Received compensation for the following: 
Speaking Activities for Bayer/Jensen J&J, 
BMS/Pfizer Alliance, Daiichi-Sankyo, Boehringer 
Ingelheim; Advisory Committee for Bayer/Jensen 
J&J, BMS/Pfizer Alliance, Daiichi-Sankyo, 
Boehringer Ingelheim.
Received compensation for the following: 
Speaking Activities for Bayer/Jensen J&J, 
BMS/Pfizer Alliance, Daiichi-Sankyo, Boehringer 
Ingelheim; Advisory Committee for Bayer/Jensen 
J&J, BMS/Pfizer Alliance, Daiichi-Sankyo, 
Boehringer Ingelheim.
Received compensation for the following: 
Speaking Activities for Bayer/Jensen J&J, 
BMS/Pfizer Alliance, Daiichi-Sankyo, Boehringer 
Ingelheim; Advisory Committee for Bayer/Jensen 
J&J, BMS/Pfizer Alliance, Daiichi-Sankyo, 
Boehringer Ingelheim.
Received compensation for the following: Speaking 
Activities for Bayer/Jensen J&J, BMS/Pfizer Alliance, 
Daiichi-Sankyo, Boehringer Ingelheim; Advisory 
Committee for Bayer/Jensen J&J, BMS/Pfizer 
Alliance, Daiichi-Sankyo, Boehringer Ingelheim.
Received compensation for the following: 
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31. In patients with AF and symptomatic carotid 
stenosis (>50%), we suggest considering carotid 
revascularisation with endarterectomy or 
stenting in addition to OAC as indicated (Weak 
recommendation, moderate quality evidence).
32. In patients with AF and carotid stenosis 
treated with revascularisation, we suggest OAC 
therapy, without long-term antiplatelet therapy 
(ungraded consensus-based statement).
Remark: There is limited evidence to guide the 
optimal treatment of patients with AF and carotid 
stenosis not requiring revascularisation. 
Remark: Short-term concomitant antiplatelet 
therapy (dual or mono) is generally used in the 
immediate post-revascularisation period (e.g. 1-3 
months)
33. For patients that present with a clinically 
documented AF (12-lead ECG or other means), 
we suggest that the presence or absence of 
symptoms must not influence the process of 
decision making with regard to the need for 
anticoagulation based on risk stratification 
(ungraded consensus-based statement).
34. In cases of AHRE (atrial high rate episodes) 
detected by a CIED of at least 5 min duration, we 
suggest that direct analysis of electrograms 
corresponding to AHRE is clinically indicated to 
exclude artifacts or other causes of inappropriate 
detection of atrial tachyarrhythmias or AF 
(ungraded consensus-based statement).
Remark: In patients with CIED detected AHRE a 
complete cardiological evaluation is indicated, 
with 12-lead ECG, general assessment of clinical 
conditions and clinical risk stratification for stroke 
using CHA2DS2VASc score.
Remark: There is no evidence in support or 
against prescription of oral anticoagulants in 
patients at risk of stroke (intermediate to high 
risk according to CHA2DS2VASc) who present 
with AHREs, corresponding to atrial 
tachyarrhythmias/AF at electrograms assessment 
of less than 24 hours duration.
35. In patients with AF, we suggest that 
prescription of oral anticoagulants could be 
considered as a result of an individualized clinical 
assessment taking into account overall AHRE 
burden (in the range of hours rather than 
minutes) and specifically, the presence of AHRE > 
24 hours, individual stroke risk (using 
CHA2DS2VASc), predicted risk benefit of oral 
anticoagulation and informed patient preferences 
(ungraded consensus-based statement).  
Remark: In patients with CIED detected AHRE 
continued patient follow-up is recommended, 
preferentially combining clinical follow up with 
remote monitoring of the CIED or else more 
frequent device interrogation than standard for 
CIED follow-up, to detect the development of 
clinical AF (symptomatic or asymptomatic), to 
monitor the evolution of AHRE or AF burden and 
specifically the transition to AHRE lasting more 
than 24 hours,onset or worsening of heart failure, 
or any clinical change that might suggest a 
change in clinical profile or clinical conditions.
36. For women receiving OAC for prevention of 
stroke/TE in AF who become pregnant, we 
suggest discontinuation of OAC with a VKA 
between weeks 6 and 12 and replacement by 
LMWH twice daily (with dose adjustment 
according to weight and target anti-Xa level 4-6 
hours post-dose 0.8-1.2 U/mL) should be 
considered, especially in patients with a warfarin 
dose required of >5 mg/day (or phenprocoumon 
>3 mg/day or acenocoumarol >2mg/day). OAC 
should then be discontinued and replaced by 
adjusted-dose LMWH (target anti-Xa level 4-6 
hours post-dose 0.8-1.2 U/mL) in the 36th week 
of gestation (ungraded consensus-based 
statement).
37. For women on treatment with long-term 
vitamin K antagonists who are attempting 
pregnancy and are candidates for LMWH 
substitution, we suggest performing frequent 
pregnancy tests and use LMWH instead of VKA 
when pregnancy is achieved rather than 
switching to LMWH while attempting pregnancy 
(ungraded consensus-based statement).
38. For pregnant women, we suggest avoiding 
the use of NOACs (ungraded consensus-based 
statement) .
Remark: For women on treatment with a NOAC 
we suggest switching to vitamin K antagonists, 
rather than switching to LMWH while attempting 
pregnancy
39. For lactating women using warfarin, 
acenocoumarol, or UFH who wish to breastfeed, 
we recommend continuing the use of warfarin, 
acenocoumarol, LMWH or UFH (ungraded 
consensus-based statement)
40. For breast-feeding women, we recommend 
alternative anticoagulants rather than NOACs 
(ungraded consensus-based statement).
41. For mild CKD (Stage II, CrCl 60-89 ml/min), we 
suggest that oral anticoagulation clinical decision 
making and treatment recommendations match 
that of patients without CKD (weak 
recommendation, very low quality evidence).
42. For moderate CKD (Stage III, CrCl 30-59 
ml/min), we suggest oral anticoagulation in 
patients with a CHA2DS2VASc ≥2 with label-
adjusted NOACs or dose adjusted vitamin K 
antagonists (Weak recommendation, very low 
quality evidence).
Remark: With VKA, good quality anticoagulation 
control (TTR>65-70%) is recommended.
43. In severe non-dialysis CKD (Stage IV CrCl 15-
30), we suggest that VKAs may be considered and 
selected NOACs (rivaroxaban 15mg od, apixaban 
2.5mg bid, edoxaban 30mg od and (in USA only) 
dabigatran 75mg bid) may be considered with 
caution, based on pharmacokinetic data 
(ungraded consensus-based statement).
44. In end-stage renal disease (CrCl < 15 or 
dialysis-dependent), we suggest that 
individualized decision-making is appropriate 
(ungraded consensus-based statement).
45. In end-stage renal disease (CrCl < 15 or 
dialysis-dependent , we suggest that well 
managed VKA may be considered with TTR>65-
70% (ungraded consensus-based statement).
Remark: NOACs should generally not be used, 
although in USA, apixaban 5mg bid is approved 
for use in AF patients in hemodialysis
Remark: In patients with CKD who initiate OAC, 
concomitant antiplatelet therapy including low-
dose aspirin is likely to substantially elevate 
bleeding risk and should be used very judiciously.
46. In patients with AF at high risk of ischaemic 
stroke who have absolute contraindications for 
OAC, we suggest that LAA occlusion might be 
considered (Weak recommendation, low quality 
evidence).
Remark: When taking into account LAAO as a 
potential option, the risk of bleeding related to 
antiplatelets agents that need to be prescribed in 
the first months has to be considered and the 
possibility to use NOACs has to be considered.
47. In AF patients at high risk of ischaemic stroke 
undergoing cardiac surgery, we suggest 
considering surgical exclusion of the LAA for 
stroke prevention, but the need for long term 
OAC is unchanged (Weak recommendation, low 
quality evidence).
48. In AF patients taking warfarin without high 
risk of thromboembolism and who do not have a 
mechanical valve, we suggest considering pre-
operative management without bridging (Weak 
recommendation, low quality evidence).
49. In AF patients on antithrombotic prophylaxis 
with warfarin with a high risk of 
thromboembolism or with a mechanical valve, we 
suggest pre-operative management with bridging 
(Weak recommendation, low quality evidence).
50. In AF patients on antithrombotic prophylaxis 
with a NOAC, we suggest pre-operative 
management without bridging (Weak 
recommendation, low quality evidence).
51. In AF patients who have previously refused 
OAC, we suggest reinforcing educational 
messages at each contact with the patient and 
revisit OAC treatment decisions (ungraded 
consensus-based statement).
Remark: Patient and physician treatment 
objectives often differ significantly and it is 
important to elicit from the patient what 
outcomes of OAC treatment are important to 
them.
Remark: Explain the risk of stroke and 
benefit/risks of treatment in terms the patient 
can understand and signpost the patient to 
appropriate educational resources 
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e-Table 2. Implications of Strength of Recommendations for different users of guidelines  
Strong Recommendation Conditional (weak) 
Recommendation 
For patients Most individuals in this 
situation would want the 
recommended course of 
action and only a small 
proportion would not. 
The majority of individuals in 
this situation would want the 
suggested course of action, 
but some would not. 
For clinicians Most individuals should 
receive the recommended 
course of action. Adherence 
to this recommendation 
according to the guideline 
could be used as a quality 
criterion or performance 
indicator. Formal decision aids 
are not likely to be needed to 
help individuals make 
decisions consistent with their 
values and preferences. 
Recognize that different 
choices will be appropriate for 
different patients, and that 
you must help each patient 
arrive at a management 
decision consistent with her 
or his values and preferences. 
Decision aids may well be 
useful helping individuals 
making decisions consistent 
with their values and 
preferences. Clinicians should 
expect to spend more time 
with patients when working 
towards a decision. 
For policy makers The recommendation can be 
adapted as policy in most 
situations including for the 
use as performance 
indicators. 
Policy making will require 
substantial debates and 
involvement of many 
stakeholders. Policies are also 
more likely to vary between 
regions. Performance 
indicators would have to focus 
on the fact that adequate 
deliberation about the 
management options has 
taken place. 
 
 
 
e-Appendix 1. Burden of Stroke in Atrial Fibrillation 
 
Epidemiology and contemporary burden of ischemic stroke in AF 
Atrial fibrillation (AF) is the commonest arrhythmia worldwide1. Health systems face increasing prevalence, 
incidence and lifetime risk of AF, which is as high as 1 in 4 in contemporary studies in high-income settings2. 
Age is an important risk factor for both AF and stroke and increasing age and demographic  change are 
projected to drive future increases in AF and stroke3. Epidemiologic studies largely represent Western 
countries and Caucasian populations4. However, reported prevalence varies substantially by world region: 
India (0.1%)5, Europe6 and North America (1–2%)7 and Australia (4%)8, with pooled age- and sex-adjusted 
prevalence estimated as 2.8% (95% CI: 2.3–3.4%)9. Figure 1 illustrates the prevalence of AF in reported 
studies outside North America and Europe4. Recent data from rural India using the approved single-lead 
electrocardiography device, Alivecor, for 2 minutes on 5 consecutive days found a higher prevalence of AF 
(~5%) than prior studies10. As well as regional variation, reported prevalence is therefore higher with more 
rigorous screening methods to detect AF, and the low prevalence reported in certain world regions may well 
be an underestimate of true AF burden. 
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e-Figure 1. Prevalence of atrial fibrillation reported in community-based studies from countries outside North 
America and Europe. The overall prevalence is presented where available; otherwise, the prevalence in men 
and women is presented separately. (from Lip et al 2012)4  
 
 
 
 
 
Individuals with AF have increased risk of serious complications, including stroke (4-5 fold increase)11, heart 
failure (2-3 fold increase)12 and mortality (2-fold increase)12,13. The Global Burden of Disease Study has shown 
that burden of disease in terms of age-adjusted disability-adjusted life years has increased by 19% between 
1990 and 20101. Patients with AF also experience higher rates of morbidity, hospital admissions, as well as 
‘premature’ dementia2,14. Recent data from population-based studies and stroke registries demonstrate a high 
AF-attributable risk of stroke, especially in the elderly. At least one in 3 to 4 individuals with an ischemic 
stroke and over 80% of those with ischemic stroke of cardioembolic subtype, also has AF15.  
 
Mechanism of development of AF 
A systematic review of the associations of 23 cardiovascular risk factors and incident AF was recently 
conducted, including both consented and electronic health record cohorts of 20,420,175 participants and 
576,602 AF events respectively. It showed significant heterogeneity in AF definition, quality of reporting, and 
adjustment for other risk factors16. Hypertension, obesity, taller height and coronary heart disease showed 
consistent, direct associations with incident AF. Higher cholesterol (0.76 [0.59-0.98] to 0.94 [0.90-0.97]) and 
higher diastolic blood pressure (0.87 [0.78-0.96] to 0.92 [0.85-0.99]) showed some evidence of being 
associated with lower risk of incident AF. Evidence for the widely-held clinical opinion that alcohol use is 
associated with incident AF in the primary preventative setting was minimal. Several of the risk factors for 
incident AF are also risk factors for stroke in AF16.  
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Ethnic differences 
Overall, non-white ethnicity shows evidence of association with lower risk of incident AF in a recent systematic 
review of electronic health record studies of AF. For African American, Asian, Chinese, Hispanic and Non-
Hispanic Black (compared to White) ethnicities, significant inverse associations (from 0.35 [NR–NR] to 0.84 
[0.82–0.85]). Only 1 country (USA) reported estimates for the association of ethnicity and incidence of AF17. 
There is likely to be considerable variation in prevalence, incidence and outcome by ethnicity and geographic 
region, but the number of studies to-date is limited. For example, incidence and long-term mortality following 
hospitalised AF is higher in Aboriginal versus non-Aboriginal individuals in Australia18. Variations which have 
been observed need to be validated. For example, the low reported prevalence rates of AF in India may 
represent under-diagnosis rather than true low rates10.  
 
The racial differences in co-morbidities in AF patients have been reported recently.19,20 The mean age, sex, 
and prevalence of several stroke-related cardiovascular co-morbidities among different races in major surveys 
and cohorts are shown in e-Table 3.21-37 The mean ages were 60 to mid-70, except in the Middle East (mean 
age 57 years). Males were generally predominant. Hypertension (52-85.2%) leads other risk factors and is 
equally distributed in different races. The prevalence rates of heart failure (18.9-47.5%) and diabetes (16-
36.8%) show no major differences among races. With one exception in China,26 coronary heart disease (CHD) 
seems more common in Caucasians and Middle East (16.0-36.4%) than in Asians (7.4-25.4%). Only 1 of the 
remaining 9 Asian cohorts has a prevalence rate of CHD more than 20%, while 7 of the 10 cohorts in 
Caucasians and the Middle East have CHD prevalence rate above 20%. A higher prevalence rate of previous 
history of stroke/transient ischemic attack (TIA) was found in Asians (10.2-23.1%) than in Caucasians and 
Middle East (9-19%). Eight out of the 10 Asian cohorts have a history of stroke/TIA above 15%, but only 1 of 
the 10 cohorts of Caucasians and the Middle East has a prevalence rate over 15%.  
 
The annual risk of AF-associated stroke in Asians is higher than that in Caucasians.20 In the recent AF cohorts 
from Taiwan29, Hong Kong,30 and Sweden38, the annual stroke risk in antithrombotic-naïve patients who had a 
CHA2DS2-VASc score 0 was 1.1%, 2.4% and 0.2%, respectively. The similar trends were shown for CHA2DS2-
VASc 1 (1.7%, 6.6%, and 0.6% respectively), CHA2DS2-VASc 2 (3.2%, 7.8%, and 2.2% respectively), 
CHA2DS2-VASc 3 (4.2%, 9.6%, and 3.2% respectively), and CHA2DS2-VASc 4 (5.8%, 11.6%, and 4.8% 
respectively). It has been suggested that the risk of stroke starts to increases at a younger age in Asians.20 In 
a Taiwanese cohort, the risk of stroke was 1.78%/year in patients who had an age of 50-64 years and a 
CHA2DS2-VASc 0.39 The risk exceeds the threshold for OAC use for stroke prevention. A modified CHA2DS2-
VASc (mCHA2DS2-VASc) score has been proposed assigning one point for patients aged 50 to 74 years.40 The 
mCHA2DS2-VASc score performed better than CHA2DS2-VASc score in predicting ischemic stroke assessed by 
C indexes and net reclassification index. For patients having an mCHA2DS2-VASc score of 1 (males) or 2 
(females) because of the resetting of the age threshold, use of warfarin was associated with a 30% lower risk 
of ischemic stroke and a similar risk of ICH compared with non-treatment. Net clinical benefit analyses also 
favored the use of warfarin in different weighted models. These findings suggest that the age threshold may 
need to be reset in East Asians.40
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e-Table 3. Co-morbidities of AF in different races in major surveys and cohorts 
 Asians Caucasians Middle 
East 
Survey/ 
cohorts 
RECORD 
AF AP 21 
RELY AF 
Southeast 
Asia 22 
GARFIELD 
East and 
Southeast 
Asia 23 
J-Rhythm 24 Fushimi 25 China 
26 
CAFR 
27 
GLORIA 1 
Chinese 
28 
Taiwan 
29 
HK 30 Euro 
Heart 
Survey 
31 
RECORD 
AF 32 
ORBIT 
AF 33 
RELY AF 
West 
Europe 
22 
EORP 
AF 34 
PREFER 
35 
GARFIELD, 
other region 
excluding 
East and 
South East 
Asia 23 
GLORIA I 
Europe 28 
SPRINT 
36 
GULF 
SAFE 37 
Age 
(mean) 
64 69.5 67.1 69.7 74.2 75 65.8 69 72.0 76.9 66 66 75 69.4 68.8 71.5 71.3 71 75.7 57 
Female(%) 40 44.6 39.8 31.1 40.7 27.1 40.4 42.8 46.0 52.1 43 43 42 38.8 40.4 39.9 44.5 50.5 44.7 48 
CHD(%) 19 10.9 7.4 11.6 15.0 59.4 7.8 25.4 15.3 18.2 32 18 32 18.2 36.4 23.4 16.0 20.3 25.1 28 
Diabetes(%) 18 29.2 23.5 22.1 23.2 36.8 24.5 19.5 26.9 22.0 18 16 29 17.1 20.6 22.4 23.7 27.1 29.7 30 
HF(%) 25 26.3 26.6 34.4 27.9 21.2 18.9 24.7 38.7 22.8 33 26 32 21.2 47.5 21.3 20.8 22.3 18.8 27 
HT(%) 58 64.1 73.1 71.1 60.6 72.5 66.1 70.1 62.9 54.7 63 68 83 59.9 70.9 72.0 82.0 85.2 73.6 52 
Stroke/ 
TIA(%) 
13 22.1 15.3 17.3 21.8 20.2 17.0 10.2 20.5 23.1 9 10 16 12 10.5 8.4 13.7 10.7 15.0 13 
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Pathophysiology – a brief overview 
AF is characterised by rapid, uncoordinated atrial activity, caused by: (a) a rapidly discharging 
atrial focus, (b) a primary re‑entrant rotor, or (c) multiple functional re‑entry circuits4 (figure w3). 
The initiation and perpetuation of AF needs both “triggers” for its onset and a “vulnerable 
substrate” for its maintenance. “Triggers” of focal spontaneous firing typically arise from the 
pulmonary veins41, but can also emanate from other foci42. The ‘vulnerable substrate’ maintains 
the arrhythmia, dependent on cardiac and non-cardiac risk factors, including genetic pre-
disposition, cardiac remodelling due to underlying heart disease, autonomic imbalance and thyroid 
dysfunction.  
 
 
 
 
e-Figure 2. Mechanisms that can maintain atrial fibrillation (from Lip et al 20164).  
AF, atrial fibrillation; AV, atrioventricular; LA, left atrium; LV, left ventricle; PV, pulmonary vein; 
RA, right atrium; RV, right ventricle; SA, sinoatrial. 
 
 
Although the micro-pathophysiology has been relatively well-established, the epidemiology of how 
risk factors individually or in combination, create the “vulnerable substrate”, is relatively unknown. 
Until the interplay of these risk factors is better understood, primary prevention strategies for AF 
are likely to be restricted, despite development of risk prediction tools for AF. Although currently 
primary prevention strategies for AF have not been conclusively proven in randomized trials, 
opportunistic screening is the recommended strategy to detect AF at population-level43. 
 
Echocardiographic risk factors for ischemic stroke in AF 
Underlying heart disease, whether as a result of hypertension, coronary artery disease or heart 
failure, is important in the aetiology and prognosis of AF. Therefore, it is not surprising that 
echocardiographic characteristics have been associated with risk of ischemic stroke in AF. There 
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may also be a role in evaluating thromboembolic risk stratification to select appropriate 
antithrombotic therapy. e-Table 4 summarizes major studies which have shown association 
between transthoracic echocardiographic (TTE) parameters and ischemic stroke.   
 
In summary, there are small-scale studies to suggest a role for various measures (LA and LV size, 
volume and strain) on TTE. However, there are very limited data to suggest that there would be 
any incremental benefit in risk prediction, and moreover there is no evidence that management (in 
terms of OAC) would be changed44. In the recent ENGAGE AF-TIMI trial, larger LV size and higher 
filling pressures (measured by E/e' ratio) were significantly associated with increased risk for 
death, but neither left atrial nor LV measures were associated with thromboembolic risk45. In 
patients undergoing transesophageal echocardiography (TEE), LA appendage thrombi46 and LA 
spontaneous echo contrast47 are both associated with increased thromboembolism, but the same 
limitations as for TTE parameters apply44. In terms of risk stratification, the role of 
echocardiography is currently restricted to the inclusion of heart failure (left ventricular systolic 
dysfunction) in the CHA2DS2-VASc score48. 
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e-Table 4. Key evidence concerning transthoracic echocardiographic parameters and prediction of stroke and thromboembolism in patients with non-
valvar AF. Adapted from Providencia et al 201344 
Study Study design and setting Main findings 
The Stroke Prevention 
in Atrial Fibrillation 
Investigators (1992)49  
Cohort 
n=568  
Non-rheumatic AF 
Mean follow-up, 1.3 years 
14 transthoracic echocardiographic variables were assessed for predicting ischemic stroke or 
systemic embolism. 
Only LA size (measured on M-mode echocardiography) and depressed LVEF were independent 
predictors of thromboembolism on multivariate analysis and improved risk stratification when 
combined with three clinical risk factors: history of hypertension, recent congestive heart failure, 
and previous thromboembolism 
Osranek et al. (2005)50  
Cohort 
n=45  
Lone AF 
Mean follow-up, 27 years 
Individuals with indexed LA volume ≥ 32 mL/m2 had worse event-free survival (HR, 4.46; P = 
0.005) 
Cerebral infarction occurred in 7 patients, all with indexed LA volumes ≥ 32 mL/m2 
Lee et al. (2008)51  
Cross-sectional 
n=330  
Persistent AF and preserved LVEF 
E/E′ ratio was independently associated with ischemic stroke on multivariate analysis 
Shin et al. (2010)52  
Cohort 
n=148  
AF and heart failure with preserved 
LVEF 
Median follow-up, 27 months 
S′ and E′, particularly when combined, were independent predictors of a composite of 
cardiovascular death, recurrent heart failure, and ischemic stroke 
Azemi et al. (2012)53  
Case-control  
n=57 in each group 
Nonvalvular AF 
CHADS2 score ≤ 1 before index 
event 
Patients with stroke presented reduced peak negative and peak positive LA strain values, when 
compared with controls 
Su et al. (2013)54 
Cohort 
196 patients with persistent AF 
Mean follow-up, 21 months  
Global left ventricular longitudinal systolic strain (GLS) was independently associated with 
adverse CV events including stroke in multivariate models. 
 
LVEF, Left ventricular ejection fraction. 
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Biomarkers 
The role of biomarkers in stroke/thromboembolism in AF has been extensively investigated. e-
Table 5 summarizes important studies involving biomarkers. Although several biomarkers of 
prothrombotic state and of endothelial dysfunction have shown associations with stroke and 
thrombosis, both study design and scale of the studies limit possible conclusions.  
Caveats with the use of biomarkers include inter- and intra- patient and assay variability, some 
have a diurnal variation and can be highly influenced by associated comorbidities and drug 
therapies.  Many biomarkers are non-specific for a particular endpoint, and can be equally 
predictive not only of stroke but bleeding, death, hospitalization, heart failure etc., as well as non-
cardiac conditions e.g., glaucoma.  
 
The importance of biomarkers probably lies in the CHA2DS2VASc=0-2 group (currently without 
anticoagulation) where they may influence the decision to anticoagulate, yet there is a paucity of 
data available in these patients. There are several other hurdles including variations in availability 
in healthcare systems, biomarker assays, access to laboratories, biomarker diurnally, by 
comorbidities and by anticoagulation and other therapies. For these reasons, the clinical 
application of biomarkers in management of AF is unlikely to be significant. 
 
The disease burden-oriented school of thought states, “Research resources should not be allocated 
disproportionately to emerging novel risk factors that may account for up to only 20% of all 
strokes at the expense of researching the determinants of the relatively few established causal 
factors that account for up to 80% of all strokes.” 55  Any biomarker, whether blood, urine or 
imaging (cardiac, cerebral or otherwise) will always improve on risk prediction based on clinical 
factors, but this needs to be balanced against the practical usefulness, cost and daily applicability 
for everyday clinical practice. 
 
 
e-Table 5. Biomarkers in prediction of various thromboembolic events in patients with atrial 
fibrillation.  
Study, Year Participants Biomarker Investigation 
Heppell et al.56 
1997  
109  (19 with 
left atrial 
thrombosis) 
BTG, vWF 
Association with presence of left atrial 
thrombosis (BTG: p=0.002; vWF: p=0.04; 
LAA velocity: p=0.001) 
Mondillo et al.57 
2000  
45 chronic AF, 
35 control 
vWF, 
thrombomodulin 
Higher levels in chronic AF; association with 
a prothrombotic state and endothelial 
dysfunction, coagulation factors and left 
atrial dimension. (Plasma fibrinogen: p<0. 
005; platelet factor 4: p<0.001; 
thromboglobulin: p<0.001; D-dimer: 
p<0.03, tPA: p<0.006, plasminogen 
activator inhibitor: p<0.04; vWF: p<0.0001 
and soluble thrombomodulin: p<0.03) 
Conway et al.58 
2003  
994 AF patients 
taking aspirin 
vWF, P-selectin 
Rise in vWF was predictive of stroke and 
vascular events. After adjustment for 
covariates, vWf was an independent 
predictor of vascular events (RR 1.2 [95% 
CI, 1.0-1.4] per 20 IU/dL increase in vWf; 
p=0.02), but not stroke. 
Conway et al.59 
2004  
106 AF; 41 
control 
IL-6, CRP, TF 
Higher levels in AF patients; TF associated 
with stroke risk (p = 0.003) 
Heeringa et al.60 
2006  
162 AF, 324 
control 
P-selectin 
Association with cardiac mortality in AF (RR 
1.27; 1.08-1.50, per 5-unit increase) 
Nozawa et al.61 
2006  
509 D-dimer 
Thromboembolic risk in patients without the 
clinical risk factors was quite low 
(0.7%/year) when D-dimer was < 150 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the 
accuracy of all data.  
Study, Year Participants Biomarker Investigation 
ng/ml, but not low (3.8%/year) when D-
dimer was >or==150 ng/ml. Association 
with thromboembolic events even in AF 
patients on anticoagulation.  
Ferro et al.62 
2007  
285 CD-40 ligand 
Predictor of vascular events (stroke and 
myocardial infarct): HR 4.63, 1.91–11.1; 
p=0.001 
Lip et al.63 
2007  
880 hsCRP 
Correlation with stroke risk factors and 
prognosis (mortality: 0.001, cardiovascular 
events: p=0.05) 
Kurl et al.64 
2009  
958 men 
NT-proBNP, NT-
proANP 
Predictor for stroke (RR 1.35; 95% CI 1.01-
1.84, p=0.049) and AF in The multivariable 
adjusted risk was for any stroke and 1.30-
fold (95% CI 0.90 to 1.91, p = 0.0150) for 
ischemic stroke for each log-transformed SD 
(0.240 pmol/l) increment in NT-proBNP.  
Pinto et al.65 
2009  
373 TNF-a, IL-6, vWF 
Predictor for new-onset stroke in persistent 
AF 
Yuce et al.66 
2010  
205 chronic AF MPV 
MPV is not related with left atrial thrombus 
in patients with chronic AF 
Sadanaga et al.67  
2011 
261 BNP 
Association with thromboembolic events in 
patients with AF during oral anticoagulant 
therapy 
Hijazi et al.68  
2012 
6 189 
NT-proBNP, 
Troponin I 
Association with risk for stroke and mortality 
 
AF = atrial fibrillation; BTG = β-thromboglobulin; CHF = chronic heart failure; CRP = C-reactive 
protein; HF = heart failure; hsCRP = highly sensitive C-reactive protein; IL = interleukin; LAA = 
left atrial appendage; MMP = metallopeptidase; MPV = mean platelet volume; NT-proANP = N-
terminal prohormone of ANP; NT-proBNP = N-terminal prohormone of BNP; OAC = oral 
anticoagulants; RR = relative risk; SPAF III = Stroke Prevention in Atrial Fibrillation III; TF = 
tissue factor; TNF = tumor necrosis factor; von Willebrand factor(vWF). (From Szymanski et al 
201569) 
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e-Table  6. Comparison of features included in risk stratification schemes 
Study Age 
(yrs) 
HTN DM Prior 
Stroke 
or TIA 
Female 
Sex 
Heart 
Failure 
Coronary 
Artery 
Disease 
Systolic 
BP 
Abnormal 
LV 
Function 
Other 
Atrial Fibrillation Investigators 
(1994)70 
>65 + + +       
Stroke Prevention in Atrial 
Fibrillation Investigators 
(1995) 71 
>75* +  ++ ++* ++  >160 ++  
European Atrial Fibrillation 
Trial Investigators (1995)**72 
   +    >160   
Atrial Fibrillation Investigators 
(1998)73 
>65 + + +     +  
Stroke Prevention in Atrial 
Fibrillation Investigators 
(1998)73 
>75# + + ++ ++#   >160   
CHADS2 (2001)74 >75 + + ++  +     
American College of Chest 
Physicians (2001)75 
>65 
>75 
++ + ++  ++ +  ++  
Framingham Heart Study 
(2003)76 
+  + + +   +   
van Walraven et al. (2003)77  + + +   + +   
American College of Chest 
Physicians (2004)78 
>65 
>75 
++ ++ ++  ++   ++  
Birmingham/NICE 
(UK)(2006)79 
>65 + + ++  ++ +  ++  
ACC/AHA/ESC Guidelines  
(2006)^80 
>75 + + ++ ^ + ^  +  
American College of Chest 
Physicians (2008)81 
>75 + + ++  +     
CHA2DS2-VASc 201082 >65 + + ++ + + ∞ + +  
American College of Chest 
Physicians (2012)83 
>75 
(±65-
74) 
+ + ++ ± + ±Vascular 
disease 
   
ESC 201284 >65 + + ++ + + ∞ + + Stepwise, to 
initially identify 
low risk 
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R2CHADS2 (2013)85 ≥75 + + ++  +    Renal 
dysfunction 
Ie. CrCl<60 
QStroke (2013)86 Range 
25-84 
+ +  Separate 
models 
for M 
and F 
 CHD + CHF Ethnicity; 
Deprivation 
score; 
Smoking; 
TC:HDL; BMI; 
FH; RA; CKD; 
Valvular HD 
ATRIA (2013)87 Range 
<65 to 
≥85 
+ + Separate 
models for 
1o  
and 2o 
prevention 
+ +    Proteinuria; 
eGFR<45ml/mi
n 
NICE201488 >65 + + ++ + + ∞ + + Stepwise, to 
initially identify 
low risk 
AHA/ACC/HRS 201487 >65 + + ++ + + ∞ + + Categorised, 
based on 
CHA2DS2-VASc 
CHADS65 (2014 CCS 
algorithm)89 
≥65 + + +  +     
ABC-Stroke (2016)90 44-90   +      Biomarkers 
(NT-ProBNP, 
hs Troponin) 
ESC 201691 >65 + + ++ + + ∞ + + Categorised, 
based on 
CHA2DS2-VASc 
risk factors 
(not score) 
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e-Table 7. Comparison of Stroke Risk Schema – additional information 
Author/Study Cohort Schemes 
compared 
Events Findings Comments 
ABC-stroke  
Hijazi et al 
201690 
Trial cohorts (ARISTOTLE 
and STABILITY) 
ABC-Stroke, 
CHA2DS2-VASc 
Stroke/SE The ABC-stroke score yielded higher c-indices than 
CHA2DS2-VASc in both the derivation cohort 
(0.68(95%CI 0.65, 0.71) vs. 0.62 (0.60, 0.65), P< 
0.001) and external validation cohort (0.66 (0.58, 0.74) 
vs. 0.58 (0.49,0.60), P < 0.001).  
Developed and internally validated in 14 701 
anticoagulated trial patients with biomarkers 
levels determined at baseline, median follow-
up of 1.9 years.  External validation in 1400 
AF patients (mixed OAC/non-OAC), median 
follow-up 3.4 years. NB all patients in the 
derivation cohort had elevated risk to get into 
the ARISTOTLE trial, and similar elevated risk 
scores in the STABILITY CAD trial 
 
Aakre 92 
 
longitudinal community-
based cohort study from 
Olmsted County  
 
8 Schemes 
compared ((AF 
investigators, 
SPAF, NICE 
guidelines, 
ACC/AHA/ESC 
guideline, 
ACCP Guideline 
Ischemic 
stroke/SE 
High risk: The Stroke Prevention in Atrial Fibrillation 
(SPAF; hazard ratio, 2.75; c=0.659), CHADS2-revised 
(hazard ratio, 3.48; c=0.654), and CHADS2-classical 
(hazard ratio, 2.90; c=0.653) risk schemes were most 
accurate in risk stratification.  
Low-risk cohort within the CHA2DS2-VASc scheme had 
the lowest event rate among all low-risk cohorts (0.11 
per 100 person-years), but only 5% of the population 
were classified as low risk,  
A direct comparison of 9 risk schemes reveals 
no profound differences in risk stratification 
accuracy for high-risk patients. Accurate 
prediction of low-risk patients is perhaps more 
valuable in determining those unlikely to 
benefit from OAC therapy. CHA2DS2-VASc 
performed best, but only small proportion 
were classified as low risk   
 
Abraham93 
 
 
 
 
 
longitudinal cohort of 
5981 women with AF not 
on warfarin at baseline 
(mean age 65.9 years) 
enrolled in the Women’s 
Health Initiative and 
followed for a median of 
11.8 years.  
CHADS2 
CHA2DS2-VASc  
Ischemic 
stroke/TIA 
CHA2DS2-VASc had a higher c statistic than CHADS2: 
0.67 (95% CI, 0.65-0.69) versus 0.65 (95% CI, 0.62-
0.67), P <.01. For CHADS2 scores <2, stroke risk almost 
doubled with every additional CHA2DS2-VASc point. 
Possible that some women were started later on 
warfarin. As all cohort were women, CHA2DS2-VASc =1 
was solely female sex 
Both CHADS2, and CHA2DS2-VASc are 
predictive of stroke risk in postmenopausal 
women with AF.  
CHA2DS2-VASc further risk-stratifies patients 
with a CHADS2 score <2. 
Abu-Assi 94 
 
 
186 patients with non-
valvular AF and off 
anticoagulant therapy  
 
4 risk 
schemes: The 
Framingham, 
the 8th ACCP, 
the 
ACC/AHA/ESC 
2006, and the 
CHA2DS2-
VASc.  
 
Ischemic 
stroke/SE 
c-statistic ranged from 0.59 [for CHA2DS2-VASc ] to 
0.73 [for Framingham].  
CHA2DS2-VASc categorized the fewest patients into low 
and intermediate-risk categories, whereas the 
Framingham schema assigned the highest patients into 
low-risk strata.  
No TE events in the low and intermediate-risk categories 
using CHA2DS2-VASc , whereas the most schemes 
assigned patients into intermediate-risk category had an 
event rate ranging from 2.5 (ACC/AHA/ESC and 8th 
ACCP schemes) to 6% (Framingham).  
The negative predictive value of TE events was of 100% 
for the no high-risk patients using CHA2DS2-VASc .  
Small study, with few events, and only 6 
patients with CHA2DS2-VASc score of 0 or 1. 
Therefore caveat on conclusion that CHA2DS2-
VASc risk stratification schema may be better 
in discriminating between patients at a low 
and intermediate risk of TE complications.  
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Abumuaileq95 
  
 
non-anticoagulated cohort 
of 154 patients; 911 
patients formed the 
cohort of patients on VKA  
 
CHA2DS2-
VASc , 
R2CHADS2 and 
ATRIA (used 
the 
conventional 
ATRIA cut-off 
of 0-5, and did 
not explore 
lower cut 
points) 
 
Ischemic 
stroke/SE 
During 11 ± 2.7 months. CHA2DS2-VASc showed 
significant association with TE: hazard ratio (HR) = 1.58 
[95%CI 1.01–2.46), but R2CHADS2 and ATRIA did not 
(HR = 1.23 (95 % CI 0.86–1.77) and 1.20 (95 % CI 
0.93–1.56), respectively.  
In the anticoagulated cohort, after 10 ± 3 months of 
follow up, the three scores showed similar association 
with TE risk: HR = 1.49 (95 % CI 1.13–1.97), 1.41 
(95 % CI 1.13–1.77) and 1.37 (95 % CI 1.12–1.66) for 
CHA2DS2-VASc , R2CHADS2 and ATRIA, respectively.  
 
Small study with only 9 TE events in total and 
only 23 patients in CHA2DS2-VASc low risk 
group. 
 
CHA2DS2-VASc better association with TE 
events than R2CHADS2 and ATRIA scores in 
the non-anticoagulated cohort.  
CHA2DS2-VASc and R2CHADS2 can identify 
patients at truly low risk regardless of the 
anticoagulation status.  
 
Chao 29 
 
186,570 AF patients 
without antithrombotic 
therapy  
 
Taiwan Health Insurance 
database 
CHA2DS2VASc, 
ATRIA (used 
the 
conventional 
ATRIA cut-off 
of 0-5, and did 
not fully 
explore lower 
cut points. 
There was a 
pointwise 
gradation of 
risk from 
ATRIA score 0 
to 5) 
 
Ischemic 
stroke 
High risk:  CHA2DS2-VASc score performed better than 
ATRIA score in predicting ischemic stroke as assessed by 
c-indexes (0.698 vs. 0.627, respectively; p < 0.0001).  
CHA2DS2-VASc score improved the net reclassification 
index by 11.7% compared with ATRIA score (p < 
0.0001).  
 
Low risk:  Among 73,242 patients categorized as low-
risk on the basis of an ATRIA score of 0 to 5, the 
CHA2DS2-VASc scores ranged from 0 to 7, and annual 
stroke rates ranged from 1.06% to 13.33% at 1-year 
follow-up. c-index of CHA2DS2-VASc score (0.629) was 
significantly higher than that of the ATRIA score (0.593) 
in this “low-risk” category (p < 0.0001).  
 
 
Patients categorized as low-risk by use of the 
ATRIA score were not necessarily low-risk, 
and the annual stroke rates can be as high as 
2.95% at 1-year follow-up. ATRIA score may 
perform better if a lower cut point is chosen  
 
CHA2DS2-VASc score of 0 had a truly low risk 
of ischemic stroke, with an annual rate of 
approximately 1%  
 
Chao 96 
 
186,570 AF patients 
without antithrombotic 
therapy  
 
Taiwan Health Insurance 
database 
CHA2DS2VASc, 
CHADS2 
Ischemic 
stroke 
CHA2DS2VASc, score performed better than CHADS2 
score in predicting ischemic stroke assessed by c-
indexes (0.698 vs 0.659, P o.0001). Among 25,286 
patients with a CHADS2 score of 0, the CHA2DS2VASc, 
score ranged from 0 to 3, and the annual stroke rate 
ranged from 1.15% to 4.47%.  
 
Very large study with high numbers of events. 
CHADS2 score of 0 were not necessarily “low 
risk,” and the annual stroke rate can be as 
high as 4.47% when further stratified by 
CHA2DS2VASc. 
CHA2DS2VASc score of 0 had a truly low risk 
of ischemic stroke, with an annual rate around 
1.15%.  
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Chen 97 
 
 
Systematic review and 
meta-analysis of the 
predictive abilities of 
CHADS2 and 
CHA2DS2VASc 
 
CHA2DS2VASc, 
CHADS2 
 Unsuitable to perform a direct meta-analysis because of 
high heterogeneity.  
 
When analyzed as a continuous variable, the C-statistic 
ranged from 0.60 to 0.80 (median 0.683) for CHADS2 
and 0.64–0.79 (median 0.673) for CHA2DS2VASc (no 
significant difference).  
The average ratio of endpoint events in the low-risk 
group of CHA2DS2VASc was less than CHADS2 (0.41% 
vs. 0.94%, P < 0.05). The average proportion of the 
moderate-risk group of CHA2DS2VASc was lower than 
CHADS2 (11.12% vs. 30.75%, P < 0.05).  
The C-statistic suggests a similar clinical utility 
of the CHADS2 and CHA2DS2VASc scores in 
predicting stroke and thromboem- bolism, but 
CHA2DS2VASc has the important advantage of 
identifying extremely low-risk patients with 
AF, as well as classi- fying a lower proportion 
of patients as moderate risk.  
Coppens98 
 
 
Trial cohort from 
AVERROES and ACTIVE all 
treated with aspirin and 
some with concomitant 
clopidogrel 
CHA2DS2VASc, 
CHADS2 
 Of 4670 patients with a baseline CHADS2  score of 1, 
26% had a CHA2DS2VASc score of 1 and 74% had a 
score of ≥2.  
After 11414 patient-years of follow-up, the annual 
incidence of SSE was 0.9% (95% CI: 0.6–1.3) and 2.1% 
(95% CI: 1.8–2.5) for patients with a CHA2DS2VASc 
score of 1 and ≥2, respectively.  
 
The c-statistic of the CHA2DS2VASc score was 0.587 
(95% CI:  
0.550–0.624). Age 65 to <75 years was the strongest of 
the three new risk factors in the CHA2DS2VASc score  
The CHA2DS2VASc score reclassifies 26% of 
patients with a CHADS2 score of 1 to a low 
annual risk of SSE of 1% and age 65-74 is the 
major contributor.  
 
Guo et al 26 
 
1034 AF patients (27.1% 
female, median age 75; 
85.6% non-
anticoagulated) with 
mean follow-up of 1.9 
years.  
 
PLA General Hospital 
electronic medical 
database 2007-2010 
CHA2DS2VASc, 
CHADS2 
Stroke/TE In patients with a CHADS2 or CHA2DS2-VASc score=1, 
the rate of stroke/TE was 2.9% and 0.9% respectively. 
In patients at “high risk” (scores≥2), this rate was 4.6% 
and 4.5%, respectively.  
The c-statistics for predicting stroke/TE with CHADS2 
and CHA2DS2-VASc were 0.58 (p = 0.109) and 0.72 (p 
<0.001), respectively. Compared to CHADS2, the use of 
CHA2DS2-VASc would result in a Net Reclassification 
Improvement (NRI) of 16.6% (p=0.009) and an 
Integrated Discrimination Improvement (IDI) of 1.1% (p 
= 0.002).  
Cumulative survival of the patients with a CHA2DS2-
VASc score ≥ 2 was decreased com- pared to those with 
a CHA2DS2-VASc score 0–1 (p < 0.001), but the 
CHADS2 was not predictive of mortality.  
Vascular disease was a strong independent 
predictor of stroke/TE in Chinese patients with 
AF, and CHA2DS2-VASc. superior to CHADS2 
at low scores. 
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Hippisley-Cox 86 
 
 
1 897 168 eligible 
patients from 451 general 
practices in England and 
Wales contributing to the 
national QResearch 
database. Excluded 
patients with prior stroke 
or TIA, and those on 
anticoagulant  
QStroke 
CHA2DS2VASc, 
CHADS2 
Stroke or 
TIA 
AF patients at baseline: 
C statistic in men was 0.71 (0.69-0.73) for QStroke, 
0.67 (0.65, 0.69) for CHA2DS2VASc, and 0.63 for 
CHADS2(0.61-0.66) 
C statistics in women was 0.65 (0.62-0.67) for QStroke, 
0.62 (0.59, 0.65) for CHA2DS2VASc, and 0.61 for 
CHADS2(0.59-0.64) 
 
4% of patients were low risk on CHA2DS2VASc 
but high risk on Qstroke and had a 10 year 
observed stroke rate of 7.6%, compared to 
2.6% for those low risk on both scores and 
21.2% for those at high risk on both scores. A 
high risk on CHA2DS2VASc but low on Qstroke 
(4% of patients) had a10 year  stroke rate of 
2.8%. These results pertain only to patients 
without a prior stroke or TIA 
Kornej 85 
 
N=2069; 66% men; 
60±10 years; 62% 
paroxysmal AF  
Referred for ablation 
CHADS2, 
CHA2DS2-
VASc, and 
R2CHADS2  
 
Stroke, 
transient 
ischemic 
attack, or 
systemic 
embolism  
 
C-indexes: CHADS2 0.72(0.70-0.739); CHA2DS2-VASc 
0.736(0.716-0.755) and R2CHADS2 0.736 (0.716-
0.755)  
CHA2DS2-VASc score further differentiated TE risk in 
patients with CHADS2 and R2CHADS2 0 to 1 (0.13% if 
CHA2DS2- VASc was 0–1 and 0.71% if CHA2DS2-VASc 
was >2) and had the best predictive value in patients 
with AF recurrences (c-index 0.894, P=0.022 versus 
CHADS2, P=0.031 versus R2CHADS2).  
 
CHA2DS2-VASc score differentiated TE risk in 
the low-risk strata based on CHADS2 and 
R2CHADS2 scores in a post-ablation cohort, 
with half of the TE events occurring in the 30 
days post ablation  
 
Lip99 
 
 
207,543 incident hospital 
discharge patients with AF 
from 1999 to 2012  
 
Danish registry linked 
data 
 
CHA2DS2VASc, 
ATRIA 
Ischemic 
stroke/TE 
Patients categorized as low risk using the ATRIA score, 
the 1-year stroke/thromboembolic event rate ranged 
from 1.13 to 36.94 per 100 person-years, when 
subdivided by CHA2DS2VASc scores.  
In patients with an ATRIA score 0 to 5 (i.e. low risk), C 
statistics at 1 year follow-up in the Cox regression model 
were significantly improved from 0.626 (95% CI, 0.612-
0.640) to 0.665 (95% CI, 0.651-0.679) when the 
CHA2DS2VASc score was used for categorizing stroke 
risk instead of the ATRIA score (P <.001).  
 
Low-risk category (i.e., CHA2DS2VASc score 0 for men 
or a score 1 for women) would identify a truly low-risk 
cohort, with annual event rates at 1- year of 1.13 per 
100 person-years.  
Patients categorized as low risk using an 
ATRIA score 0 to 5 are not necessarily low 
risk, with 1-year event rates as high as 36.94 
per 100 person-years. However, no 
exploration on risk at ATRIA scores between 0-
5, and whether a lower ATRIA cut point would 
perform differently 
 
CHA2DS2VASc score best at identifying 
the “truly low risk” subjects with AF 
compared to ATRIA  0-5 low risk 
definition 
Lip100 22,582 non-
anticoagulated hospital 
discharged patients age < 
65 years with a CHADS2 
score of 0 who were 
stratified according to the 
CHA2DS2-VASc score, 
except female sex, which 
would be an indication for 
OAC according to the ESC 
guidelines.  
CHA2DS2VASc, 
CHADS65 
Ischemic 
stroke/TE/ 
TIA 
Overall rate of the combined end point of ischemic 
stroke/systemic embolism/transient ischemic attack was 
4.32 per 100 person-years (95% CI 3.26-5.74) at 1 
year, among the patients who would have had an 
indication for OAC therapy according to 2012 ESC 
guidelines (based on CHA2DS2VASc score) and “OAC 
not recommended” according to CCS algorithm.  
Subgroup of patients with previous vascular disease and 
CHADS2 score of 0 (i.e., recommended only aspirin 
treatment according to the CCS algorithm) had an event 
rate of 4.84 (95% CI, 3.53-6.62) per 100 person-years 
Based on the 2014 CCS algorithm, the “OAC 
not recommended” subgroup can have a high 
1-year stroke rate overall, showing that such 
patients are not “low risk.”  
Use of CHA2DS2-VASc offers refinement of 
stroke risk stratification in such patients.  
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Danish Registry linked 
data 
at 1-year follow-up. Sensitivity analysis yielded similar 
result with events restricted to stroke/systemic 
embolism 
Nielsen et al101 
 
 
Supplemental information 
to Can J Cardiol 2015 31; 
24-28 responding to 
Cairns et al editorial on 
the original Lip et al 
article 
 
CHA2DS2VASc, 
CHADS65 
 Contrasting low risk CHA2DS2-VASc (that is, score 0 
(male) or 1 (female)) as a reference population vs those 
with ≥1 additional non-sex stroke risk factors (i.e. 
CHA2DS2- VASc score =1 (male) or =2 (females)) to 
express the hazard attributable to vascular disease 
resulted in a crude HR of 2.7 (95%CI 1.7-4.2).  
‘Vascular disease’ Event rates per 100 person-
years:  MI 2.5 (1.4-4.3); PAD 3.0 (1.3-6.7); Both 
15.0 (4.8-46.4) 
Any stroke RF other than sex (including 
vascular disease) in CHA2DS2-VASc provides a 
high enough risk of adverse events to warrant 
a recommendation for anticoagulation 
Nielsen  102 
 
198697 hospital 
discharged AF patients, of 
which 15% truly low risk 
 
Danish registry linked 
data (NB Lip and Nielsen 
papers from the same 
cohorts) 
CHA2DS2-
VASc, but 
compares 
guideline 
approaches 
and addresses 
the varying 
event rates 
reported for 
different 
guideline  cut-
offs and 
different 
analysis 
approaches 
Ischemic 
stroke, and 
composite 
of ischemic 
stroke and 
systemic 
embolism  
Rate of composite endpoint using  censoring of 
observation at time of OAC commencement  was 
0.54/100 person-years for truly low risk (CHA2DS2-
VASc 0 males, 1 females), 1.53 for CHA2DS2-VASc =1 
in males, 2.33 for CHA2DS2-VASc =2, and 5.49 for 
CHA2DS2-VASc >2. The analysis using conditioning  on 
the future revealed an event rate of only 1.17/100 
patient-years for CHA2DS2-VASc =1 (males) 
Stroke and TE event rates vary according to 
method of analysis. Some evidence that 
formal approach, and conditioning on the 
future (exclusion of patients who commence 
OAC) will underestimate the event rate, and 
this is most important for CHA2DS2-VASc =1 
(males) 
 
 
Okumura  103 
 
6,387 patients taking 
warfarin and the other 
997 not taking warfarin 
were prospectively 
examined for 2 years.  
 
J-Rhythm registry 
CHADS2;  
modified 
CHA2DS2- 
VASc 
(mCHA2DS2-
VASc) using 
coronary 
disease only 
 
Thrombo-
embolism 
(combined 
ischemic 
stroke, TIA 
and systemic 
embolism) 
mCHA2DS2-VASc score 0, 1, and ≥2, thromboembolism 
occurred in 2/141 (0.7%/year), 4/233 (0.9%/year), and 
24/623 (1.9%/year), respectively, in the non-warfarin 
group, and in 1/346 (0.1%/year, P=0.19 vs. non-
warfarin), 4/912 (0.2%/year, P=0.05), and 92/5,129 
(0.9%/year, P=0.0005), respectively, in the warfarin 
group.  
 
When female sex was excluded from the score, 
thromboembolism occurred in 2/180 patients 
(0.6%/year), 5/245 (1.0%/year), and 23/572 
(1.6%/year), respectively, in the non-warfarin group, 
and in 1/422 (0.1%/year, P=0.20 vs. non-warfarin), 
5/1,096 (0.2%/year, P=0.02), and 91/4,869 
(0.9%/year, P=0.0005), respectively, in the warfarin 
group.  
Small numbers and no information on OAC 
use at follow-up in the non-warfarin group. 
 
In Japanese NVAF patients, the mCHA2DS2-
VASc score is useful for identifying patients at 
truly low risk. Concluded that ‘Female sex 
may be excluded as a risk from the score.’ 
But numbers are too small to substantiate 
that conclusion. 
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Palm104 
 
Ludwigshafen Stroke 
Study (LuSSt), 
prospective ongoing 
population-based stroke 
register, 187 patients 
with a first-ever ischemic 
stroke (FEIS) owing to AF 
in 2006 and 2007.  
 
CHA2DS2VASc, 
CHADS2 
First 
ischemic 
stroke 
Retrospective pre- stroke risk stratification according to 
CHADS2 score indicated low/intermediate risk in 34 
patients (18%) and high risk (CHADS2 ≥2) in 153 
patients (82%). Application of CHA2DS2-VASc score 
reduced number of patients at low/intermediate risk 
(CHA2DS2-VASc score 0–1) to five patients (2.7%).  
 
Small, retrospective study of people with 
ischemic stroke. 
CHA2DS2-VASc score appears to be a more 
valuable risk stratification tool than CHADS2 
score.  
 
Philippart105 
 
 
Loire Valley AF project: 
Among 8053 patients 
seen in Cardiology Dept 
with non-valvular AF (ESC 
guidelines definition), 
patients were categorized 
into Group 1 (no valve 
disease, n=6851; 85%) 
and Group 2 (valve 
disease with neither 
rheumatic mitral stenosis 
nor valve prothesis, n = 
1202; 15%).  
 
CHA2DS2VASc 
in ‘non-
valvular’ and 
(non-
rheumatic or 
prosthetic 
‘valvular’ AF 
Stroke/TE For Group 1, the rate of events was 0.87%/year when 
CHA2DS2VASc score was 0–1, rising to 9.67%/year 
when score was ≥6. For patients in Group 2, similar 
finding were evident with a rate of stroke/TE events 
increasing from 0.90%/year with a CHA2- DS2VASc 
score 0–1 to 11.07%/year when CHA2DS2VASc score 
was ≥6.  
 
Main purpose of the study was to compare stroke/TE 
rates, and prediction of these by CHA2DS2VASc in 
patients with AF with and with “valvular” AF other than 
rheumatic mitral or prosthetic 
  
CHA2DS2VASc performs similar in both 
groups 
If low risk (score 0-1), event rates low, 
approx. 0.9%/year, but 56-60% were on 
OAC, so rate is underestimated.  
 
 
Potpara.106 
 
Cohort of 345 "lone" AF 
patients with a 12-year 
follow-up. 
CHA(2)DS(2)-
VASc, 
CHADS(2), and 
van Walraven 
risk 
stratification 
schemes   
 
Ischemic 
stroke 
(absence of) 
 
i.e. 
Prediction of 
LOW RISK 
 In the multivariable analysis, only the CHA(2)DS(2)-VASc 
score of 0 was significantly related to the absence of 
stroke (odds ratio 5.1, 95% CI: 1.5-16.8, P=0.008).  
 
Only the CHA(2)DS(2)-VASc score had a significant 
prediction ability for absence of ischemic stroke (c-statistic 
0.72 [0.61-0.84], P=0.031). 
 
Small study of lone AF with 12 year follow-
up 
 
CHA(2)DS(2)-VASc score reliably identified 
the "lone" AF patients who were at "truly 
low risk" for TE 
Ruff107 
 
Biomarker sub-study of 
ENGAGE-AF, using cardiac 
troponin I, N-terminal 
pro-B-type natriuretic 
peptide, and d-dimer  in 
4880 patients with all 3 
biomarkers available  
CHA(2)DS(2)-
VASc 
± biomarkers 
Stroke or 
systemic 
embolism 
When added to the CHA2DS2-VASc score, the biomarker 
score significantly enhanced prognostic accuracy by 
improving the C statistic from 0.586 (95% CI, 0.565-
0.607) to 0.708 (95% CI, 0.688-0.728) (P < .001) and 
reclassification with a net reclassification improvement of 
59.4% (P < .001). 
 
All patients were anticoagulated, and all 
patients were CHADS2 =2 or greater, so 
cannot comment on discrimination of low 
risk patients without anticoagulant 
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Singer 108 
 
Derivation ATRIA cohort 
consisted of 10 927 
patients with non-valvular 
AF contributing 32 609 
person-years off warfarin 
and 685 thromboembolic 
events (TEs). The 
external validation ATRIA-
CVRN cohort included 25 
306 AF patients 
contributing 26 263 
person-years off warfarin 
and 496 TEs.  
ATRIA, 
CHA(2)DS(2)-
VASc, 
CHADS(2), 
Ischemic 
stroke/TE 
c-index in the ATRIA cohort was 0.73 (95% CI, 0.71 to 
0.75), increasing to 0.76 (95% CI, 0.74 to 0.79) when 
only severe events were considered.  
The C-index was greater and net reclassification 
improvement positive comparing the ATRIA score with 
CHA(2)DS(2)-VASc, or CHADS(2) 
The NRI improvement was primarily seen for predicting 
severe strokes. No analysis was done to determine the 
relative performance of scores to detect a truly low risk 
group who should not be treated rather than a low 
intermediate and high risk group 
Follow-up was censored at the date of the 
outcome event, death or health plan 
disenrollment.  
 
Analysis based on all person-time off 
warfarin.  
Results comparing risk scores were very 
similar when restricted the analysis to the 
4342 patients who did not take warfarin at 
any point during follow-up  
(… but ‘conditioning on the future’).  
 
Siu30 
 
9727 hospitalized AF 
patients, follow-up for 
3.19 years 
CHA(2)DS(2)-
VASc, 
CHADS(2), 
Ischemic 
stroke 
c-statistics revealed that CHA(2)DS(2)-VASc scores 
(0.525, 95% CI 0.509–0.541, P = .017) was better than 
CHADS(2) scores (0.506, 95% CI 0.490–0.522, P = .584) 
in predicting ischemic stroke.  
 
Net clinical benefit favors warfarin over aspirin and no 
therapy for stroke prevention in a broad range of Chinese 
AF patients. 
CHA(2)DS(2)-VASc and HAS-BLED scores 
appear to be the appropriate risk 
stratification tools for stroke risk and ICH, 
respectively, for Chinese. C-Statistics 
relatively low for prediction of ischemic 
stroke compared to other cohorts. Annual 
risk of stroke relatively higher in low risk 
groups (CHA(2)DS(2)-VASc score =0 or 1) 
in Chinese than that in Europeans 
Tomita109 
 
 
997 AF patients in 
JRHYTHM registry with no 
warfarin at baseline 
 
Same cohort as Okamura 
without the cohort taking 
warfarin as comparison 
mCHA2DS2- 
VASc and 
mCHA2DS2-VA 
scores (i.e. 
excluding 
female sex) 
 
Modified as 
based on 
coronary 
artery disease 
(no 
information on 
PAD) 
Thrombo-
embolic 
events 
including 
symptomatic 
cerebral 
infarction, 
transient 
ischemic 
attack (TIA), 
and systemic 
embolism  
 
No sex difference was found in patient groups stratified by 
CHA2DS2-VASc and CHA2DS2-VA scores.  
Significant c-statistic difference (0.029, Z=2.3, P=0.02) 
and NRI (0.11, 95% CI 0.01–0.20, P=0.02), with the 
CHA2DS2-VA score being superior to the CHA2DS2-VASc 
score.  
In patients with CHA2DS2-VASc scores 0 and 1 (n=374), 
there were significant c-statistic difference (0.053, Z=6.6, 
P<0.0001) and NRI (0.11, 95% CI 0.07–0.14, P<0.0001), 
again supporting superiority of CHA2DS2-VA to CHA2DS2-
VASc score.  
Small numbers and no information on OAC 
use at follow-up in the non-warfarin group 
(may explain low absolute event rates even 
at high scores). 
Very few females in study and only 90 with 
CHA2DS2-VASc =1 or 2. 
NB CHA2DS2-VASc score of 1 in a woman 
is excluded in ESC guidelines  
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Van den 
Ham. 110 
 
60,594 patients with AF  
 
CPRD UK cohort (primary 
care based but incident 
AF could be hospital 
discharge) in incident AF, 
censored at warfarin 
prescription or outcome 
event) 
 
 CHADS2, 
CHA2DS2-
VASc and 
ATRIA 
 
Ischemic 
stroke 
C statistics for the full point scores were 0.70 (95% 
confidence interval [CI]: 0.69 to 0.71) for the ATRIA risk 
score, 0.68 (95% CI: 0.67 to 0.69) for CHADS2, and 0.68 
(95% CI: 0.67 to 0.69) for CHA2DS2-VASc risk score.  
The net reclassification improvement was 0.23 (95% CI: 
0.22 to 0.25) for ATRIA compared with CHA2DS2-VASc. 
 
Median follow-up was only 0.74 years over a 15-year 
study period; though mean follow-up was 2.8 years, 
indicating distribution of follow-up is skewed. 
Using ATRIA, 40% were categorized as low-risk (that is, 
ATRIA score of ≤5, with annualized stroke rates of 0.40% 
to 1.99%), 
ATRIA score performed better than either 
CHADS2, CHA2DS2-VASc for predicting 
events.  
 
ATRIA identified 40% as low-risk patients 
vs CHA2DS2-VASc score, which identified 
only 6.6% as low risk, and assigned these 
patients to higher-risk categories.  
 
Aspberg111 
 
152 153 AF patients not 
receiving warfarin in 
Swedish AF cohort – 
hospitalized or visiting 
hospital OPD.  
future analysis 
 
CHADS2, 
CHA2DS2-
VASc and 
ATRIA 
 
Ischemic 
stroke 
ATRIA had a good C of 0.708 (0.704–0.713), significantly 
better than CHADS2 0.690 (0.685–0.695) or CHA2DS2-
VASc 0.694 (0.690–0.700).  
 
Net reclassification improvement favored ATRIA 0.16 
(0.14–0.17) vs. CHADS2 and 0.21 (0.20–0.23) vs. 
CHA2DS2-VASc (with a reclassification down for the 
comparison with CHA2DS2-VASc, and a reclassification up 
for the comparison with CHADS2.  
 
Analyses restricted to patients who did not 
use any anticoagulant therapy during the 
follow-up period – thus ‘conditioning on the 
future’. When categorical cut-points were 
optimized to the stroke rate of the 
population, the differences between scores 
in NRI and C statistic disappeared 
 
Xiong112 
 
Systematic review and 
meta-analysis, East Asian 
patients. 
Included 6 cohort studies 
with 31,539 patients 
CHA(2)DS(2)-
VASc, 
CHADS(2), 
Predomin-
antly 
ischemic 
stroke, 2 
with 
thrombo-
embolism 
Meta-analysis revealed that when compared with the 
CHA2DS2-VASc score, there was a 1.71-fold elevated risk 
of stroke when patients were stratified as ‘low risk’ using a 
CHADS2 score = 0, or a 1.40-fold increase with a CHADS2 
score = 1.  
  
 
CHA2DS2-VASc score is superior to the 
CHADS2 score in identifying ‘low risk’ East 
Asian AF patients.    
 
Zhu113  
 
Systematic review and 
meta-analysis 
 
Included 12 cohort 
studies with 205,939 
patients 
CHA2DS2-
VASc, 
CHADS2, 
Stroke, 
Thrombo-
embolism 
CHA2DS2-VASc scores ≥2 have a greater risk of stroke 
(risk ratio [RR]=5.15; 95% confidence interval [CI], 3.85–
6.88; P <0.00001) and  
thromboembolism (RR=5.96; 95% CI, 5.50–6.45; P 
<0.00001) (Pdiff=0.34) than do patients with CHA2DS2-
VASc scores <2, independent of anticoagulation therapy 
(RR=5.76;  95% CI, 5.23–6.35; P <0.00001 in 
anticoagulated patients; and RR=6.12; 95% CI, 5.40–  
6.93; P <0.00001 in patients not taking anticoagulants; P 
=0.45).  
In the comparison of the rates of endpoint events among 
low-risk patients (1.67% vs 0.75%; P <0.001), the 
findings imply that some CHADS(2) low- risk patients 
might still benefit from anticoagulation   
Superior diagnostic performance of 
CHA2DS2-VASc over CHADS2 for 
identifying genuinely low-risk patients with 
AF. 
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Kim114 5855 oral anticoagulant 
naive NVAF patients 
enrolled from Korea 
National Health Insurance 
Service-Sample Cohort  
 
CHA2DS2-
VASc, 
CHADS2 and 
ATRIA 
Ischaemic 
stroke 
CHA2DS2-VASc had the best sensitivity (98.8% versus 
85.7% in CHADS2 and 74.8% in ATRIA) and negative 
predictive value (98.8% versus 95.3% for CHADS2 and 
93.7% for ATRIA) for the prediction of stroke incidence 
and was best for the prediction of the absence of ischemic 
stroke during 5 years of follow-up (odds ratio, 16.4 [95% 
confidence interval, 8.8-30.8]). 
CHA2DS2-VASc score shows good 
performance in defining truly low-risk Asian 
patients with atrial fibrillation for stroke 
compared with CHADS2 and ATRIA 
 
Rivera-
Caravaca115 
1125 NVAF patients  Compared 
long-term 
predictive 
performances 
of the ABC-
stroke and 
CHA2DS2-
VASc  
 
Ischaemic 
stroke 
114 ischemic strokes (1.55% per year) at 6.5 years.  
 
ABC-stroke c-index at 3.5 years (0.663) was higher than 
CHA2DS2-VASc (0.600, P=0.046), but nonsignificantly 
different at 6.5 years.  
For ABC-stroke, net reclassification improvement was 
nonsignificantly different at 3.5 years, and a negative 
reclassification at 6.5 years, vs CHA2DS2-VASc.  
Decision curve analyses did not show marked 
improvement in clinical usefulness of the ABC-stroke score 
over the CHA2DS2-VASc score. 
ABC-stroke score did not offer better ‘real 
world’ predictive performance compared 
with the CHA2DS2-VASc score over long 
term 
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e-Table 8. Major bleeding rates with VKAs in observational studies 
Study Patients on VKA, n Age, years Mean follow-up Major bleeding, per year 
EURO HEART SURVEY 
(2010)116 
2115 66.8 1 y 1.5% 
ATRIA (2011)117 9186 71 3.5 y 1.4% 
Olesen et al. (2011)118 37425 70.6 10 y 4.62% 
Gallego et al. (2012)119 965 76 861 d 3.6% 
Donze et al. (2012)120 515 71.2 1 y 6.8% 
Friberg et al. (2012)38 48599 76.2 1.5 y 1.9% 
Burgess et al. (2013)121 321 69.2 2.5 y 3.8% 
ORBIT-AF (2013)122 4804 76 6 m 1.8% 
Seet et al. (2013)123 100 79.3 19 m 9.79% 
Guo et al. (2013)26 149 63 1.9 y 2.7% 
Deitelzweig et al. (2013)124 48260 67.3 802 d 10.4% 
MAQI2 (2014)125 2600 70.1 1 y 4.5% 
Wang et al. (2016)126 15418 65 4.6 m 5.5% 
d=day; m= month; VKA=vitamin-K antagonist; y=year 
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e-Table 9. Major bleeding rates on oral anticoagulants in randomized clinical trials 
Trial Patients on anticoagulants, n Age, year Mean follow-up Major bleeding, per year 
BAATAF (1990)127 212 (VKA) 68.5 2.2 y 2 patients in 2.2 y (VKA) 
CAFA (1991)128 187 (VKA) 68 15.2 m 2.5% (VKA) 
SPAF I (1991)129 1330 (VKA) 67 1.3 y 1.5% (VKA) 
SPINAF (1992)130 260 (VKA) 67 1.8 y 1.3% (VKA) 
EAFT (1993)131 1007, 225(VKA) 77 2.3 y 2.8% (VKA) 
SPAF II (1994)132 1100 (VKA) 64 (age75) 
80 (age>75) 
2.3 y 1.7% (age75) (VKA) 
4.2% (age>75) (VKA) 
SPAF III, (1996)133 523 (VKA) 71 1.1 y 2.1% (VKA) 
AFASAK2, (1998)134 170 (VKA) 73.2 1 2.4% (VKA) 
Pengo et al. (1998)135 153 (VKA) 73.6 14.5 m 2.6% (VKA) 
Hellemons et al. (1999)136 131 (VKA) 70 2.7 y 0.5% (VKA) 
Yamaguchi et al. (2000)137 55 (VKA) 65.7 658 d 6.6% (VKA) 
SPORTIFF III (2003)138 1703 (VKA) 
1704 (Ximelagatran) 
70.1 (VKA) 
70.3 (Ximelagatran) 
17.4 m 1.8% (VKA) 
1.3% (Ximelagatran) 
NASPEAF, (2004)139 496 (VKA) 69.6 (Intermediate) 
66.6 (High intensity) 
965 d (Intermediate) 
1075 d (High intensity) 
 
1.8% (Intermediate) (VKA) 
2.13% (High intensity) (VKA) 
SPORTIFF V (2005)140 1962 (VKA) 
1960 (Ximelagatran) 
71.6 (VKA) 
71.6 (Ximelagatran) 
20 m 3.1% (VKA)* 
2.4% (Ximelagatran)* 
ACTIVE W (2006)141 3371 (VKA) 70.2 1.28 y 2.21% (VKA) 
Chinese ATAFS (2006)142 704 (VKA) 63.3 19 m 1.5% (VKA) 
AMADEUS (2008)143 2293 70.2 10.7 m 1.4% 
RE-LY (2009)144 6022 (VKA) 
6076 (D, 110 mg) 
6015 (D, 150 mg) 
71.6 (VKA) 
71.5 (D, 110 mg) 
71.4 (D, 150 mg) 
2 y 3.36% (VKA) 
2.71% (D, 110 mg) 
3.11% (D, 150 mg) 
ROCKET AF (2011)145 7133 (VKA) 
7131 (R, 20 mg) 
73 (VKA) 
73 (R, 20 mg) 
2 y 3.4% (VKA) 
3.6% (R, 20 mg) 
ARISTOTLE (2011)146 9120 (VKA) 
9081 (A, 5 mg) 
70 (VKA) 
70 (A, 5 mg) 
1.8 y 3.09% (VKA) 
2.13% (A, 5 mg) 
J-ROCKET (2012)147 639 (VKA) 
639 (R, 15 mg) 
71.2 (VKA) 
71 (R, 15 mg) 
 3.59% (VKA) 
3.00 (R, 15 mg) 
ENGAGE AF (2013)148 7036 (VKA) 
7035 (E, 30 mg) 
6015 (E, 60 mg) 
72 (VKA) 
72 (E, 30 mg) 
72 (E, 60 mg) 
907 d 3.43% (VKA) 
1.61% (E, 30 mg) 
2.75% (E, 60 mg) 
*= major extra-cerebral bleeding 
A=apixaban; D=dabigatran; d=day; E=edoxaban; m=month; R=rivaroxaban; VKA= vitamin-K antagonist; y=year 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
e-Table 10. Studies comparing bleeding risk schemas 
 
Study Cohort Schemes 
compared 
Events Findings Comments 
Barnes et al149 
 
2,600 patients in 7 
anticoagulation clinics, 
2009-2013. Only 
warfarin used. 
Warfarin initiators 
followed with 
retrospective scores. 
First major bleed only 
included 
CHADS2,  
CHA2DS2-VASc, 
HEMORR2HAGES,  
HAS-BLED, 
ATRIA 
116 major bleeds 
(ISTH definition) 
NB mean follow up only 1.0 years. AUC under ROC 
compared with C statistic and NRI. Used low mod 
and high cutoffs from scores. C stat similar for 3 
bleeding risk scores (0.66.to 0.69), and all bleeding 
scores performed better than CHADS2 or CHA2DS2-
VASc (C stat 0.53 to 0.56). For NRI, HAS_BLED 
better than ATRIA or HEMORRHAGES, and ATRIA 
better than  HEMORR2HAGES, while all 3 better 
than CHADS2 or  CHA2DS2-VASc  
 
NRI differences for HAS-BLED vs 
other bleeding risk scores only 
significant  for low vs mod/high. Diff 
of NRI in bleeding risk scores not 
significant for low/mod vs High risk.  
All bleeding risk scores had only 
moderate prediction i.e. C statistic is 
only 0.66-0.69 
Caldeira et al150 Systematic review of  
HEMORR2HAGES,  
HAS-BLED, ATRIA 
scores 
HEMORR2HAGES,  
HAS-BLED, 
ATRIA. 
 
Compared high 
risk category 
only 
Major bleeds in 
studies reviewed 
from search 
6 studies found 
5 studies compared  HEMORR2HAGES and  
HAS-BLED, 4 studies compared HAS-BLED vs 
ATRIA. 
HAS-BLED had significantly higher sensitivity (but 
therefore also lower specificity for major bleeding. 
Conclusion was a preference for HAS-BLED because 
of higher sensitivity coupled with ease of use 
Systematic review 
Christersson et al 151 Aristotle trial in 14,878 
out of 18,201 pts 
randomized to warfarin 
or apixaban. Follow-up 
in trial 
HAS-BLED alone 
vs adding D-
Dimer 
647 Major bleeds 
(2.6%), and 1276 
with clinically 
relevant non-major 
bleeds (5.1%) 
(admission to 
hospital but without 
drop in Hb of 2g or 
2 unit transfusion) 
C statistic was 0.61 and 0.618 in the no-VKA and 
on VKA groups respectively and adding D-Dimer 
increased the C statistic to 0.641, and 0.635 resp. 
NRI was 23 to 28% 
Modest increase in C statistic only. 
D-Dimer predictive in its own right 
with similar C-statistic 
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Suzuki et al..152 231 patients starting 
warfarin. Prospective 
study 
HAS-BLED 
exploring various 
cut points of 
renal function (3 
groups)  in 
Japanese 
population 
(eGFR) using 
Japanese MDRD 
formula 
44 ISTH major 
bleeds 
Moderate kidney disease (eGFR 30-59) also 
associated with increased major hemorrhage. C 
statistic including moderate renal disease in HAS-
BLED increased from 0.64 to 0.67 (p, NS) but NRI 
improved significantly 
Small trial, so hard to draw solid 
conclusions, but perhaps even 
moderate renal disease will be 
important and therefore may need to 
include in the HAS-BLED definition 
O’Brien et al. 153 ORBIT AF registry, 
7411 pts taking OAC. 
Median 2 year follow-
up. 
External validation in 
14,264 pts in ROCKET-
AF study warfarin and 
Rivaroxaban pts (not 
all elements of all 
scores available) 
ORBIT score (full 
score, and 5 
factor score) vs 
HAS-BLED and 
ATRIA bleeding 
scores 
581 (7.8%) ISTH 
major bleeding 
events in ORBIT 
registry 
See table 4 for topline results. C indices of 0.69 and 
0.67 for the full and 5 factor ORBIT score in ORBIT 
registry, compared to 0.64 and 0.66 for HAS-BLED 
and ATRIA resp.  In ROCKET-AF, Full and 5 factor 
ORBIT model C stat 0.63 and 0.62 respectively, vs 
0.59 and 0.60 for HAS-BLED and ATRIA 
respectively. Model calibration better for ORBIT 
score in ROCKET-AF, followed by HAS-BLED then 
ATRIA 
All scores showed only moderate 
predictive ability and discrimination 
Zhu et al. 154 Systematic review and 
meta-analysis of HAS-
BLED score vs  other 
scores, in 11 studies 
identified  
 
HAS_BLED vs  
CHADS2, 
CHADSVASc, 
HEMORR2HAGES 
and ATRIA 
Variable events in 
the 11 studies 
C statistic not significantly  different between HAS-
BLED and other 2 bleeding risk scores (0.65 vs 
0.63 and 0.63 synthesized result), but better than  
CHADS2 and CHADSVASc. HAS-BLED superior to all 
other scores for NRI (NB not in all studies). 
Calibration analysis shows HAS-BLEC over predicts 
in the low and under-predicts in the mod and high 
risk categories.  
All scores perform better than the 
stroke risk scores, and HAS-BLED 
has a marginal advantage over  
HEMORR2HAGES and ATRIA 
 
Esteve-Pastor et al. 
155 
FANTSIIA registry, 571 
pts undergoing 
cardioversion, 1276 
pts with persistent AF. 
Most VKA, some NOAC 
ORBIT vs HAS-
BLED 
21 ISTH major 
bleeds in the 571 
cardioversion pts, 
and 46 in the 
persistent AF 
population 
C statistic in cardioversion group 0.77 vs 0.82 HAS-
BLED vs ORBIT (ns), and in persistent AF group 
0.63 vs 0.70 (ns) 
Relatively small number of major 
bleeding events in both arms of the 
study, so not much weight can be 
put on the study. Prediction only 
modest for both scores 
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Hijazi et al. ABC-
Bleeding score.156 
ARISTOTLE study 
14,537 pts apixaban vs 
warfarin) for 
development and RELY 
study (8468 pts on 
warfarin or 
Dabigatran) for 
validation.  
ABC-bleeding 
score (Age; 
Biomarker GDF-
15, CTnT hs, Hb; 
Clinical history of 
bleeding) vs 
HAS-BLED and 
ORBIT bleeding 
risk scores 
ISTH major bleeds: 
662 in ARISTOTLE, 
and 463 in RELY. 
ABC score discriminated in all risk groups of HAS-
BLED and ORBIT in both derivation and validation 
cohorts. C statistic significantly higher 0.68 for ABC 
bleeding vs 0.61 and 0.68 HAS-BLED and ORBIT in 
ARISTOTLE, and also in RELY 0.71, vs 0.62 and 
0.68 for HAS-BLED and ORBIT resp. Similar results 
when hematocrit, CTnIhs and Cystatin C or 
Creatinine clearance substituted. 
Simplicity and bedside use favor the 
simpler scores, though substitution 
of more readily available biomarkers 
would be an option. Even with 
Biomarkers, performance still only 
moderate 
Nielsen et al. 157 Danish national 
registry 210,299 pats 
with AF 
Recalibration of 
HAS-BLED using 
an extra point 
for hemorrhagic 
stroke (S in 
HAS-BLED) 
ISTH major 
bleeding 4.3/100 
patient/years 
No significant difference for C statistic for the 2 
scores, and modest for both (0.613 original and 
0.616 for the additional point HAS-BLED). NRI was 
10%  and relative IDI 23.6% 
Minor gain by adding an extra point 
for ICH to the one point for stroke. It 
is reasonably intuitive that someone 
with a prior ICH is really at high 
danger of a major bleed 
Proietti et al. 158 SPORTIF III and V 
trials. 3,551/3,665 pts 
assigned to warfarin. 
Only 20% VKA naïve at 
baseline 
HAS-BLED vs  
HEMORR2HAGES
,  
ATRIA, and 
ORBIT scores 
plus additional 
analysis for latter 
3 scores plus a 
term for TTR 
127 adjudicated 
major bleeds. 1.6 
years median F/U. 
162 investigator 
level major bleeds 
Rather complex analysis quoting similar AUC, 
without C statistics quoted. Analyzed both 
adjudicated and investigator level major bleeds 
(latter not usually included in other studies), then 
added TTR to the 3 scores that do not contain it, 
again against both endpoints. These scores 
improved prediction, indicating TTR is likely to be 
an important issue that is not included in scores 
other than HAS-BLED 
All scores showed only moderate 
prediction, but HAS-BLED performed 
best in 1 respect of having no 
investigator level major bleeds ion 
the low risk stratum. While low TTR 
may be useful to assess risk, it has 
no role in the VKA naïve patient. 
Relatively low risk of major bleeds in 
this stud 
Senoo et al. 159 2293 patients 
receiving VKA in 
AMADEUS trial 
(idraparinux vs VKA in 
AF).  
HAS-BLED vs 
ATRIA and 
ORBIT 
39 Major bleeds and 
251 clinically 
relevant bleeds 
(these are not 
usually counted in 
prior analyses of 
scores) 
No difference in AUC between 3 scores in major 
bleeds. Some difference in clinically relevant 
bleeds, with HAS-BLED having greater AUC. Modest 
improvement for ATRIA and ORBIT by adding TTR 
All scores showed modest at best 
prediction of bleeding. While low TTR 
may be useful to assess risk, and is 
only included in HAS-BLED, it has no 
role in the VKA naïve patient. Low 
risk group as patients with major 
bleeds excluded from study 
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Steinberg et al. 160 
 
9715 patients in ORBIT 
registry. Probably 
some overlap with the 
O’Brien study above 
HAS-BLED, 
ATRIA, and 
physician 
assessment 
Major bleeds (not 
defined), and no 
numbers given, just 
incidence rate /100 
patient/years in 
each stratum 
C statistic 0.63 ATRIA and 0.60 HAS-BLED not 
significantly different. Both better than physician 
assessment (C Stat 0.55), which did not add 
anything to the bleeding risk scores 
Physician assessment overall poor 
and worse that scores 
Wang et al..161 USA United Health 
OAC initiator (VKA and 
Dabigatran. 21,934 
patients included 
CHADS2, 
CHADSVASc, and 
HAS-BLED 
Approx. 1000 major 
bleed (4.6%). Used 
ISTH, TIMI or 
GUSTO major bleed 
definition 
C statistic of 0.60 for major bleeding. No difference 
according to major bleed definition. Calibration of 
rates of major bleeding using model data from 
RELY trial showed great underestimation of major 
bleeding, especially for warfarin initiators in high 
risk HAS-BLED category 
Trial data based models (RCT) giving 
rates of major bleeding taken from 
bleeding risk models underestimate 
the true rate of major bleeds in real 
world practice for that risk stratum, 
esp. in warfarin initiators 
Poli et al.162 4,579 patients in a 
prospective registry 
(START) of NVAF 
HAS-BED (omit 
the L for labile 
INR) as all are 
inception 
patients, vs 
CHADS2 and 
CHADSVASc 
115 ISTH major 
bleeds (1.6 per 100 
pt. years 
C statistic 0.58 and 0.61 for HAS-BED and HAS-
BLED. Similar to CHADS2 and CHADSVASc (0.58, 
0.56 respectively) 
Cannot understand how a HAS-BLED 
score was calculated in the study, as 
all were initiators (77% VKA), and 
why it should be different to HAS-
BED, unless they used TTR after 
registry commenced in the 77% on 
VKA. Low bleeding risk cohort overall 
in this registry 
Esteve-Pastor et al163 1120 "real-world" 
anticoagulated NVAF 
patients with long-
term follow-up. 
 
HAS-BLED vs 
ABC-bleeding 
score 
After 6.5 years of 
follow-up, 207 
(2.84 %/year major 
bleeding events, of 
which 65 
(0.89 %/year) were 
intracranial 
haemorrhage (ICH) 
and 85 
(1.17 %/year) 
gastrointestinal 
bleeding (GIB).  
c-index of HAS-BLED was significantly higher than 
ABC-Bleeding for major bleeding (0.583 vs 0.518; 
p=0.025), GIB (0.596 vs 0.519; p=0.017) and for 
the composite of ICH-GIB (0.593 vs 0.527; 
p=0.030).  
NRI showed negative reclassification for major 
bleeding and for the composite of ICH-GIB with the 
ABC-Bleeding score.  
Using DCAs, the use of HAS-BLED score gave an 
approximate net benefit of 4 % over the ABC-
Bleeding score.  
 
HAS-BLED performed significantly 
better than the ABC-Bleeding score 
in predicting major bleeding, GIB 
and the composite of GIB and ICH 
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Guo et al164 Hospital based cohort HEMORR2HAGES
, HAS-BLED, 
ATRIA, and 
ORBIT, vs 
‘European score’ 
based on 
modifiable 
bleeding risk 
factors 
 
 European score c-index for major bleeding 0.63, 
95% CI 0.56-0.69) and intracranial hemorrhage 
(0.72, 0.65-0.79)  
HAS-BLED score was superior to European score 
(Delong test, all P < .05), net reclassification 
improvement values of 13.0%-34.5% (all P < .05), 
and integrated discrimination improvement values 
of 0.7%-1.4% (all P < .05).  
European score performed worst compared to 
HEMORR2HAGES, HAS-BLED, ATRIA, and ORBIT 
Relying on bleeding risk assessment 
using modifiable bleeding risk factors 
alone is an inferior strategy 
 
Esteve-Pastor et al165 AMADEUS trial cohort HAS-BLED vs 
modifiable 
bleeding risk 
factors based on 
ESC guidelines 
597 (13.0%) 
experienced any 
clinically relevant 
bleeding event and 
113 (2.5%) major 
bleeding 
 
Only the HAS-BLED score was significantly 
associated with the risk of any clinically relevant 
bleeding (hazard ratio 1.38; 95%CI 1.10–1.72; 
p = 0.005).  
The HAS-BLED score performed best in predicting 
any clinically relevant bleeding (c-indexes for HAS-
BLED, 0.545 vs. ‘modifiable bleeding risk factors 
score’, 0.530; c-index difference 0.015, z-
score = 2.063, p = 0.04). 
While modifiable bleeding risk 
factors should be addressed in all AF 
patients, the use of a formal 
bleeding risk score (HAS-BLED) has 
better predictive value for bleeding 
risks 
 
Chao et al166 Nationwide cohort 
study of 40,450 NVAF 
patients who received 
warfarin 
 
HAS-BLED, 
HEMORR2HAGES, 
ATRIA, ORBIT, 
Modifiable 
bleeding risk 
(MBR) approach 
(based on ESC 
guidelines) 
581 (3.91%) 
patients sustained 
ICH and 6889 
(17.03%) patients 
sustained major 
bleeding events 
 
When HAS-BLED was compared to other bleeding 
scores, c-indexes were significantly higher 
compared to MBR factors (p<0.001) and ORBIT 
(p=0.05) scores for major bleeding. C-indexes for 
the MBR factors score significantly lower vs. all 
other scores (De long test, all p<0.001).  
All contemporary bleeding risk 
scores had modest predictive value 
for predicting major bleeding but the 
best predictive value and NRI was 
found for the HAS-BLED score.  
Simply depending on modifiable 
bleeding risk factors had suboptimal 
predictive value for the prediction of 
major bleeding  
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e-Table 11. GRADE Evidence Profile on Bleeding Risk Scores 
Question: Bleeding Risk tools for patients with Atrial Fibrillation 
Bibliography: W. Zhu et al. The HAS-BLED Score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: A systematic review and meta-analysis. Clin Cardiol. 2015. 
38:55-561 
Quality assessment  
 
Impact 
 
 
Quality 
 
 
Importance № of 
studies 
 
Study design 
 
Risk of 
bias 
 
Inconsistency 
 
Indirectness 
 
Imprecision 
 
Other considerations 
HAS-BLED 
7 
observational 
studies 
not 
serious 
not serious not serious not serious none C-statistic range: 0.60–0.69 (median, 0.66); 
pooled c-statistic: 0.65 (0.61-0.69) 
⨁⨁   
LOW 
CRITICAL 
HEMORR2HAGES 
5 
observational 
studies 
not 
serious 
not serious not serious not serious none C-statistic range: 0.60–0.67 (median, 0.63); 
pooled c-statistic: 0.63 (0.61-0.66) 
⨁⨁   
LOW 
CRITICAL 
ATRIA 
3 
observational 
studies 
not 
serious 
not serious not serious not serious none C-statistic range: 0.59–0.69 (median, 0.61); 
pooled c-statistic: 0.63 (0.56-0.72) 
⨁⨁   
LOW 
CRITICAL 
CHADS2 
3 
observational 
studies 
not 
serious 
not serious not serious not serious none C-statistic range: 0.51–0.59 (median, 0.53); 
pooled c-statistic: 0.55 (0.49-0.61) 
⨁⨁   
LOW 
CRITICAL 
CHA2DS2-VASc 
3 
observational 
studies 
not 
serious 
not serious not serious not serious none C-statistic range: 0.53–0.58 (median, 0.56); 
pooled c-statistic: 0.56 (0.53-0.59) 
⨁⨁   
LOW 
CRITICAL 
 
CI: Confidence interval 
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e-Table 12. GRADE Evidence Profile of VKA compared to Placebo or control 
 
Question: VKA compared to Placebo or control 
Bibliography: Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of internal medicine. 2007;146(12):857-867. 
Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations VKA Placebo 
Relative 
(95% CI) 
Absolute 
(95% CI) 
All Stroke 
6  randomised 
trials  
serious a not serious  not serious  not serious  none  54/1450 (3.7%)  133/1450 (9.2%)  RR 0.36 
(0.26 to 0.51)  
56 fewer per 
1,000 
(from 42 
fewer to 66 
fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
a. One study did not report appropriate randomization methods; Partial blinding reported in 3 trials 
 
 
 
 
 
e-Table 13. GRADE Evidence Profile of Aspirin compared to placebo or control 
 
Question: Aspriin compared to placebo or control 
Bibliography: Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of internal medicine. 2007;146(12):857-867. 
Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations 
Aspirin + 
Antiplatelets 
Control 
Relative 
(95% CI) 
Absolute 
(95% CI) 
All Stroke 
8  randomised 
trials  
serious a not serious  not serious  not serious  none  245/2602 (9.4%)  296/2594 (11.4%)  RR 0.78 
(0.94 to 0.65)  
25 fewer per 
1,000 
(from 7 fewer 
to 40 fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
a. Unclear randomization and blinding methods in several studies  
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e-Table 14. GRADE Evidence Profile of VKA compared to antiplatelet therapy 
 
Question: VKA compared to Antiplatelet therapy 
Bibliography: Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of internal medicine. 2007;146(12):857-867. 
Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations VKA AP 
Relative 
(95% CI) 
Absolute 
(95% CI) 
All Stroke 
12  randomised 
trials  
serious a not serious  not serious  not serious  none  205/6558 (3.1%)  341/6575 (5.2%)  RR 0.61 
(0.78 to 0.48)  
20 fewer per 
1,000 
(from 11 
fewer to 27 
fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
a. Unclear randomization and blinding methods in several studies  
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e-Table 15. GRADE Evidence Profile of VKA compared to NOAC (not stratified by specific agent) 
 
Question: VKA compared to Antiplatelet therapy 
Bibliography: Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. 
 
Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations VKA NOAC 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Stroke or SE events 
4  randomised 
trials  
serious a not serious  not serious  not serious  none  1107/29229 
(3.8%)  
911/29312 (3.1%)  RR 0.81 
(0.73 to 0.91)  
6 fewer per 
1,000 
(from 3 fewer 
to 8 fewer)  
⨁⨁⨁◯ 
MODERATE  
CRITICAL  
Major Bleeding 
4  randomised 
trials  
serious a serious b not serious  serious c none  1802/29211 
(6.2%)  
1541/29287 
(5.3%)  
RR 0.86 
(0.73 to 1.00)  
7 fewer per 
1,000 
(from 0 fewer 
to 14 fewer)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
a. Issues with allocation concealment and blinding of participants and personnel  
b. I-squared value of 83% indicating substantial heterogeneity  
c. 95% CI includes no effect  
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e-Table 16. GRADE Evidence Profile of NOAC vs. Aspirin 
 
Bibliography: Connolly SJ, et al. Apixaban in patients with atrial fibrillation. The New England journal of medicine. 2011;364(9):806-817. 
Quality assessment № of patients Effect 
Quality Importance 
№ of 
studies 
Study 
design 
Risk of bias Inconsistency Indirectness Imprecision Other considerations NOAC Aspirin 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Stroke or SE 
1  randomised 
trials  
not serious  not serious  not serious  not serious  none  51/2802 (1.8%)  113/2791 (4.0%)  HR 0.45 
(0.32 to 0.62)  
22 fewer per 
1,000 
(from 15 
fewer to 27 
fewer)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
Major Bleeding 
1  randomised 
trials  
not serious  not serious  not serious  not serious  none  44/2802 (1.6%)  39/2791 (1.4%)  HR 1.13 
(0.74 to 1.75)  
2 more per 
1,000 
(from 4 fewer 
to 10 more)  
⨁⨁⨁⨁ 
HIGH  
CRITICAL  
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e-Table 17. GRADE Evidence Profile of NOAC vs. VKA for electric cardioversion 
 
Question: NOAC compared to VKA for Patients with Atrial Fibrillation undergoing elective-cardioversion 
Bibliography: Cappato 2014, Flaker 2014, Goette 2016, Nagarakanti 2011, Piccini 2013, Plitt 2016 
Quality assessment № of patients Effect  
Quality 
 
Importance 
№ of 
studie
s 
Study 
desig
n 
Risk 
of 
bias 
 
Inconsistency 
 
Indirectness 
 
Imprecision 
Other 
consideration
s 
 
NOAC 
 
VKA 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Stroke/S E 
6 randomised 
trials  
serious a not serious  not serious  serious b none 16/4136 
(0.4%) 
12/2928 
(0.4%) 
RR 0.82 
(0.38 to 1.75) 
1 fewer 
per 1,000 
(from 3 
fewer to 3 
more) 
⨁⨁◯◯ 
LOW 
CRITICAL 
Mortality - all cause (follow up: range 30 to 60; assessed with: all cause) 
4 randomised 
trials  
serious a not serious  not serious  serious b none 9/2679 
(0.3%) 
10/2132 
(0.5%) 
RR 0.72 
(0.27 to 1.90) 
1 fewer 
per 1,000 
(from 3 
fewer to 4 
more) 
⨁⨁◯◯ 
LOW 
CRITICAL 
MI 
3 randomised 
trials  
serious a not serious  not serious  serious b none 4/2428 
(0.2%) 
5/2018 
(0.2%) 
RR 0.72 
(0.19 to 2.71) 
1 fewer 
per 1,000 
(from 2 
fewer to 4 
more) 
⨁⨁◯◯ 
LOW 
CRITICAL 
CI: Confidence interval; RR: Risk ratio 
a. Issues with allocation concealment and blinding of participants and personnel; studies underpowered to detect a difference 
b. Low number of events; Fairly wide confidence intervals around estimate of effect 
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e-Figure 3. NOACs versus warfarin in the TEE-guided approach to cardioversion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e-Table 18. GRADE Evidence Profile of NOAC vs. VKA for TEE-guided cardioversion 
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e-Table 19. GRADE Evidence Profile of Heparinoids compared to Aspirin/placebo for patients with acute ischemic stroke or TIA 
 
Question: Heparinoids compared to Aspirin/placebo for patients with acute ischemic stroke or TIA 
Bibliography: Paciarno 2007 
Certainty assessment № of patients Effect  
Certainty 
 
Importance 
№ of 
studies 
Study 
design 
Ris of 
bias 
 
Inconsistency 
 
Indirectness 
 
Imprecision 
Other 
considerations 
 
Heparinoids 
 
Aspirin/placebo 
Relative 
(95% CI) 
Absolute (95% CI) 
Recurrent ischemic stroke 
5 randomised 
trials 
serious a not serious not serious serious b none   OR 0.68 
(0.44 to 
1.06) 
1 fewer per 1,000 
(from 0 fewer to 1 
fewer) 
⨁⨁◯◯ 
LOW CRITICAL 
Death 
6 randomised 
trials 
serious a not serious not serious not serious none 1729/2351 
(73.5%) 
1637/2217 
(73.8%) 
OR 1.01 
(0.82 to 
1.24) 
2 more per 1,000 
(from 39 more to 40 
fewer) 
⨁⨁⨁◯ 
MODERATE CRITICAL 
CI:  Confidence interval; OR:  Odds ratio 
 
Explanations 
 
a. issues with allocation concealment and blinding of participants and personnel 
b. wide 95% CI that crosses no effect 
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e-Table 20. Relationship between CIED-detected AHREs > 5-6 min and thromboembolic events/stroke 
 
Trial No. of 
patients  
Duration 
of follow-
up 
AHRE or AF 
burden threshold 
Atrial 
rate 
cut-off 
(bpm) 
Risk of 
clinical AF 
Clinical 
AF during 
follow-up 
Risk of thromboembolic event Thromboembolic event rate 
(below vs above AF burden 
threshold; %) 
Ancillary MOST 
(2003)167 
312 27 months 
(median) 
>5 min in a day >220 HR 5.93, 
95% CI 
2.88–12.2, 
P = 0.0001 
25% in 
patients 
with 
AHREs 
HR 6.7, 95% CI 1.4–33.2, P = 0.020 for 
stroke or SEE  
3.2 overall (1.3 vs 5.0) 
Italian AT500 
Registry 
(2005)168 
725 22 months 
(median) 
> 24 h >174 NA NA HR 3.1, 95% CI 1.1–10.5, P = 0.044 for 
stroke or SEE 
1.2 annual rate 
Botto et al. 
(2009)169  
568 1 year 
(mean) 
CHADS2 and AF 
burden (≥5 min in a 
day or >24 h) 
>174 NA NA NA 2.5 overall (5.0 vs 0.8, P = 0.035 by 
comparing high vs low risk on the 
basis of CHADS2 and AF burden ) 
TRENDS 
(2009)170 
2,486 1.4 years 
(mean) 
≥5.5 h in a day 
occurring in a 
30-day window 
>175 NA NA HR 2.2, 95% CI 0.96–5.05, P = 0.06 for 
stroke, TIA, or SEE, by comparing AF 
burden ≥5.5 h vs zero burden  
1.2 annual rate overall (1.1 for zero 
burden or AF burden <5.5 h vs 2.4 
for AF burden ≥5.5 h) 
Home Monitor 
CRT (2012)171 
560 370 days 
(median) 
≥3.8 h in a day  >180 NA NA HR 9.4, 95% CI 1.8–47.0, P = 0.006 for 
stroke or SEE, by comparing daily AF 
burden ≥3.8 h vs zero burden  
2.0 overall 
ASSERT 
(2012)172 
2,580 2.5 years 
(mean) 
>6 min in a day >190 HR 5.56, 
95% CI 
3.78–8.17, 
P <0.001 
15.7% in 
patients 
with 
AHREs 
HR 2.49, 95% CI 1.28–4.85, P = 0.007 
for ischemic stroke or systemic embolism 
1.69 vs 0.69 annual rate in patients 
with vs without device-detected atrial 
tachyarrhythmias 
SOS (2014)173 10,016 2 years 
(median) 
≥5 min and ≥1 h >175 NA NA HR 1.76, 95% CI 1.02–3.02, P = 0.041 
for ischemic stroke with AF burden 
≥5 min vs <5 min. HR 2.11, 95% CI 
1.22–3.64, P = 0.008 for ischemic stroke 
with AF burden ≥1 h vs <1 h 
0.39 annual rate in the whole cohort 
AF, atrial fibrillation; AHRE, atrial high-rate episode; ICD, implantable cardioverter–defibrillator; NA, not available; SEE, stroke or systemic embolism; TIA, transient ischemic attack. 
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e-Table 21. Time relationships between device-detected atrial tachyarrhythmias and ischemic stroke, transient ischemic attacks or systemic embolism in 
patients with CIEDs under continuous monitoring of the atrial rhythm    
 
 N. of TE events 
(Ischemic Stroke 
/TIA/SE) 
Minimum device detected 
AF/AT duration/burden 
Device 
detected AF/AT 
at any time 
before TE 
event 
Device detected 
AF/AT in the 30 
days before TE 
event  
Device detected 
AF/AT at the time of 
TE event 
Device detected 
AF/AT only after 
TE event 
Daoud et al., 2011 
174 
40 Ischemic 
Stroke/TIA/SE 
≥ 20 sec 50% 28% 15% 15%. 
Boriani et al., 2012 
175 
33 Ischemic 
Stroke/TIA/SE 
≥5 min 64% 33% 15% NA 
Shanmugam et al., 
2012 171 
11 Ischemic 
Stroke/TIA/SE 
Around 6-10 s 64% NA 27% NA 
Brambatti et al., 
2014 176 
51 Ischemic 
Stroke/SE 
>6 min  35% 8% 2% 16% 
Martin et al., 2015 
177 
69 Ischemic 
Stroke/SE 
Around 6-10 s 13% 6% NA 7% 
AF: atrial fibrillation; AT: atrial tachyarrhythmias; CIED: cardiac implantable electronic device; SE: systemic embolism; TE: thromboembolic; TIA: transient 
ischemic attack; NA: not available  
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e-Table 22. GRADE Evidence Profile of Warfarin compared to no treatment/placebo for CKD 
 
Question: Warfarin compared to No anticoagulation/placebo for CKD  
Bibliography:  Harel 2017 
Certainty assessment Effect 
Certainty Importance 
№ of 
studies 
Study design 
Risk of 
bias 
Inconsistency Indirectness Imprecision 
Other 
considerations 
Relative 
(95% CI) 
Absolute 
(95% CI) 
Ischemic Stroke 
14  observational 
studies  
not serious  serious a not serious  not serious a none  HR 0.85 
(0.62 to 1.15)  
1 fewer per 1,000 
(from 1 fewer to 1 fewer)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Intracranial Hemorrhage 
4  observational 
studies  
not serious  not serious  not serious  serious b none  HR 1.93 
(0.93 to 4.00)  
2 fewer per 1,000 
(from 1 fewer to 4 fewer)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
CI: Confidence interval; HR: Hazard Ratio 
Explanations 
a. I-squared value of 69% represents serious heterogeneity  
b. wide 95% CI  
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e-Table 23. Factors to be considered in estimating the bleeding and thromboembolic risk associated 
with a surgical procedure or intervention in a patient on oral anticoagulants for AF or previous venous 
thromboembolism. Modified from Boriani G et al. 178 
 
Hemorrhagic risk related to surgical or 
interventional procedures  
Thromboembolic risk related to oral 
anticoagulation interruption 
  
Low hemorrhagic risk (2-day risk of major 
bleeding between 0 and 2%) 
Low thromboembolic risk (annual risk of arterial 
thromboembolism < 5% or 1-month risk of venous 
thromboembolism < 2%) 
Cataract and other  ophthalmic surgery , with 
the exception of vitro-retinal surgery  
Nonvalvular atrial fibrillation with CHADS2 score 0 or 1 
Simple dental extractions Single previous remote venous thromboembolism (> 12 
months)  with no other risk factors 
Skin  excision  
Carpal tunnel repair  
Central venous catheter removal  
Non-coronary angiography  
Pacemaker and cardiac defibrillator implant   
Bronchoscopy  with biopsy  
Cutaneous and lymph node biopsies (for 
bladder, prostate, thyroid, breast masses)  
 
Abdominal hysterectomy  
Hemorrhoidal surgery  
Abdominal hernia repair  
Hydrocele repair  
Knee or hip replacement and shoulder, hand  or 
foot surgery and arthroscopy 
 
Cholecystectomy  
Gastrointestinal endoscopy or biopsy, 
enteroscopy, biliary or pancreatic stent without  
sphincterotomy 
 
 Intermediate thromboembolic risk (annual risk of 
arterial thromboembolism between 5 and 10% or  
1-month risk of venous thromboembolism between 
2 and 10%) 
 Previous venous thromboembolism within 3 and 12 
months 
 Valvular prosthesis in aortic position without risk factors 
 Nonvalvular atrial fibrillation with CHADS2 score 2 or 3 
 Recurrent stroke or transient ischemic attack without risk 
factors for cardiac embolism 
High hemorrhagic risk (2-day risk of major 
bleeding between 2 and 4%) 
High thromboembolic risk (annual risk of arterial 
thromboembolism >10% or    1-month risk of 
venous thromboembolism >10%) 
Heart valve replacement Recent venous thromboembolism (<3 months)   
Coronary artery bypass Recent stroke or transient ischemic attack, (< 3 months) 
Surgery for aortic diseases Previous thromboembolic event with known 
hypercoagulability due to genetic factors (Protein S or C 
deficiency, anti-thrombin deficiency, homozygous factor 
V Leiden mutation, antiphospholipid syndrome) or 
paraneoplastic thromboembolism or recurrent idiopathic 
thromboembolism 
Vascular and general surgery Non valvular atrial fibrillation  with CHADS2 score ≥ 4 
Neurosurgery Atrial fibrillation with rheumatic heart disease, 
mechanical valvular prosthesis or previous stroke 
Surgery for urologic, thoracic, abdominal or 
breast cancer  
Any valvular prosthesis in mitral position or older valvular 
prosthesis (caged-ball; tilting-disc) in aortic position 
Transurethral prostate resection Prosthetic heart valve with other risk factors (prior 
thromboembolism, severe left ventricular dysfunction)  or 
recently placed (<3 months)  or associated with 
hypercoagulable state 
Bilateral knee replacement Intra-cardiac thrombus detected by echocardiography or 
other imaging techniques 
Laminectomy  
Kidney biopsy  
Polypectomy, variceal treatment, biliary 
sphincterectomy, pneumatic dilatation 
 
Placement of a percutaneous endoscopic 
gastrostomy (PEG) 
 
Endoscopically guided fine-needle aspiration  
Multiple tooth extractions  
Any major operation  with a procedure duration 
> 45 minutes 
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e-Table 24. Decision-making and management of a patient under treatment with a NOAC in the 
phases before and after a procedure/intervention. 
 
Interruption before the procedure/intervention 
 CrCl  Minor procedure/ 
intervention without 
an important risk of 
bleeding and with 
possible adequate 
local haemostasis 
Procedure/ 
intervention at low 
risk of bleeding  
Procedure/ intervention at 
high risk of bleeding 
Apixaban,  CrCl > 
30 
mL/min 
Plan to perform the 
procedure/intervention 
at trough level (i.e. 12 
h after last intake) 
Give last dose 
2 days before 
procedure/intervention  
(i.e., skip 2 doses 
on the day before the 
procedure/intervention  
and skip the  dose  the 
day of the procedure/ 
intervention) 
Give last dose 
3 days before 
procedure/intervention  (i.e., 
skip 4 doses 
on the 2 days before the 
procedure/intervention  and 
skip the  dose  the day of the 
procedure/ 
intervention) 
CrCl  
15-30 
mL/min 
Plan to perform the 
procedure/intervention 
at trough level (i.e. 12 
h after last intake) or 
at 24 hours from last 
intake 
Give last dose 
2 days before 
procedure/intervention  
(i.e., skip 2 doses 
on the day before the 
procedure/intervention  
and skip the  dose  the 
day of the procedure/ 
intervention) 
Give last dose 
3 days before 
procedure/intervention  (i.e., 
skip 4 doses 
on the 2 days before the 
procedure/intervention  and 
skip the  dose  the day of the 
procedure/ 
intervention) 
Edoxaban, 
Rivaroxaban 
CrCl > 
30 
mL/min 
Plan to perform the 
procedure/intervention 
at trough level (i.e. 24 
h after last intake) 
Give last dose 
2 days before 
procedure/intervention 
(i.e., skip 1 dose 
on the day before the 
procedure/intervention 
and skip the  dose  the 
day of the procedure/ 
intervention) 
Give last dose 
3 days before 
procedure/intervention (i.e., 
skip 2 doses 
on the 2 days before the 
procedure/intervention  and 
skip the  dose  the day of the 
procedure/ 
intervention) 
CrCl  
15-30 
mL/min 
Plan to perform the 
procedure/intervention 
at trough level (i.e. 24 
h after last intake) or 
at 36  hours from last 
intake 
Give last dose 
2 days before 
procedure/intervention 
(i.e., skip 1 dose 
on the day before the 
procedure/intervention 
and skip the  dose  the 
day of the procedure/ 
intervention) 
Give last dose 
3 days before 
procedure/intervention (i.e., 
skip 2 doses 
on the 2 days before the 
procedure/intervention  and 
skip the  dose  the day of the 
procedure/ 
intervention) 
Dabigatran CrCl > 
50 
mL/min 
Plan to perform the 
procedure/intervention 
at trough level (i.e. 12 
h after last intake) 
Give last dose 
2 days before 
procedure/intervention  
(i.e., skip 2 doses 
on the day before the 
procedure/intervention  
and skip the  dose  the 
day of the procedure/ 
intervention) 
Give last dose 
3 days before 
procedure/intervention  (i.e., 
skip 4 doses 
on the 2 days before the 
procedure/intervention  and 
skip the  dose  the day of the 
procedure/ 
intervention) 
CrCl 
30–50 
mL/min 
Plan to perform the 
procedure/intervention 
at trough level (i.e. 12 
h after last intake) or 
at 24 hours from last 
intake 
Give last dose 
3 days 
before 
procedure/intervention  
(i.e., skip 4 doses 
on the 2 
days before the 
procedure and skip the  
dose  the day of the 
procedure/ 
intervention) 
Give last dose 
5 days before 
procedure/intervention  (i.e., 
skip 8 doses on the 4  days 
before the 
procedure and skip the  dose  
the day of the procedure/ 
intervention) 
Resumption after the procedure/intervention  
Apixaban, 
Dabigatran, 
Edoxaban, 
Rivaroxaban  
 The drug can be 
resumed without 
skipping expected 
doses 
  
The drug can be 
resumed 24 
hours after 
the procedure/ 
intervention  
The drug can be resumed 48-
72 
hours after 
the procedure/ intervention  
 
For all the DOACs usually there is no need for bridging with LMWH/UFH 
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Section 19 The Patient 
Shared decision-making 
More recently there have been calls for a more co-ordinated approach to the management of AF, 
‘integrated AF care’.179-183 Physicians are encouraged to adopt a shared-decision making approach184-
186 to empower the patient to contribute to treatment decisions and participate in the management of 
their AF.    
It is imperative to elicit from each patient what outcomes of treatment are important for them rather 
than assume that all patients have the same treatment goals,184 and to be aware that patients and 
physicians treatment objectives often differ significantly.  Research has overwhelmingly demonstrated 
that patients with AF wish to avoid a stroke and are often willing to accept major bleeding to achieve 
this,187-190  as many patients view a major disabling stroke as a consequence worse than death.189  
Bleeds, although feared, are considered by many patients to be preferable to a stroke.  In contrast, 
some physicians are more concerned with reducing the risk of death187 and decreasing the chance of 
bleeding rather than the prevention of stroke.188,191  Physicians should note that in addition to 
reducing the risk of stroke, OAC also significantly reduces the risk of death.192  However, it is 
important to note that preferences for avoidance of stroke do not always translate into 
actions/decisions to take OAC; in a study of elderly AF patients, 12% would not take OAC even if was 
100% effective for stroke prevention.189  External factors, such as negative media coverage (TV 
adverts, particularly in the US) can create fear among patients on OAC about severe or fatal bleeding, 
which may translate into patients stopping OAC or failing to initiate. 
Patient preferences for OAC 
Since the introduction of NOACs, 7 studies193-199 have investigated which factor patients perceive as 
the important attribute when choosing OAC.  In 4 studies195-198 patients rated stroke prevention as the 
most important characteristic for OAC, while in others, the lack of interactions with food/drugs,193 
availability of an antidote,199 or ease of administration194 were of greatest importance.  However, 
methodological differences between studies may explain the inconsistency in outcomes, particularly 
where efficacy and safety were not included in the attributes presented.194 None of the studies asked 
patients to actively generate the attributes they felt were most important; all used pre-defined lists 
generated by researchers for patients to rank, which might have led to exclusion of certain responses 
of importance to patients. Further, most of these studies193-199 did not examine patient perceptions of 
AF and stroke, or knowledge about stroke, which may determine these preferences.   
Only a few studies have compared patient preferences for vitamin K antagonists (VKAs) and 
NOACs.193,194,197-201  Generally NOACs were preferred to VKAs due to convenience factors mainly 
related to absence of INR monitoring194,198-201 and a lower risk of bleeding.201  Cost of OAC, 
particularly NOACs, is problematic in countries where healthcare is not free or fully reimbursed, 
particularly in the US, and consequently affordability can drive patient (and physician) OAC 
preferences. Only three OAC preference studies in AF patients195-197 have examined the impact of 
cost/affordability on factors that were important in choosing an OAC; all reported stroke prevention to 
be the most important factor. One197 found that NOACs were preferred over warfarin as their cost 
decreased.  In two North American studies, one found that cost was the fifth most important attribute 
of OAC,195 while in a larger US study of AF patients with and without stroke,196 cost was the least 
important attribute.  Consequently, patient preferences are likely to vary considerably based on the 
healthcare system in which they operate as well as their health expectations and previous 
experiences.   
Patient education and counselling 
Communication with patients is crucial as physicians may deliberately or inadvertently persuade 
patients to concur with their treatment decision by creating fear (either fear of stroke or fear of 
bleeding to death).  Therefore, explaining risk of stroke and benefit/risks of treatment in terms the 
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patient can understand is paramount in enabling the patient to choose whether or not they wish to 
take OAC.  Many patient decision aids have been created to assist physicians in these discussions with 
patients (see e-Table 26).  Eliciting the barriers patients perceive they may have with NOACs/OAC 
allows HCPs to give clear explanations/offer strategies to overcome these barriers and improve OAC 
uptake,  adherence, and persistence.  In addition, it is important to dispel myths patients may hold 
about alternatives to OAC for stroke prevention. 
Adherence and persistence with OAC is paramount to treatment efficacy and safety.202 Educating 
patients on why adherence and persistence is so important, discussions on how to be adherent (timing 
of medication, frequency, with/without food, interacting medications to avoid, what to do if dose 
missed/overdose etc.) requires specific instructions from the HCP prescribing the medication; this 
could be facilitated by the use of patient education checklist (e-Table 26) and enhanced by devising 
and sharing strategies to increase adherence and persistence (reminders, medication tracking etc.).  
Understanding the necessity of OAC therapy and the potential adverse complications of non-adherence 
(stroke or bleeding) increases patient adherence and persistence.203  
Physician education is also important to ensure that they are familiar with the latest guidelines and 
current preferred AF management strategies, implementing them in order to prevent under-treatment 
(choice of drug and dose should be decided on the basis of patient characteristics, and to use their 
knowledge to inform patients about the specifics of the OAC to improve shared-decision making and 
adherence and persistence. Comprehensive reviews of ‘best practice’ for patient education for AF and 
OAC are available.204-207  
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e-Table 25. Patient and healthcare provider decision aids and apps, patient resources, and patient and 
patient and professional organisations*† 
Patient decision aids 
 
Reference/URL 
AFGuST 208 
Keele University Decision support http://www.anticoagulation-dst.co.uk/  
NICE 2014 PDA https://www.nice.org.uk/guidance/cg180/resources/e
ndorsed-resource-decision-support-tool-552601405 
‘Patient pages’ for AF and OAC 
Causes, symptoms and treatment of AF 209,210 
Living with AF 211 
Prevention of stroke in AF 212,213 
Management of vitamin K antagonists 214,215 
Non-vitamin K antagonists oral anticoagulants 
(NOACs) 
216 
Left atrial appendage occlusion devices 217 
Patient apps 
European Society of Cardiology Patient app (My AF) 218  Free to download to all smartphones- search for 
‘My AF’  
mAFA 219 
Health Buddies app 220 
CardioVisual app http://cardiovisual.com 
Afib Companion app http://afibcompanion.com 
Medication tracker apps  
Medisafe https://www.medisafe.com 
Mango Health https://www.mangohealth.com 
HCP apps 
European Society of Cardiology Healthcare 
Professional app (AF manager) 
218  Free to download to all smartphones- search for 
‘AF manager’ 
Patient advocacy groups and foundations 
Anticoagulation Europe http://www.anticoagulationeurope.org/ 
Arrhythmia Alliance International www.aa-international.org 
 
Atrial Fibrillation Association International www.afa-international.org 
Heart and Stroke Foundation-Canada http://www.world-heart-federation.org/what-we-
do/awareness/atrial-fibrillation/ 
My AFib Experience http://myafibexperience.org/ 
Sign Against Stroke in Atrial Fibrillation https://www.signagainststroke.com/en 
 
Stop Afib.org http://www.stopafib.org/ 
 
World Heart Federation:  http://www.world-heart-federation.org/what-we-
do/awareness/atrial-fibrillation/ 
Professional societies or organizations 
American College of Cardiology:   
 
https://www.cardiosmart.org/Heart-Conditions/Atrial-
Fibrillation 
American Heart Association http://www.heart.org/HEARTORG/Conditions/Arrhyth
mia/AboutArrhythmia/AFib-Resources-and-
FAQ_UCM_423786_Article.jsp# 
European Heart Rhythm Association http://www.afibmatters.org/ 
Heart Rhythm Society http://www.hrsonline.org/Patient-Resources/Heart-
Diseases-Disorders/Atrial-Fibrillation-
AFib#axzz3L30TnuiT 
*Taken in part from205; †not an exhaustive list 
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e-Table 26. Patient education checklist for atrial fibrillation patients initiating oral anticoagulation 
Patient education checklist for oral anticoagulation for stroke prevention in atrial 
fibrillation  
Tick when 
completed 
The condition - Atrial fibrillation  
What is atrial fibrillation?  
What is the link between AF and stroke?  
Discuss patient’s risk of stroke (CHA2DS2-VASc score & associated co-morbidities)  
Why is OAC recommended for stroke prevention?  
Duration of treatment (usually lifelong)  
Treatment options  
What are the treatment options? VKA or NOAC?  
Patient values/preferences for treatment (stroke prevention; lowest risk of bleeding; no 
routine monitoring; fewest side effects; once/twice daily dosing; cost etc.) 
 
Mode of action of chosen OAC (VKA or NOAC)  
Benefits/risks of specific OAC (stroke risk reduction vs. bleeding risk)  
For VKA patients, need for INR monitoring & explanation of INR tests; importance of TTR  
Why INR monitoring is not necessary (for VKA-experienced patients)  
Dosing  
How often the drug needs to be taken (once or twice daily)?  
What time(s) of day the OAC must be taken?  
Take with/without food  
If twice daily drug, NEVER take both doses together  
What to do if a dose is missed/overdose  
Highlight importance of medication adherence/ potential consequences of non-adherence  
Discuss how medication will be incorporated into daily routine  
Tools to assist patient to remember (if necessary)  
Bleeding  
Discuss patient’s risk of bleeding on OAC treatment  
Distinction between minor and major bleeding  
Signs and symptoms of bleeding  
When to seek medical care or attend emergency room  
What do to in the case of head injury  
Presence/absence of antidote  
Lifestyle  
Concomitant medication (interactions; avoid antiplatelets/other OAC; minimize NSAID use; 
discuss permissible pain medication) 
 
Diet (for VKA patients)  
Alcohol intake (particularly for VKA patients)  
Natural remedies/health-food supplements  
For women: menstruation, pregnancy, breastfeeding  
Holidays and travel  
Exercise and potentially dangerous hobbies  
Occupational hazards  
Surgical or dental procedures  
Before discharge  
Confirm patient understands dosing regimen, bleeding signs/symptoms and management 
of bleeding, when to seek medical attention and from whom 
 
Provide written education materials and Patient Alert card (if available)  
Arrange follow-up and provide contact details of prescribing physician  
Patient aware of laboratory tests needed – why, how and when  
AF, atrial fibrillation; NSAIDs, non-steroidal anti-inflammatory drugs; OAC, oral anticoagulation; VKA, vitamin 
K antagonist 
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